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Preface
It was the German pathologist Rudolf Virchow who described glial cells for the first
time. In 1846, he analyzed postmortem human tissues, and considered those cells
to be merely a “glue” having only a passive supporting role. Nowadays, glial cells
are considered more than passive components and have become active partners
with neurons. Thus, they seem to be much more actively involved in brain function
than was formerly thought. Glial cells comprise microglia, oligodendrocytes, and
astrocytes in the central nervous system, and Schwann cells, satellite cells, and enteric
glial cells in the peripheral nervous system. It is already well established that neuron–
glia interactions control several processes of brain development such as neurogenesis,
myelination, synapse formation, neuronal migration, proliferation, differentiation,
and even neuronal signaling. In all these processes astrocytes have important roles:
neurotransmitter clearance, ion buffering, and neuronal trophic support by secreting
members of the epidermal growth factor family, transforming growth factor,
neuregulin, fibroblast growth factor, nerve growth factor, and ciliary neurotrophic
factor, for instance. Moreover, astrocytes are also involved in other functions, such as
synapse development, blood–brain barrier formation, and neurogenesis.
Despite all the roles of glial cells in a healthy nervous system, they are also involved
in neurological disorders or diseases. In response to injury and diseases, glial cells
suffer a process termed astrogliosis that induces proliferation, progressive cell
hypertrophy, progressive alteration in molecular expression, and scar formation.
Studies have demonstrated that the malfunction of glial cells plays a pivotal role in
several neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson’s
disease, Alzheimer’s disease (AD), and multiple sclerosis (MS). During the
development of several neurological diseases, there is an increase in the inflammation
process that is related to the progression and worsening of the symptoms.
In this book, we will highlight the role played by glial cells in the central and
peripheral nervous systems in healthy and unhealthy individuals by giving
particular attention to the enteric nervous system (ENS). Among all processes
involved, we will specifically discuss the importance of ENS in the control of gut
homeostasis, in the interaction with the immune system, and its participation in
pathological conditions such as metabolic syndrome.
In particular, the relevance of astrocytes will be explored during synaptic
transmission and regulation of plasticity by releasing gliotransmitters.
Ultimately, we will highlight the influence of astrocytes during the development
of a number of neurodegenerative diseases, such as MS and AD. We will focus on
how the serum levels of the astrocytic protein S100B can be used as a biomarker
for clinical decisions for the onset and progression of neurodegenerative diseases.
Tania Spohr
Instituto Estadual do Cérebro Paulo Niemeyer,
Rio de Janeiro, Brazil
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In recent decades, astrocytes have gained ground in their protagonist role at the 
synapses, challenging the old-historic idea that neurons are the unique functional 
units in the nervous system. Although for a long time considered merely supportive 
elements, astrocytes are now recognized as a source of gliotransmitter release 
that regulates synaptic transmission and plasticity. Despite the initial evidence 
that supported gliotransmission depends on intracellular Ca2+-mediated vesicular 
release, recent data indicate that hemichannels may constitute an alternative 
non-vesicular route for gliotransmitter efflux. These channels are plasma mem-
brane channels formed by the oligomerization of six connexins around a central 
pore. Hemichannels are permeable to ions and signaling molecules—such as ATP, 
glutamate, and Ca2+—constituting a pathway of diffusional interchange between 
the cytoplasm and the extracellular milieu. Connexin 43 is the main hemichannel-
forming protein in astrocytes and is highly regulated under physiological and 
pathological conditions. In this chapter, the available data supporting the idea that 
hemichannels are chief components in tuning the synaptic gain in either resting or 
stimulated conditions is discussed.
Keywords: connexin 43, astrocyte, gliotransmission, brain, neuron
1. Introduction
In order to ensure a proper response to external stimuli, organisms have created 
complex and coordinated neural structures that allow the sophisticated analysis of 
information. As the central nervous system (CNS) evolved from a basic network 
structure to compacted ganglia and centralized brains, two types of connections 
emerged as specialized structures favoring the integration of neural networks [1]. 
In 1897, Sherrington proposed the point of functional contact between neurons 
as the specific area at which transfer of information takes place and named it 
“synapsis,” soon shortened to the “synapse,” from the Greek word sunáptō (to 
clasp) [2]. This specialized structure is known today as the chemical synapse and 
transfers electrical information unidirectionally from presynaptic to postsynaptic 
neurons through the release of neurotransmitters, which, acting upon postsynap-
tic receptors, initiate a second electrical signal [1]. In the late 1950s, Furshpan and 
Potter reported a series of experiments revealing that synaptic transmission in the 
crayfish is bidirectional and voltage-dependent, two properties substantially out of 
range of the criteria established for chemical transmission [3]. This study revealed 
the pioneer evidence in favor of the existence of electrical synaptic transmis-
sion. Unlike chemical synapse, the electrical synapse permits the bidirectional 
3
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flow of ions between coupled neurons that come markedly close at intercellular 
specializations called gap junctions [4] (Figure 1). Nowadays, a growing body of 
evidence indicates that both mechanisms of synaptic transmission—chemical and 
electrical—are complementary and highly intermodulated to ensure proper brain 
development and function [1].
The traditional notion of neurons being the only functional elements in the 
synapse has been questioned with the finding that intracellular Ca2+ ([Ca2+]i) waves 
within and among astrocytes underlie the regenerative (nondissipative) transfer 
of biological signals [5–7]. Although astrocytes are not electrically silent cells [8], 
[Ca2+]i signals are their principal fast time-scale mechanism for allowing intra- and 
intercellular signaling [9]. These signals base their origin on the extracellular influx 
of Ca2+ via ion channels and through Ca2+ release from intracellular stores, resulting 
in [Ca2+]i transients that differ in frequency, kinetics, and spatial spread depending 
on the astroglial anatomical region [10]. Endowed with this machinery and along 
with pre- and postsynaptic neuronal elements, astrocytes embrace the “tripartite 
synapse”—the Rosetta stone of the chemical synaptic transmission—in where they 
sense neurotransmission and respond to it by releasing biomolecules that regulate 
neuronal activity called “gliotransmitters” (i.e., glutamate, D-serine, and ATP) [11]. 
Intracellular [Ca2+]i waves can spread among astrocytes to finally reach the terminal 
processes or “endfeet” of specialized astrocytes that contact the endothelium [12]. 
There, vasoactive molecules are released, permitting astrocytes to modulate the 
cerebral blood flow (CBF) and delivery of energy substances (i.e., glucose and 
lactate) with potentially significant consequences for neuronal firing and higher 
brain functions [13]. Indeed, a single astrocyte may contact over 100,000 synapses 
in rodents and up to 2,000,000 synapses in humans, revealing that they actually 
form a syncytium with multiple connections [14].
Nowadays, diverse mechanisms have been proposed to lead to gliotransmitter 
release (Figure 1), including Ca2+-dependent exocytosis [15–17], carrier membrane 
transport [18], and opening of a wide range of channels. Among the latter group, 
volume-regulated anion channels [19–21], P2X7 receptors [22–24], Ca2+-dependent 
Cl− channel bestrophin 1 [25, 26], and hemichannels [27–30] are included. This 
Figure 1. 
Basic structure of connexin-based channels. Connexins have four α-helical transmembrane domains connected 
by two extracellular loops and one cytoplasmic loop; both the amino- and carboxy-termini are intracellular. 
The relative positions of the extracellular loop cysteines (red balls) are also shown. Hemichannels (also known 
as connexons) are formed by the oligomerization of six subunit connexins around a central pore. Under resting 
conditions, hemichannels remain preferentially closed, but they may be activated by diverse physiological and 
pathological conditions and offer a diffuse transmembrane route between the intra- and extracellular milieu. 
Hemichannels dock each other to form functional cell-to-cell channels termed gap junction channels (right 
panel). Gap junction channels aggregate in well-known anatomical structures called gap junctions to facilitate 
the intercellular cytoplasmic exchange of metabolites, second messengers, and ions.
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chapter reviews and discusses recent data supporting a role for hemichannels as 
pathways for gliotransmission and relevant actors in that tuning of synaptic trans-
mission and plasticity.
2. Structure and major functions of hemichannels
During the past decade, a growing body of evidence began to support a novel 
mechanism of autocrine/paracrine communication underlying gliotransmission 
and astrocyte-to-neuron communication: hemichannel-mediated signaling [31]. 
Each hemichannel is composed of the oligomerization of six protein subunits called 
connexins around a central pore (Figure 1). Connexins embrace a highly conserved 
protein family encoded by 21 genes in humans and 20 in mice, with orthologs in 
other vertebrate species [32]. These proteins are abundantly expressed in brain cells 
[33], including astrocytes [34], and they are named after their predicted molecular 
mass expressed in kDa, for instance, connexin 43 (Cx43) has a molecular mass of 
~43 kDa [35]. For several years, the key function attributed to hemichannels was to 
constitute the building blocks of the gap junction channels, which are intercellular 
channels that allow the direct cytoplasmic exchange between contacting cells [35]. 
Nonetheless, in the 1990s, pioneering findings by Paul and colleagues revealed the 
presence of functional and solitary hemichannels in “nonjunctional” membranes 
[36]. Today, it is well accepted that these channels act like aqueous pores, provid-
ing a diffusional route of exchange for ions and molecules between the intra- and 
extracellular space [37]. Across the different tissues, hemichannels allow the cellular 
release of relevant quantities of autocrine and paracrine signaling molecules (e.g., 
ATP, glutamate, D-serine, NAD+, and PGE2), as well as the influx of other sub-
stances (i.e., Ca2+ and glucose) [37].
Since their discovery, hemichannels have been linked with cellular damage. This 
idea came from early studies suggesting that osmotic and ionic imbalances induced 
by the uncontrolled influx of Na2+ and Cl− through hemichannels could result in 
further cell swelling and plasma membrane breakdown [36]. In addition, it has 
been proposed that because hemichannels are permeable to Ca2+, their uncontrolled 
opening could lead to Ca2+ overload and the consequent production of free radicals, 
lipid peroxidation, and plasma membrane damage [38]. Alternatively, exacerbated 
hemichannel activity could also induce the release of molecules that at high con-
centration may be toxic for neighboring cells, such as glutamate, in the case of the 
CNS [39]. Despite the above, in the last decade, a substantial body of studies has 
proposed that hemichannels may underpin pivotal neurophysiological functions, 
such as synaptic efficacy, neural activity, signal processing, cognition, and behavior 
[27, 28, 40–44].
3.  Astroglial hemichannels and their role in synaptic transmission and 
plasticity
Although rat, mouse, and human astrocytes express abundantly Cx30 and Cx43, 
as well as Cx26 [45–49], at the moment, Cx43 is the only connexin probed to form 
functional hemichannels in astrocytes [50]. The opening of astroglial Cx43 hemi-
channels has been linked with the release of different gliotransmitters (e.g., gluta-
mate, ATP, D-serine, lactate), as well as with the influx of extracellular Ca2+ and 
glucose. Seminal studies by Torres and colleagues demonstrated for the first time 
that astrocyte hemichannels may act as both sensors and modulators of synaptic 
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activity [43]. Using UV-photolysis of caged MNI-glutamate in hippocampal slices, 
they found that specific deletion of Cx43 abrogates ATP-dependent spreading of 
slow Ca2+ waves among astrocytes. Furthermore, these slow Ca2+ waves were poten-
tiated when authors used slices from transgenic mice with an astrocyte-targeted 
point mutation (Cx43G138R) that leads to an increased Cx43 hemichannel opening 
[51]. In addition, they observed that depolarization of inhibitory interneurons from 
the stratum radiatum reduced CA1 excitatory transmission via the astroglial Cx43 
hemichannel-mediated release of ATP and subsequent stimulation of interneuronal 
P2Y1 receptors [43]. These data shed light for the first time about how astrocyte 
Cx43 hemichannels may underpin a negative feedback mechanism elicited during 
sustained excitation to prevent excitotoxicity (Figure 2).
Although in normal astrocytes few Cx43 hemichannels are in the plasma mem-
brane and most of them with a low open probability, recent findings have described 
that they facilitate the release of ATP under basal conditions [27, 41]. Chever and 
co-workers observed that basal release of ATP via astroglial Cx43 hemichannels is 
enough to boost the CA1 synaptic transmission triggered by stimulation of Schaffer 
collaterals, an effect mediated by purinergic receptors [27] (Figure 2). Likely the 
insertion of postsynaptic AMPA receptors as a result of the activation of P2X7 
receptors could explain the ATP-dependent potentiation of glutamatergic transmis-
sion, as reported before in other brain areas [52]. Astroglial hemichannels also have 
been found to regulate neuronal activity in the olfactory bulb (OB) [41]. There, the 
group of Giaume demonstrated that pharmacological inhibition of Cx43 hemichan-
nels decreased the firing and amplitude of depolarized states in mitral cells. Similar 
findings were observed in mitral cells of OB slices with specific astroglial deletion of 
Cx43 [41] or in slices treated with A1 adenosine receptor antagonists. These findings 
denote that likely astrocyte Cx43 hemichannels enhance the amplitude of depolar-
ized states of mitral cells through the release of ATP and its further breakdown to 
Figure 2. 
Possible role of astroglial hemichannels in hippocampal synaptic transmission. During the basal firing of 
glutamatergic neurons in the hippocampus, Ca2+ influx into neurons results in a localized reduction in [Ca2+]e, 
which in turn opens Cx43 hemichannels (HCs) on astrocytes [43]. The latter lead to the release of ATP, being 
this crucial for sustaining basal excitatory synaptic transmission [27]. Likely this phenomenon takes place 
via the activation of P2X7 receptors and further insertion of AMPA receptors in postsynaptic terminals [52]. 
Alternatively, the conversion of ATP to ADP could depolarize and augment firing in interneurons via P2Y1 
receptors, therefore, enhancing inhibitory transmission [43].
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adenosine (Figure 3). Usually, A1 receptors induce the presynaptic inhibition of 
glutamate release, reduced postsynaptic NMDAR activation, and decreased Ca2+ 
influx [53]. Therefore, it is possible that the adenosine-mediated enhancement of 
depolarized states is due to the suppression of inhibitory juxtaglomerular interneu-
rons, as occurred in other brain areas [54] (Figure 3).
Astroglial Cx43 hemichannels have been involved not only in synaptic function 
and transmission but also in synaptic plasticity. High-frequency stimulation (HFS) 
Figure 3. 
Implications of astroglial hemichannel activity in neuronal oscillations of the olfactory bulb. Spontaneous 
neuronal activity in the glomerular layer of the olfactory bulb requires glutamatergic transmission. In this 
scenario, astrocytes display a basal release of ATP via Cx43 hemichannels (HCs) [41]. The adenosine derived 
from ATP may reduce the activity of GABAergic inhibitory juxtaglomerular neurons through the stimulation 
of A1 adenosine receptors. This permits the basal slow oscillations of up and down states of mitral cells in the 
olfactory bulb.
Figure 4. 
Astroglial hemichannels and their impact on synaptic plasticity in the prefrontal cortex. In the prefrontal 
cortex, continuous stimulation of layer 2/3 neurons induces long-term potentiation (LTP) of NMDA and 
AMPA receptor currents in layer 5 pyramidal neurons. In this context, [Ca2+]i is needed for the opening of 
Cx43 hemichannels (HCs) in astrocytes [28], which cause release of D-serine. This gliotransmitter facilitates 
LTP of NMDA and AMPA excitatory synaptic currents mediated by high-frequency stimulation.
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Astroglial hemichannels and their impact on synaptic plasticity in the prefrontal cortex. In the prefrontal 
cortex, continuous stimulation of layer 2/3 neurons induces long-term potentiation (LTP) of NMDA and 
AMPA receptor currents in layer 5 pyramidal neurons. In this context, [Ca2+]i is needed for the opening of 
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of neuronal layer 2/3 (L2/3) triggers glutamatergic synaptic transmission in pyra-
midal cells at layer 5 (L5) of the prefrontal cortex (PFC) [55]. In this context and 
using PFC slices, Meunier and colleagues observed that genetic ablation of Cx43 
or inhibition of Cx43 hemichannels strongly counteracts the NMDAR-dependent 
excitatory postsynaptic currents (EPSCs) and increases AMPA/NMDA current 
ratio induced by HSF in L5 [28]. Relevantly, the latter responses did not occur when 
D-serine was added at the recording media, revealing that the release of D-serine 
and astroglial hemichannel function are linked and modulate NMDAR-dependent 
synaptic transmission in PFC pyramidal cells. Furthermore, when [Ca2+]i was 
clamped or D-serine production was inhibited in the L5 astroglial network, HFS 
failed to potentiate the NMDAR-dependent synaptic currents [28] (Figure 4). 
Accordingly, the authors hypothesized that potentiation of glutamatergic transmis-
sion at the PFC relies on [Ca2+]i-mediated opening of astroglial Cx43 hemichannels 
and the further release of D-serine (Figure 4).
The impact of astroglial hemichannels on synaptic transmission and plastic-
ity has a subsequent echo on higher brain function and behavior. Indeed, in vivo 
inhibition of Cx43 hemichannels at the basolateral amygdala causes transitory and 
specific amnesia for auditory fear conditioning [42]. Remarkably, learning capacity 
was restored by the co-administration of a cocktail of supposed gliotransmitters 
(lactate, glutamate, D-serine, glutamine, glycine, and ATP), evidencing for the first 
time a physiological involvement for astroglial Cx43 hemichannels in higher brain 
function. In the same line, a recent study found that intraventricular administration 
of Gap19, a specific Cx43 hemichannel blocker [56], significantly impairs the spatial 
short-term memory, as assayed with the delayed spontaneous alternation Y maze 
task [44].
4. Conclusions
The impact of functional astroglial hemichannels in synaptic transmission and 
plasticity may depend on the number of channels available in the plasma mem-
brane, their open probability, and their conductance and/or selectivity. Of particu-
lar relevance is to disentangle how synaptic function is modulated by regulations in 
gating properties of astroglial hemichannels, as well as changes in their trafficking 
or de novo synthesis. Elucidating the latter will allow us to understand whether 
hemichannel opening in astrocytes tunes the temporal outcome for sculpting either 
short-term (milliseconds to a few minutes) or long-term (minutes to hours) plastic-
ity in the nervous system. One point of concern is the urgent need of developing 
new molecular and pharmacological tools to specifically dissect the contribution 
of astroglial hemichannels to the function of neural networks without affecting 
other hemichannel-forming proteins in other brain cells (e.g., microglia, oligo-
dendrocytes, and endothelial cells). Finally, although growing evidence in ex vivo 
preparations has extended our knowledge about the role of astroglial hemichannels 
in gliotransmission, additional data are necessary to demonstrate whether this truly 
occurs in vivo.
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Astrocytic S100B, Blood-Brain 
Barrier and Neurodegenerative 
Diseases
Anuradha Krishnan, Hao Wu and Venkat Venkataraman
Abstract
Increased life span and expectations of a better quality of life have resulted in 
a spotlight on neurodegenerative and cardiovascular diseases generally associated 
with aging. The drive toward evidence-based medicine has necessitated a constant 
search for objective biomarkers to assay disease onset, progress, and outcomes 
to make the best clinical decisions. Enhancement of their use depends on the 
mechanistic understanding of the biomarker’s role in the disease process itself. This 
chapter focuses on S100B. It is a calcium sensor protein that is primarily astrocytic. 
While it plays a complex, interlinked role in signaling, serum levels of S100B as a 
biomarker for clinical decisions is also an area of intense investigation. Both aspects 
are presented, with an emphasis on the role of S100B in in maintaining a blood-
brain barrier, especially in the context of suggesting a unified mechanism for the 
onset and progression of neurodegenerative diseases.
Keywords: S100B, calcium, blood-brain barrier, biomarker, neurodegeneration,  
tight junctions
1. Introduction
Rudolph Virchow first proposed the concept of neuroglia as a component of the 
connective tissue of the brain “nervekitt” [1]. The term “astrocyte” is attributed 
to Michael von Lenhosseck, coined to denote the stellate (star-like) morphology, 
with independent contributions also by Kolliker and Anderiezen (reviewed in [2]). 
The diversity of this group of cells was brought into clear focus by the excellent 
drawings by Cajal [3]. Glial cells, including astrocytes, were once believed to be 
limited to passive support in the functioning of the brain. Work over the last few 
decades has ushered in the understanding that they actively participate in normal 
metabolism and physiology of the brain, even more so during injury response and 
repair. They alter the microenvironment through secretion of a variety of signals 
including cytokines as a result of intracellular process collectively termed “activa-
tion,” which operates at both ends of time scale—acute and short-term (trauma) 
as well as chronic and long-term (neurodegenerative diseases). While meant to be 
adaptive and reparative, they could also lead to exacerbation of injury or disease 
(for some reviews, please see [4–12]). Understanding the process of activation and 
its effect on the microenvironment is fundamental to devising positive interven-
tions. One of the important signaling molecules involved in this process is S100B, 
a calcium sensor protein, which is secreted to act at the extracellular level but also 
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functions intracellularly (reviewed in [13–15]). While primarily astrocytic, it is 
expressed in other glial cells, non-neuronal cells, and is also detected in the serum. 
In this chapter, the role for S100B in the neurovascular unit (NVU)—important for 
the blood-brain barrier (BBB)—is discussed. A summary of conditions in which the 
serum S100B levels are proposed to be of values as a biomarker provides the back-
drop. Based on the findings, a mechanism that places the NVU, with a central role 
of S100B, at the heart of neurodegenerative diseases is suggested.
2. S100B: the protein
S100B, an astrocytic protein, was originally obtained from the bovine brain [16], 
as a mixture with S100A1—the fraction was termed “S100” due to partial solubility 
in 100% saturated ammonium sulfate solution [16], reviewed in [15]. Over 50 years 
after the identification of S100B, the S100 family now includes more than 20 genes 
paralogous to S100B, with functions in healthy as well as diseased states [17]. The 
S100 proteins exist mostly as dimers—homodimers or heterodimers—and share 
common structural motifs such as the Ca-binding EF hand.
S100B is a homodimer of a 92-amino acid protein, termed S100b, with a molecu-
lar mass of 10,713 Da, but migrates between 9 and 14 kDa on SDS-polyacrylamide 
gels. Crystal structures and refined NMR structures [18, 19] reveal that the mono-
mer contains two EF-hands—one non-canonical and one conventional—that bind 
calcium; the dimer is in antiparallel orientation. Upon binding calcium, the mol-
ecule switches to a more open conformation with hydrophobic patches exposed to 
facilitate interaction with other molecules. However, these conformational changes 
are unlike other more conventional EF-containing proteins and are unique for 
S100B protein—experimentally supported through calcium-induced mobility shift 
assays [20]. Thus, the S100B protein is specialized to sense changes in calcium levels 
and mediate appropriate responses, especially in the nervous system.
Expression of S100B in the nervous system is primarily in the glial cells—astro-
cytes in the central nervous system and Schwann cells in the peripheral nervous sys-
tem, where they carry out intracellular as well as extracellular functions [reviewed 
in [14, 15]]. Since these functions are relevant to both healthy and diseased states 
and S100B is detectable in serum, specifically humans, a focused effort has been 
underway to determine if S100B could serve as a biomarker.
3. S100B: the biomarker
Biological marker (biomarker) is defined as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathological 
processes or pharmacological responses to a therapeutic intervention” (Biomarker 
Definitions Working Group). An optimal biomarker is ideally measurable easily, 
quantitatively related to the extent of the condition, yields reproducible results, and 
provides guidance regarding outcomes/clinical decisions [21]. The quest for a bio-
marker may pass through several avenues that include imaging, functional imaging, 
microRNAs, and microarrays. Even as these journeys have increased the knowledge 
base, they have also highlighted the complexity of the process. Typically, however, 
biomarker levels in body fluids—blood, cerebrospinal fluid, saliva, or urine—are 
more common.
A summary of current information on the correlation of serum S100B levels to 
different conditions is provided in Table 1.
17






 Moderate [23–26] Not a reliable predictor of 
good vs. bad outcome
 Severe [24] Useful to predict if 
the patient will regain 
consciousness 3–6 min 
after injury, in addition to 
predicting the outcome
 Children [27, 28] Normal serum levels are 
higher than in adults. Cannot 
be used as a predictor of 






 Non-traumatic intracerebral hemorrhage [30, 31]
 Stroke (ischemic and hemorrhagic) [32, 33]
Heart-related
 Cardiopulmonary bypass surgery [34] Meta-analyses
 Congestive heart failure [35] Further increase if 
accompanied by renal 
insufficiency
 Dilated cardiomyopathy [36]
Skeleton-related
 Orthopedic trauma [37]
 Hip arthroplasty [38]
Cancer-related
 Brain metastases of lung cancer [39]
 Estrogen receptor-positive breast cancer [40] Elevated levels indicate poor 
disease-free survival
 Malignant melanoma [41–44] Elevated levels indicate poor 
disease outcome
Neonates-related
 Congenital heart disease [45] Levels dropped to normal 7 
days post-operative
 Intraventricular hemorrhage, intrauterine 
growth restrictions, perinatal asphyxia
[21]
 Hypoxic ischemic encephalopathy [46]
Other diseases
 Epilepsy [47, 48]
 Delirium [49, 50]
 Neuromyelitis optica (AQP4+ve) [51]
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 Congestive heart failure [35] Further increase if 
accompanied by renal 
insufficiency
 Dilated cardiomyopathy [36]
Skeleton-related
 Orthopedic trauma [37]
 Hip arthroplasty [38]
Cancer-related
 Brain metastases of lung cancer [39]
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[21]
 Hypoxic ischemic encephalopathy [46]
Other diseases
 Epilepsy [47, 48]
 Delirium [49, 50]
 Neuromyelitis optica (AQP4+ve) [51]
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In all of the conditions above, serum S100B levels are elevated. It is noted that 
there are some sporadic reports of decreased levels, particularly in the case of 
diabetes and anorexia nervosa [58, 59].
The diverse nature of the pathologies with which elevated serum S100B levels 
are associated, coupled with the lack of functional correlation, has made mecha-
nistic explanations difficult to say the least. While S100B is currently known to be 
expressed in multiple tissues, the primary source of serum S100B is believed to be 
of astrocytic origin [60, 61]. Therefore, for S100B levels in serum to be elevated, 
astrocytic S100B must be able to reach the blood, which would not normally happen 
due to the presence of the blood-brain barrier (BBB).
The BBB comprises the physiological and functional barrier that separates the 
nervous system from the circulatory system [62, 63] and its breakdown allows for 
the leakage of damaging humoral elements into the brain parenchyma [63–67].
4. S100B and blood-brain barrier (BBB)
4.1 BBB and neurodegenerative diseases
The BBB is mainly formed by a monolayer of brain vascular endothelial cells 
(BVECs) that are sealed by tight junctions (TJs) [reviewed in [68–70]]. It actively 
regulates transportation of metabolic wastes and nutrients, such as ions, glucose, 
and amino acids, between blood and brain interstitial fluid (ISF) [reviewed in 
[69]]. On the other hand, other plasma components such as immunoglobulins and 
cells such as leukocytes are restricted. Thus, the BBB enables neurons and support-
ing cells to receive nutrients and remove wastes. In addition, they provide protec-
tion from the immune system. The concept of the neurovascular unit (NVU), to 
maintain the function of the BBB in health and underlie its response during disease, 
has been proposed [71–74].
Impaired function of the BBB has been linked to a variety of pathological 
conditions that affect the brain [reviewed in [62, 63, 67, 75]]. These include epi-
lepsy [reviewed in [76]], psychiatric diseases such as neuropsychiatric lupus [77], 
dementias such as Parkinson’s disease [78–80], Alzheimer’s disease (AD) [81–86], 
other neurodegenerative diseases such as Huntington’s disease [87], amyotrophic 
lateral sclerosis [88, 89], multiple sclerosis [90, 91], and those caused by viral 
infections [92–94]. The compromise of the BBB has been tightly linked causally or 
as a diagnostic marker to chronic neurodegenerative diseases such as AD [95–97] 
and acute conditions such as delirium [98]. Yet, the causes and consequences of the 
BBB breach in those diseases remain elusive. Work carried out in this laboratory has 




 Obstructive sleep apnea [53]
 Proliferative diabetic retinopathy [54]
 Schizophrenia [55, 56]
 Systemic lupus erythematous [57]
Table 1. 
Conditions with elevated serum S100B levels.
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4.2 S100B is essential to maintain BBB
The detection of leaked serum components, such as IgG, has been widely used to 
assess impairment of BBB function [64]. In a study from this laboratory by Wu and 
coworkers [66], vascular leaks in the brain were evaluated by immunostaining brain 
sections from S100BKO mice to detect extravascular IgG. Previous studies have 
shown that intravenous injection of pertussis toxin [PT] generates leaks in the BBB 
[64, 99]. Therefore, wild type and S100BKO mice were injected with PT and the 
effect on BBB permeability was investigated.
Extravasated IgG from the blood vessels was detected as perivascular leakage 
clouds marking sites of BBB breach. In wild-type mice, leak clouds were detected only 
upon injection of PT; in the S100BKO mice, however, they were detected even without 
PT injection by 6 months of age and were exacerbated by PT injection. Thus, there is 
an endogenous BBB deficiency in S100BKO mice, which is increased by treatment with 
PT. The BBB breach was chronic and age-dependent, increasing with age [66]. Thus, 
the system mimics the chronic, age-associated compromise of BBB in humans. In addi-
tion, selective binding of neurons by IgG was also temporally and spatially associated 
with these leak clouds, suggesting that neuron-binding autoantibodies are present and 
BBB compromise allows their access to neurons in the brain; an increase in the brain-
reactive autoantibodies was also associated with increased BBB breach [66].
Interestingly, despite detectable pathology, there was very little glial response 
as measured by increased expression of glial fibrillary acidic protein (GFAP) [66]. 
Is it possible that S100B is necessary to trigger the astroglial response to neuronal 
injury/insult? The question remains to be answered.
The potential reason for the BBB breach, however, could be identified: Based 
on electron microscopic analyses, disorganization of endothelial tight junctions is 
proposed to cause the observed BBB breach [66].
4.3 S100B is essential to maintain blood-retinal barrier (BRB)
Tight junctions are also important for the maintenance of the blood-retinal barrier 
(BRB). The existence of blood-retinal barrier (BRB) is well established [100–104], 
although its similarity to the BBB remains to be completely elucidated [105, 106] and 
its establishment, less understood [107]. If S100B was essential for the maintenance 
of tight junctions in vascular endothelial cells and lack of it caused BBB breach, would 
similar breaches be observed BRB also? The results presented below show that this is, 
indeed, the case.
In untreated wild-type mice (Figure 1A), staining for IgG was restricted to within 
blood vessels, which indicates an intact barrier. In PT-injected wild-type mice, IgG 
extravasated from the blood vessels. However, the perivascular leakage clouds were 
not obvious while the IgG-bound ganglion cells were detected (indicated by arrows 
in Figure 1B). The results suggest that neuron-binding autoantibodies are present 
and BRB compromise allows their access to neurons in the retina. Leak clouds outside 
the blood vessels were observed in S100BKO mice in the absence of PT (Figure 1C). 
Upon PT injection of S100BKO mice, the perivascular leak clouds persist (Figure 1D). 
Thus, an endogenous BRB deficiency in S100BKO mice was observed. The presence of 
retina-specific autoantibodies was confirmed independently by Western blot analyses 
(Figure 1E). The result shows that their appearance is age-dependent, as in the BBB.
Thus, the effect of S100B deprivation leads to chronic barrier disruption in both 
brain and retina through disruption of the endothelial tight junctions, most likely. 
The details of the mechanistic aspects of the action of S100B on tight junction 
maintenance remain to be established: both intracellular and extracellular routes are 
possible [14]. An intracellular mechanism is supported by observations that S100B is 
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The detection of leaked serum components, such as IgG, has been widely used to 
assess impairment of BBB function [64]. In a study from this laboratory by Wu and 
coworkers [66], vascular leaks in the brain were evaluated by immunostaining brain 
sections from S100BKO mice to detect extravascular IgG. Previous studies have 
shown that intravenous injection of pertussis toxin [PT] generates leaks in the BBB 
[64, 99]. Therefore, wild type and S100BKO mice were injected with PT and the 
effect on BBB permeability was investigated.
Extravasated IgG from the blood vessels was detected as perivascular leakage 
clouds marking sites of BBB breach. In wild-type mice, leak clouds were detected only 
upon injection of PT; in the S100BKO mice, however, they were detected even without 
PT injection by 6 months of age and were exacerbated by PT injection. Thus, there is 
an endogenous BBB deficiency in S100BKO mice, which is increased by treatment with 
PT. The BBB breach was chronic and age-dependent, increasing with age [66]. Thus, 
the system mimics the chronic, age-associated compromise of BBB in humans. In addi-
tion, selective binding of neurons by IgG was also temporally and spatially associated 
with these leak clouds, suggesting that neuron-binding autoantibodies are present and 
BBB compromise allows their access to neurons in the brain; an increase in the brain-
reactive autoantibodies was also associated with increased BBB breach [66].
Interestingly, despite detectable pathology, there was very little glial response 
as measured by increased expression of glial fibrillary acidic protein (GFAP) [66]. 
Is it possible that S100B is necessary to trigger the astroglial response to neuronal 
injury/insult? The question remains to be answered.
The potential reason for the BBB breach, however, could be identified: Based 
on electron microscopic analyses, disorganization of endothelial tight junctions is 
proposed to cause the observed BBB breach [66].
4.3 S100B is essential to maintain blood-retinal barrier (BRB)
Tight junctions are also important for the maintenance of the blood-retinal barrier 
(BRB). The existence of blood-retinal barrier (BRB) is well established [100–104], 
although its similarity to the BBB remains to be completely elucidated [105, 106] and 
its establishment, less understood [107]. If S100B was essential for the maintenance 
of tight junctions in vascular endothelial cells and lack of it caused BBB breach, would 
similar breaches be observed BRB also? The results presented below show that this is, 
indeed, the case.
In untreated wild-type mice (Figure 1A), staining for IgG was restricted to within 
blood vessels, which indicates an intact barrier. In PT-injected wild-type mice, IgG 
extravasated from the blood vessels. However, the perivascular leakage clouds were 
not obvious while the IgG-bound ganglion cells were detected (indicated by arrows 
in Figure 1B). The results suggest that neuron-binding autoantibodies are present 
and BRB compromise allows their access to neurons in the retina. Leak clouds outside 
the blood vessels were observed in S100BKO mice in the absence of PT (Figure 1C). 
Upon PT injection of S100BKO mice, the perivascular leak clouds persist (Figure 1D). 
Thus, an endogenous BRB deficiency in S100BKO mice was observed. The presence of 
retina-specific autoantibodies was confirmed independently by Western blot analyses 
(Figure 1E). The result shows that their appearance is age-dependent, as in the BBB.
Thus, the effect of S100B deprivation leads to chronic barrier disruption in both 
brain and retina through disruption of the endothelial tight junctions, most likely. 
The details of the mechanistic aspects of the action of S100B on tight junction 
maintenance remain to be established: both intracellular and extracellular routes are 
possible [14]. An intracellular mechanism is supported by observations that S100B is 
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expressed in endothelial cells [108, 109]; furthermore, assembling and maintaining 
functional tight junctions is dependent upon several signaling pathways [reviewed in 
[110–112]], all of which are known to be influenced by S100B: calcium homeostasis 
[13, 14, 113], guanylate cyclase activation [114, 115], modulation of rhoGTPases such 
as Rac1 [116] and protein kinase C activity [108]. Extracellularly, S100B, most likely, 
acts through the receptor for advanced glycation end products (RAGE) expressed on 
endothelial cells [117] and results in the activation of the Ras-ERK1/2-NF-κB pathway 
[reviewed in [14]]. This pathway regulates endothelial hyperpermeability [reviewed 
in [111]], particularly the assembly of TJ proteins [118]. Moreover, the expression of 
NF-κB itself is regulated by S100B [119, 120]. Additional receptors for S100B, such as 
CD166/ALCAM and Toll-Like Receptors (TLR), are also known. Therefore, extracel-
lular S100B may also be critical for endothelial function in maintaining the BBB.
5. Blood-brain barrier (BBB) and neurodegenerative diseases
5.1 Autoantibodies and neurodegenerative diseases
The BBB breach allows autoantibodies in the blood vessels to gain access to neu-
rons and other cell types, causing compromise in function and, in extreme cases, 
cell death. The breach itself could be generated over time through age or disorders 
or acutely through traumatic injuries. Debris released from sick or dead cells would 
now be encountered by the immune system, which would mount an antibody 
response, generating autoantibodies. This results in a potentially devastating feed-
back loop: the autoantibodies cause compromise of cells, releasing debris, which, in 
turn, augments the response. The only way to halt this cycle will be through the loss 
of the targeted antigens: either through endocytosis or receptor stripping. Typically, 
that would also lead to dysfunctions in neurons and other cells [121, 122].
This “positive feedback loop” hypothesis is suggested by a decreased expression of 
MAP2, shown to be indicative of neuronal stress [123, 124], in both in vivo [66] and in 
vitro model systems of BBB [125] or BRB [126] breach. Previous studies have also shown 
a widespread presence of brain-reactive autoantibodies in human serum [127] and 
changing autoantibody profiles upon disease [96, 122, 128–130]. Much evidence now 
Figure 1. 
S100BKO mice demonstrate significant BRB compromise in the retina and express retina-specific 
autoantibodies. Overlay of IgG immunostaining (red) with DAPI (blue) is presented from the retinal sections 
of untreated wild-type mice (A), PT-treated WT mice (B), S100BKO mice (C), and S100BKO mice treated 
with PT (D). Scale bar, 20 μm. Western blots (E) of the swine retinal protein extract were probed with pooled 
sera from wild-type mice (WT) or from S100BKO mice at 3 (3 Mon), 6 (6 Mon), or 9 (9 Mon) months of age. 
A representative result is shown. Molecular size markers are indicated alongside.
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suggests that BBB breakdown also contributes to acute dysfunctions such as post-opera-
tive delirium and recovery from anesthesia [131, 132]. An increase in BBB permeability, 
like in S100BKO mice reported here, has been observed previously in humans with age 
[82] and with many chronic dysfunctions Table 1. Therefore, the S100BKO mouse may 
serve as a useful model to mimic the status of the aged BBB. It is well documented that 
the elderly population is highly susceptible to neurodegenerative diseases and delirium.
Increased levels of autoimmune antibodies (generally associated with increased 
BBB permeability) have been reported in several diseases (reviewed in [129–134]). 
A positive correlation between autoantibody prevalence and age/diseased state has 
propelled the idea that they are potential diagnostic tools in AD and Parkinson’s 
disease [122, 129–136].
5.2 Toward a unified mechanism
A clear understanding of the structural components and functions of the BBB 
may be the key to delineating pathologies of the brain. Here, we propose the idea 
that neurodegeneration is a multi-step process (Figure 2) involving BBB breach, 
Figure 2. 
Blood-brain barrier breach, autoantibodies and neurodegeneration. A unified mechanism is proposed 
for neurodegenerative diseases. Early changes include changes in the NVU, serum, and other insults on the 
BBB. Once the BBB is breached, it leads to the extravasation of serum components and access/production of 
brain-reactive auto antibodies. This results in a positive feedback loop, altering homeostasis and eventually 
resulting in the disease phenotype through neuronal injury/death.
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infiltration of auto antibodies and other damaging plasma components into the brain 
parenchyma with death of the neurons as the long-term sequelae. Multiple studies 
indicate that the BBB is very important to the brain health, neuronal integrity, and 
homeostasis; when BBB breach occurs, it allows for the extravasation of blood-borne 
molecules (such as Aβ42 in AD), brain-reactive antibodies, and inflammatory factors 
into the normally immune-privileged brain parenchyma [127, 137–139]. Access of 
the previously excluded and potentially damaging blood-borne plasma elements to 
the brain interstitium results in disruption of brain homeostasis, impaired neuronal 
function, and eventually, neuronal loss [64, 134, 140, 141]. Furthermore, injury or 
disease of the central nervous system (CNS), such as AD, causes gliosis, which is 
characterized by the activation of astrocytes, microglia, and other cell types.
Insults to the BBB can be brought about by several pathological conditions and 
result in the compromise of this protective layer. Studies from our lab show that 
the inner blood-retinal barrier (BRB) is very similar to the BBB and can be used 
as a model system to study BBB [126]. The use of brain-reactive autoantibodies to 
diagnose neurodegenerative diseases with a high degree of confidence has also been 
reported [122, 135, 136, 142–145].
Taken together, investigations into the BBB maintenance will yield rich divi-
dends toward the mechanistic understanding that may underlie multiple neuro-
degenerative diseases, increased diagnostic tools in terms of model systems and 
biomarkers and, perhaps, also drug delivery options. Delineation of S100B signal-
ing pathways is likely to contribute significantly toward this end.
6. Conclusions
S100B, primarily astrocytic in origin, is a unique signaling molecule that 
impacts multiple signaling pathways—sometimes negatively, sometimes positively 
[15, 146]. The dual nature of action—intra- and extracellular—poses a significant 
challenge in delineating the precise mechanism of action in many instances. Yet, 
S100B is emerging as a central molecule (Figure 3) in regulating normal and 
Figure 3. 
A central role for S100B, an astrocytic protein. The figure depicts the multiple cell-types contributing to an intact 
BBB that form the NVU. By virtue of being an extracellular signal as well as being expressed intracellularly, 
S100B is proposed to play a central role in maintaining BBB and serve as a marker for neurodegeneration.
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disease processes—especially where astrocytes/glial cells are involved—the enteric 
glial cells being a recent and exciting example [147]. It is hoped that a fundamental 
mechanistic understanding would enable decipher the process, refine the clinical 
relevance biomarker, and carry the laboratory bench knowledge to the patient 
bedside to improve quality of life and clinical interventions.
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Abstract
The enteric nervous system (ENS), also known as second brain, innervates our 
gastrointestinal tract controlling its functions, such as motility, fluid secretion, 
nutrient absorption, and even involvement in the control of immunity and inflam-
matory processes. In the gut, the gliocytes are known as enteric glial cells (EGCs). 
Enteric glial cells form a network that permeates the entire gut. Enteric glia express 
the cell surface hemichannel of connexin-43 (Cx43) necessary for the propagation 
of Ca2 + responses, necessary to maintain their functions. In this chapter, besides 
the development of ENS and its glial cells and the similarities with the astrocytes in 
the central nervous system, we approached the important role of the glial network 
in the control of gut homeostasis, in the interaction with the immune system, and 
its participation in pathological conditions. EGCs are even capable of replacing lost 
neurons. Thus the enteric glia is a multifunctional cell, which through its multiple 
interactions maintains the integrity of the ENS allowing it to be resistant to the 
different and constant aggressions suffered by the digestive system.
Keywords: enteric glial cells, glial network, gut homeostasis, gut inflammation, 
enteric neurodegeneration
1. Introduction
The enteric nervous system (ENS), also known as second brain, innervates our 
gastrointestinal tract from the esophagus to the rectum including the pancreas and 
gallbladder, controlling its functions. The ENS develops from the neural crest cells 
(NCCs). At the vagal (at the level of somites 1–7) and sacral (posterior to somite 
28) regions of the anteroposterior axis, some of NCCs, the enteric neural crest 
cells (ENCCs), enter the rudimental digestive system, proliferate, and migrate to 
colonize the primitive gut [1].
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The differentiation of enteric neurons starts prior to the enteric glial cells 
(EGCs). Behind the migratory wavefront, the first neurons arise at E10–E10.5 in 
the foregut level. Genes of multipotent ENCCs, such as Sox10, FoxD3, and P75, 
are downregulated, and cells begin to express specific neuronal markers, such as 
βIIItubulin, RET, HuC/D, and peripherin. Subsequently, at E11.5, the glial dif-
ferentiation takes place, and the ENCCs downregulate RET expression, while 
markers such as Sox10, FoxD3, and P75 continue to be expressed. Additionally, 
other genes that are known to be specifically expressed in EGCs appear, including 
S100B, glial fibrillary acidic protein (GFAP), and proteolipid protein 1 (PLP1). The 
development of the mature ENS network is not complete at birth, and the neuronal 
differentiation is extended to up to 2 weeks after birth (for a detailed description of 
enteric neurons and glial cells development, [1]).
Initially, ENCCs migrate as intersections of narrow chains of cells. Later on, as devel-
opment progresses further, these cells aggregate into numerous ganglia that are con-
nected by neuronal projections and EGCs (Figure 1). The role of bone morphogenetic 
proteins (BMPs)-2 and (BMPs)-4 in the neural cell adhesion molecule (NCAM) regula-
tion that are differentially expressed by the cells to form these ganglion-like aggregates 
is already known [2–6]. The growth factor endothelin3 (EDN3) is important to keep 
ENS progenitors cells in a proliferative state. It inhibits reversibly the commitment and 
differentiation of these cells, and in this way it is involved in the correct migration of 
enteric neural crest cells to colonize the gut [4]. Lack of EDN3 leads to aganglionosis 
of the distal bowel [5]. It is well known that thyroid hormone 3,5,3′-triiodothyronine 
(T3) plays an important role in CNS development, and also appears to play a role in the 
development of the ENS. In vitro, T3 inhibits cell proliferation and stimulated neurite 
growth of differentiating murine enteric neural crest cells [6]. But, interestingly, this 
work also showed that spheres of neonate mice ENS progenitor cells increased EDN3 
expression by more than 3-fold after T3 treatment, demonstrating a likely crosstalk 
between these signalling pathways [6]. In the adult mammalian, the ENS is organized 
into the myenteric and submucosal ganglionated plexuses composed of neurons and 
EGCs and non-ganglionated plexuses, composed of EGCs that tightly follow neuronal 
projections that reach all regions of the intestines, including the mucosa. The myenteric 
plexus (or Auerbach’s plexus) is located between the outer longitudinal and circular 
muscle layers, and the submucosal plexus (or Meissner’s plexus) lies in the submucosal 
region (between the mucosa and the muscular layers) [1].
Figure 1. 
(A) Transverse section of mouse embryo gut at embryonic day (E)14.5 stained for the glial marker P75. The 
cells are not yet organized in ganglia. (B) Longitudinal muscle with the adherent myenteric plexus (LMMP) of 
adult mouse colon. The enteric glial network is evidenced by GFAP staining. Scale bars: 50 μm.
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EGCs are distributed across all layers of the intestine and are currently clas-
sified into four different subtypes based on their location and morphology. 
Intraganglionic EGCs (type I) present numerous short and irregular processes 
and resemble the protoplasmic astrocytes of the central nervous system (CNS); 
the interganglionic EGCs surround neuronal projections that connect multiple 
ganglia (type II); the mucosal EGCs (type III) are found around neuronal projec-
tions located in the mucosal region and present long and branched processes; and 
intramuscular EGCs (type IV) are bipolar and elongated and accompany the nerve 
fibers that cross the muscle layers [7, 8]. In fact, their wide distribution reflects on 
their performance in different physiological aspects of the gastrointestinal (GI) 
tract. Indeed, EGCs were shown to participate in the homeostasis of the intestinal 
epithelial barrier (IEB), to coordinate the GI motility taking part in neurotransmis-
sion, and also to modulate inflammation and immune responses.
2.  Enteric glia: a unique glial cell type - similarities and differences with 
astrocytes
In the first studies about enteric glia, the ultrastructure of the glial cell of myen-
teric plexus was described as a small cell body with many processes. It was sug-
gested that the star-like morphology, as well as the anatomical relation to neurons, 
resembles astrocytes from the CNS rather than Schwann cells [9]. Jessen et al. [10] 
showed that intraganglionic EGCs express the characteristic marker of an astrocytic 
cell, glial fibrillary acidic protein (GFAP), corroborating the assumption that ENS 
glial cells are analogous to CNS astrocytes [11, 12], although they have different 
embryological origins.
EGCs and astrocytes exhibit molecular similarities in their electrophysiologi-
cal properties [13] and express the same group of proteins, including the GFAP 
[14], and the S100β-linked binding pathway [15]. However, not all properties of 
the EGCs are similar to astrocytes. They have different embryological origins, 
for example, astrocytes coming from neuroepithelium and EGCs from neural 
crest. During the embryonic stages, neuregulin signaling via the ErbB3 receptor is 
critical for the development of the EGCs, whereas astrocytes do not require such 
signaling [16]. Unlike astrocytes, EGCs do not express the protein of the aldehyde 
dehydrogenase 1 L1 (Aldh1L1) [8] but express the transcription factor Sox10 [17] 
and the protein PLP1, implicated in myelin production and most commonly found 
in oligodendrocytes and Schwann cells. In fact genic signature of EGCs seems to be 
more similar to that of oligodendrocytes and Schwann cells than to astrocytes [18].
Similar to astrocytes, EGCs interact with and modulate the performance of differ-
ent cell types, as we will see throughout this chapter. In addition to interacting with 
neurons, EGCs establish multidirectional communication with other cell types, such as 
intestinal mucosal epithelial, muscle, mesenchymal, and immune cells [19].
3.  Formation of the gut glial network and the communication through 
connexin-43 (Cx43) hemichannels
Yet during development, EGCs begin to form a network of interconnected cells 
that permeate the entire gut (Figure 1).
Gabella noted that a striking feature of EGC is the presence of numerous 
intramembrane particles on its surface [20], and a small part are gap junctions. 
These intramembrane particles are believed to be hemichannels. It has recently 
been found that, as astrocytes, enteric glial hemichannels are connexin-43 (Cx43) 
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The differentiation of enteric neurons starts prior to the enteric glial cells 
(EGCs). Behind the migratory wavefront, the first neurons arise at E10–E10.5 in 
the foregut level. Genes of multipotent ENCCs, such as Sox10, FoxD3, and P75, 
are downregulated, and cells begin to express specific neuronal markers, such as 
βIIItubulin, RET, HuC/D, and peripherin. Subsequently, at E11.5, the glial dif-
ferentiation takes place, and the ENCCs downregulate RET expression, while 
markers such as Sox10, FoxD3, and P75 continue to be expressed. Additionally, 
other genes that are known to be specifically expressed in EGCs appear, including 
S100B, glial fibrillary acidic protein (GFAP), and proteolipid protein 1 (PLP1). The 
development of the mature ENS network is not complete at birth, and the neuronal 
differentiation is extended to up to 2 weeks after birth (for a detailed description of 
enteric neurons and glial cells development, [1]).
Initially, ENCCs migrate as intersections of narrow chains of cells. Later on, as devel-
opment progresses further, these cells aggregate into numerous ganglia that are con-
nected by neuronal projections and EGCs (Figure 1). The role of bone morphogenetic 
proteins (BMPs)-2 and (BMPs)-4 in the neural cell adhesion molecule (NCAM) regula-
tion that are differentially expressed by the cells to form these ganglion-like aggregates 
is already known [2–6]. The growth factor endothelin3 (EDN3) is important to keep 
ENS progenitors cells in a proliferative state. It inhibits reversibly the commitment and 
differentiation of these cells, and in this way it is involved in the correct migration of 
enteric neural crest cells to colonize the gut [4]. Lack of EDN3 leads to aganglionosis 
of the distal bowel [5]. It is well known that thyroid hormone 3,5,3′-triiodothyronine 
(T3) plays an important role in CNS development, and also appears to play a role in the 
development of the ENS. In vitro, T3 inhibits cell proliferation and stimulated neurite 
growth of differentiating murine enteric neural crest cells [6]. But, interestingly, this 
work also showed that spheres of neonate mice ENS progenitor cells increased EDN3 
expression by more than 3-fold after T3 treatment, demonstrating a likely crosstalk 
between these signalling pathways [6]. In the adult mammalian, the ENS is organized 
into the myenteric and submucosal ganglionated plexuses composed of neurons and 
EGCs and non-ganglionated plexuses, composed of EGCs that tightly follow neuronal 
projections that reach all regions of the intestines, including the mucosa. The myenteric 
plexus (or Auerbach’s plexus) is located between the outer longitudinal and circular 
muscle layers, and the submucosal plexus (or Meissner’s plexus) lies in the submucosal 
region (between the mucosa and the muscular layers) [1].
Figure 1. 
(A) Transverse section of mouse embryo gut at embryonic day (E)14.5 stained for the glial marker P75. The 
cells are not yet organized in ganglia. (B) Longitudinal muscle with the adherent myenteric plexus (LMMP) of 
adult mouse colon. The enteric glial network is evidenced by GFAP staining. Scale bars: 50 μm.
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EGCs are distributed across all layers of the intestine and are currently clas-
sified into four different subtypes based on their location and morphology. 
Intraganglionic EGCs (type I) present numerous short and irregular processes 
and resemble the protoplasmic astrocytes of the central nervous system (CNS); 
the interganglionic EGCs surround neuronal projections that connect multiple 
ganglia (type II); the mucosal EGCs (type III) are found around neuronal projec-
tions located in the mucosal region and present long and branched processes; and 
intramuscular EGCs (type IV) are bipolar and elongated and accompany the nerve 
fibers that cross the muscle layers [7, 8]. In fact, their wide distribution reflects on 
their performance in different physiological aspects of the gastrointestinal (GI) 
tract. Indeed, EGCs were shown to participate in the homeostasis of the intestinal 
epithelial barrier (IEB), to coordinate the GI motility taking part in neurotransmis-
sion, and also to modulate inflammation and immune responses.
2.  Enteric glia: a unique glial cell type - similarities and differences with 
astrocytes
In the first studies about enteric glia, the ultrastructure of the glial cell of myen-
teric plexus was described as a small cell body with many processes. It was sug-
gested that the star-like morphology, as well as the anatomical relation to neurons, 
resembles astrocytes from the CNS rather than Schwann cells [9]. Jessen et al. [10] 
showed that intraganglionic EGCs express the characteristic marker of an astrocytic 
cell, glial fibrillary acidic protein (GFAP), corroborating the assumption that ENS 
glial cells are analogous to CNS astrocytes [11, 12], although they have different 
embryological origins.
EGCs and astrocytes exhibit molecular similarities in their electrophysiologi-
cal properties [13] and express the same group of proteins, including the GFAP 
[14], and the S100β-linked binding pathway [15]. However, not all properties of 
the EGCs are similar to astrocytes. They have different embryological origins, 
for example, astrocytes coming from neuroepithelium and EGCs from neural 
crest. During the embryonic stages, neuregulin signaling via the ErbB3 receptor is 
critical for the development of the EGCs, whereas astrocytes do not require such 
signaling [16]. Unlike astrocytes, EGCs do not express the protein of the aldehyde 
dehydrogenase 1 L1 (Aldh1L1) [8] but express the transcription factor Sox10 [17] 
and the protein PLP1, implicated in myelin production and most commonly found 
in oligodendrocytes and Schwann cells. In fact genic signature of EGCs seems to be 
more similar to that of oligodendrocytes and Schwann cells than to astrocytes [18].
Similar to astrocytes, EGCs interact with and modulate the performance of differ-
ent cell types, as we will see throughout this chapter. In addition to interacting with 
neurons, EGCs establish multidirectional communication with other cell types, such as 
intestinal mucosal epithelial, muscle, mesenchymal, and immune cells [19].
3.  Formation of the gut glial network and the communication through 
connexin-43 (Cx43) hemichannels
Yet during development, EGCs begin to form a network of interconnected cells 
that permeate the entire gut (Figure 1).
Gabella noted that a striking feature of EGC is the presence of numerous 
intramembrane particles on its surface [20], and a small part are gap junctions. 
These intramembrane particles are believed to be hemichannels. It has recently 
been found that, as astrocytes, enteric glial hemichannels are connexin-43 (Cx43) 
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compounds [21]. Cx43 hemichannels are Ca2+−permeable channels that are also 
controlled by Ca2+ [21].
Like astrocytes, activated EGCs have excitability mediated by transitory intra-
cellular Ca2+ elevations, considered central to many functions. Most of the enteric 
glial receptors for neuroactive compounds are G-protein-coupled receptors, and 
most of these leads to activation of downstream effectors that elevate intracellular 
Ca2+. As mentioned by Gulbransen in his book (2014, p. 28) [22], being able to 
detect the increase in Ca2+ levels was essential to establish that neuron-glial com-
munication occurs in ENS and to identify involved mediators. The study realized by 
McClain et al. [21] also showed the role of Cx43 hemichannels in the propagation 
of “calcium waves” through the enteric glia network and in the regulation of GI 
motility [21]. It was shown that glial “calcium waves” activated by extracellular 
ATP or ADP were disrupted by glial specific loss of Cx43 and result in aberrant ENS 
network activity and GI dysmotility.
Cx43 expression in EGCs is also related to inflammatory process. Neuronal loss 
is one of the intestinal inflammation characteristics caused by purinergic receptor 
activation [23]. Recently, inhibition or genetic ablation of Cx43 in EGCs prevented 
inflammation-induced neuronal death [24]. This is interesting because it shows that 
ATP released by EGCs, through Cx43 hemichannels, is involved in both inflamma-
tion and motility [21], as mentioned above.
It is possible that Cx43 expression in EGCs is also related to regulation of the 
intestinal epithelium barrier (IEB). Animals with ablated Cx43 in EGCs also 
exhibited an increased fluid content in stools [21]; this may imply a role of Cx43 in 
regulating the IEB, since EGCs have protective effects on enterocytes. A co-culture 
study showed that EGCs induced in enterocytes an increase in transcription of 
genes involved in cell-to-cell and cell-to-matrix adhesion and also an increase in cell 
adhesion [25]. Some of the glia-derived factors, for example, ATP and prostaglan-
dins, could be released through the Cx43 hemichannels [26]. The other effects may 
come from cell-to-cell contact. EGCs and enterocytes express Cx43 [27], so they 
may perhaps be joined by Cx43 gap junctions. In fact, the membrane potential of 
differentiating enterocytes becomes more positive exclusively when they migrate 
away from the crypt-villous junction [28], possibly due to gap junctions with EGCs 
(they have higher membrane potential) in this region [29].
In addition to the Cx43 hemichannels, EGCs also have sodium, potassium, and 
aquaporin-4 channels, whose presence and subtypes vary among their subtypes. 
Aquaporin channels, for example, are expressed in EGCs within the plexus, but not 
in extraganglionic EGCs [22].
Even in autism, it has been speculated that inadequate Cx43 expression in EGC 
could affect GI motility, which is in fact altered in some patients. Some monogenetic 
autism spectrum disorders are caused by mutations in genes that encode transcrip-
tional or epigenetic factors, for example, methylCpG2-binding protein (MeCP2) in 
Rett syndrome or TCF4 in Pitt-Hopkins syndrome. These mutations could affect the 
transcription machinery required for proper expression of Cx43 in EGCs [30].
Thus, EGCs act largely through the release of different molecules, which can 
happen through the Cx43 hemichannels.
4.  Functions of EGCs in gut homeostasis: released factors by EGCs 
play a role in intestinal epithelial barrier, neurotransmission, and 
gliotransmission
As already mentioned, EGCs are located throughout intestinal layers and 
interact with different cell types within the gut. Thus, this cell type is expected 
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to play a number of important roles in the coordination of gut functions. In fact, 
studies using genetic tools to abrogate GFAP expressing cells resulted in disruption 
in epithelial integrity, extensive intestinal necrosis, and inflammation, followed by 
degeneration of enteric neurons [31, 32], evidencing the importance of EGCs for 
intestinal homeostasis.
EGCs exert their function through the release of important molecules. In the 
intestine, glial-derived neurotrophic factor (GDNF) is released by EGCs and acts 
as an anti-apoptotic factor to epithelial cells, neurons, and EGCs [33–36]. GDNF 
inhibits epithelial cell apoptosis by the activation of GFRα1–GFRα3 receptors and 
RET co-receptor and the activation of mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol-3-kinase/serine–threonine kinase (PI3K/AKT) signaling 
pathways [37, 38]. GDNF also inhibits apoptosis of EGCs in an autocrine manner 
[34]. Mu opioid receptor activation by morphine in EGCs decreases their GDNF 
synthesis, with consequent IEB disruption [39]. Moreover, GDNF has been shown 
to increase the integrity of the IEB via ZO-1 upregulation [38].
Among neuroactive molecules, ATP is the most well-characterized molecule 
released from EGCs. ATP is released through the opening of Cx 43 hemichannels 
[21, 40]. More specifically, the released ATP modifies adjacent glia, triggering intercel-
lular Ca2+ waves and influencing adjacent neurons. The ATP released by EGCs may 
induce neuronal cell death, as discussed above (topic 2). Nitric oxide (NO), a key inhibi-
tory neurotransmitter in the ENS and a factor that drives oxidative stress in disease, is 
also produced by EGCs [41, 42]. This molecule is produced by the enzyme inducible 
nitric oxide synthase (iNOS). Under pathological stimuli, EGCs express iNOS and 
produce large amounts of NO, which may be protective or deleterious depending on the 
circumstances. Some evidence, however, suggest that EGCs may constitutively express 
iNOS and that NO plays a physiological role by modulating epithelial ion transport [41].
The data above have suggested that EGCs play an essential role in neuronal sup-
port and neurotransmission. Indeed, EGCs actively participate in neurotransmis-
sion. Intraganglionic EGCs provide enteric neurons with essential precursors for the 
synthesis of neurotransmitters such as NO [43, 44], glutamate, and γ-aminobutyric 
acid (GABA) [45]. In health, EGCs provide antioxidants, like reduced glutathione 
[46, 47], and growth factors (e.g., GDNF) [48] to neurons. In addition, EGCs sup-
port neurotransmission by regulating the bioavailability of neuroactive substances 
in the extracellular environment. EGC enzymes are essential for the removal of 
neuroactive compounds surrounding enteric neurons. Moreover, glial potassium 
channels maintain neurotransmission and prevent the death of excitotoxic neurons 
by regulating and buffering potassium [13, 49].
A poorly understood question is how EGCs interpret and process the signals they 
receive from enteric neurons to eventually play their presumptive roles in neurons 
and GI function.
Little is known about EGCs activating ligands, but the Ca2+ transients probably 
trigger different modes of gliotransmission, such as Ca2+−dependent exocytosis or 
factor release through the Cx43 hemichannels [50].
Boesmans et al. [51] demonstrated that enteric neurons can communicate with 
adjacent EGCs, releasing purines through their panexin channels. In fact, ATP 
and purines are the most ubiquitous signaling molecules involved in the enteric 
transmission of neurons to glia in vitro [52, 53] and in situ [21, 23, 54–56], but EGCs 
also have other receptors that allow glia to initiate responses to neurotransmit-
ters released by neurons and other neuroactive substances, including receptors to 
norepinephrine, glutamate, thrombin, lipid signaling molecules, serotonin, brady-
kinin, histamine, and endothelin [22].
As mentioned before, it is already known that in vitro propagation of Ca2+ 
responses between EGCs depends on ATP release through hemichannels [40]. And 
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Little is known about EGCs activating ligands, but the Ca2+ transients probably 
trigger different modes of gliotransmission, such as Ca2+−dependent exocytosis or 
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Boesmans et al. [51] demonstrated that enteric neurons can communicate with 
adjacent EGCs, releasing purines through their panexin channels. In fact, ATP 
and purines are the most ubiquitous signaling molecules involved in the enteric 
transmission of neurons to glia in vitro [52, 53] and in situ [21, 23, 54–56], but EGCs 
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As mentioned before, it is already known that in vitro propagation of Ca2+ 
responses between EGCs depends on ATP release through hemichannels [40]. And 
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later it was seen that substances released by Cx43 hemichannels mediate intercel-
lular communication between EGCs [21].
How other populations of EGCs outside the enteric ganglia interact with enteric 
neurons is currently unknown.
5. EGC plasticity
The ENS has a significant ability to adapt to microenvironmental influences 
throughout life, either by inflammatory bowel diseases or by changes in eating 
habits [57]. The mechanisms of cellular communication involved in the plasticity of 
EGCs are not yet fully understood. Understanding how EGCs act and especially how 
they perform the role of progenitor cell and differentiate into neuron is of para-
mount importance for a better understanding of how the ENS performs its complex 
functions.
It has already been shown that numerous neural crest-derived stem cells are 
found in different locations in the adult organism, including the intestine [58]. 
When isolated by flow cytometry for p75 markers [59] or integrin-α2 [60], or also 
through dissociation for in vitro cultivation of neurospheres [61, 62], EGCs can 
give rise to a large number of other cells including glial cells, neurons, and even 
myofibroblasts. Following transplantation of these cells into intestinal explants, 
EGCs differentiate into glial and neuronal cells [61, 63]. These data underscore the 
plastic potential of EGCs that, when transplanted into the CNS, are able to func-
tion as oligodendrocytes and astrocytes [26]. It is noteworthy that under different 
physiological conditions and after injury [60], EGCs proliferate and differentiate 
into neuron only upon specific injury situations [64, 65]. Liu and colleagues have 
shown that it is possible to induce neurogenesis in the myenteric plexus in vivo by 
activating the serotonin receptor upon administration of the 5-hydroxytryptamine 
4 (5-HT 4) agonist [66]. Indeed, other studies in postnatal bowel suggest that 
serotonin also promotes ENS repair and neurogenesis via 5-HT4 receptor [67, 68]. 
Moreover, studies have shown that mouse and human EGCs undergo neurogenesis 
after colitis [65, 69].
Under chemical injury with benzalkonium chloride detergent (BAC), it was pos-
sible to observe neurogenesis in vivo. About 3 months after injury, EGCs adjacent 
to the aganglionic area give rise to sox10-positive glial cells expressing the neuronal 
marker HuC/D [64]. It has been proposed that interruption of contact between cells 
(ganglion structure dissociation) may initiate neurogenesis from precursor cells 
expressing EGCs markers (sox10, p75, S100β, GFAP). These studies suggest that tis-
sue dissociation to establish cell culture, as well as that observed in chemical injury, 
could activate the neurogenic potential of EGCs.
A recent work, however, suggested that constitutive neurogenesis occurs in the 
gut [70], contrasting with data obtained by other groups that suggest that intestinal 
neurons are not easily replaced under healthy conditions [71–73]. Moreover, this 
study highlighted a population of nestin-positive adult progenitor cells that give rise 
to new neurons, different from that of GFAP-positive EGCs. These data contrast 
with previous works that had shown nestin and GFAP co-expression by EGCs [60]. 
Furthermore, nestin-expressing intestinal NSCs cells give rise to neurosphere-
derived neurons and glia in vitro. Besides these cells can differentiate into glial, 
neuronal, and mesenchymal lineages in vitro and also generate neurons in vivo [74].
EGCs do not produce extracellular matrix (ECM). However, their processes con-
tact basal lamina proteins including heparan sulfate proteoglycan, type IV collagen, 
and laminin [11, 75, 76]. This suggests that the microenvironment is also a factor 
of great relevance for the function of EGCs and neurons. Recent data demonstrate 
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that EGCs in vitro, in absence of appropriate substrates were stimulated to initiate 
neuronal differentiation. Therefore, it seems that the contact of adult EGCs with 
laminin plays a crucial role in inhibiting their potential for neuronal differentiation 
(Veríssimo et al., 2009).
6. Implications of EGCs in pathological conditions
The importance of the correct neuron-glial communication is evidenced in a 
situation of intestinal inflammation and neurodegeneration, when EGCs act as a 
direct mediator of neuronal cell death.
6.1 EGCs in inflammatory bowel diseases (IBD)
Chronic inflammation in the GI tract can cause important changes in the ENS, 
as demonstrated by several studies in patients with IBD, such as ulcerative colitis 
(UC) and Crohn’s disease (CD)[77, 78]. Both UC and CD are characterized by 
inflammation, which is accompanied by the release of a range of pro-inflammatory 
cytokines, following intestinal dysmotility [79, 80].
An increase in GDNF and GFAP immunolabeling was observed in EGCs in 
inflamed colonic mucosa of patients with UC, CD, and Clostridioides difficile (C. 
difficile) infectious colitis [78]. In addition, S100B upregulation has also been 
identified in a variety of diseases, such as UC [42, 81, 82], celiac disease [83], and 
intestinal mucositis induced by antineoplastic drugs [84, 85]. Increased expression 
of S100B was also found in the intestine of humans with C. difficile infection (CDI), 
in animal model of CDI, and in mouse ileal loop injected with C. difficile toxin A 
(TcdA) (unpublished data).
In intestinal injury, reactive gliosis is a response of EGCs to protect the neuronal 
network during intestinal inflammation [86]. However, depending on the degree 
of inflammation, this event may cause damage to neurons and to EGCs themselves 
due to a deregulated response of these cells to the virulence factors of pathogenic 
bacteria or pro-inflammatory mediators released by immune cells, neurons, or 
EGCs. This dual effects may have an important effect in the instability of the release 
of protective and dangerous factors, such as GDNF, an anti-apoptotic factor, and 
S100B, a pro-inflammatory cytokine, by EGCs [34, 35].
6.1.1 Ulcerative colitis and Crohn’s disease
A strong upregulation in levels of GDNF was reported in the intestinal crypts 
and in the myenteric and submucosal plexuses in patients with CD. In UC, GDNF 
immunoreactivity was reported to be less pronounced than CD. However, no altera-
tion in GFR-1 was evidenced in patients with CD and UC. GFR-1 is a receptor for 
GDNF binding that is predominantly found at the basolateral parts of the human 
colonic epithelium [37].
The EGCs regulate the epithelial barrier function and inflammation through the 
release of S-nitrosoglutathione (GSNO), a potent nitric oxide donor. Interestingly, 
EGCs are the main source of GSNO within the intestine. It has been shown that the 
levels of GSNO are reduced in CD and UC [35]. GSNO regulates the intestinal perme-
ability by stimulating in enterocytes the upregulation of proteins of tight junctions, 
such as occludins and ZO-1, and inhibiting the increase of phosphorylated myosin 
light chain (PMLC), as well as improving the location of these proteins [87].
EGCs from human colonic tissues with Crohn’s disease have reduced 
15-hydroxyeicosatetraenoic (15-HETE) synthesis. As GSNO, 15-HETE controls 
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later it was seen that substances released by Cx43 hemichannels mediate intercel-
lular communication between EGCs [21].
How other populations of EGCs outside the enteric ganglia interact with enteric 
neurons is currently unknown.
5. EGC plasticity
The ENS has a significant ability to adapt to microenvironmental influences 
throughout life, either by inflammatory bowel diseases or by changes in eating 
habits [57]. The mechanisms of cellular communication involved in the plasticity of 
EGCs are not yet fully understood. Understanding how EGCs act and especially how 
they perform the role of progenitor cell and differentiate into neuron is of para-
mount importance for a better understanding of how the ENS performs its complex 
functions.
It has already been shown that numerous neural crest-derived stem cells are 
found in different locations in the adult organism, including the intestine [58]. 
When isolated by flow cytometry for p75 markers [59] or integrin-α2 [60], or also 
through dissociation for in vitro cultivation of neurospheres [61, 62], EGCs can 
give rise to a large number of other cells including glial cells, neurons, and even 
myofibroblasts. Following transplantation of these cells into intestinal explants, 
EGCs differentiate into glial and neuronal cells [61, 63]. These data underscore the 
plastic potential of EGCs that, when transplanted into the CNS, are able to func-
tion as oligodendrocytes and astrocytes [26]. It is noteworthy that under different 
physiological conditions and after injury [60], EGCs proliferate and differentiate 
into neuron only upon specific injury situations [64, 65]. Liu and colleagues have 
shown that it is possible to induce neurogenesis in the myenteric plexus in vivo by 
activating the serotonin receptor upon administration of the 5-hydroxytryptamine 
4 (5-HT 4) agonist [66]. Indeed, other studies in postnatal bowel suggest that 
serotonin also promotes ENS repair and neurogenesis via 5-HT4 receptor [67, 68]. 
Moreover, studies have shown that mouse and human EGCs undergo neurogenesis 
after colitis [65, 69].
Under chemical injury with benzalkonium chloride detergent (BAC), it was pos-
sible to observe neurogenesis in vivo. About 3 months after injury, EGCs adjacent 
to the aganglionic area give rise to sox10-positive glial cells expressing the neuronal 
marker HuC/D [64]. It has been proposed that interruption of contact between cells 
(ganglion structure dissociation) may initiate neurogenesis from precursor cells 
expressing EGCs markers (sox10, p75, S100β, GFAP). These studies suggest that tis-
sue dissociation to establish cell culture, as well as that observed in chemical injury, 
could activate the neurogenic potential of EGCs.
A recent work, however, suggested that constitutive neurogenesis occurs in the 
gut [70], contrasting with data obtained by other groups that suggest that intestinal 
neurons are not easily replaced under healthy conditions [71–73]. Moreover, this 
study highlighted a population of nestin-positive adult progenitor cells that give rise 
to new neurons, different from that of GFAP-positive EGCs. These data contrast 
with previous works that had shown nestin and GFAP co-expression by EGCs [60]. 
Furthermore, nestin-expressing intestinal NSCs cells give rise to neurosphere-
derived neurons and glia in vitro. Besides these cells can differentiate into glial, 
neuronal, and mesenchymal lineages in vitro and also generate neurons in vivo [74].
EGCs do not produce extracellular matrix (ECM). However, their processes con-
tact basal lamina proteins including heparan sulfate proteoglycan, type IV collagen, 
and laminin [11, 75, 76]. This suggests that the microenvironment is also a factor 
of great relevance for the function of EGCs and neurons. Recent data demonstrate 
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that EGCs in vitro, in absence of appropriate substrates were stimulated to initiate 
neuronal differentiation. Therefore, it seems that the contact of adult EGCs with 
laminin plays a crucial role in inhibiting their potential for neuronal differentiation 
(Veríssimo et al., 2009).
6. Implications of EGCs in pathological conditions
The importance of the correct neuron-glial communication is evidenced in a 
situation of intestinal inflammation and neurodegeneration, when EGCs act as a 
direct mediator of neuronal cell death.
6.1 EGCs in inflammatory bowel diseases (IBD)
Chronic inflammation in the GI tract can cause important changes in the ENS, 
as demonstrated by several studies in patients with IBD, such as ulcerative colitis 
(UC) and Crohn’s disease (CD)[77, 78]. Both UC and CD are characterized by 
inflammation, which is accompanied by the release of a range of pro-inflammatory 
cytokines, following intestinal dysmotility [79, 80].
An increase in GDNF and GFAP immunolabeling was observed in EGCs in 
inflamed colonic mucosa of patients with UC, CD, and Clostridioides difficile (C. 
difficile) infectious colitis [78]. In addition, S100B upregulation has also been 
identified in a variety of diseases, such as UC [42, 81, 82], celiac disease [83], and 
intestinal mucositis induced by antineoplastic drugs [84, 85]. Increased expression 
of S100B was also found in the intestine of humans with C. difficile infection (CDI), 
in animal model of CDI, and in mouse ileal loop injected with C. difficile toxin A 
(TcdA) (unpublished data).
In intestinal injury, reactive gliosis is a response of EGCs to protect the neuronal 
network during intestinal inflammation [86]. However, depending on the degree 
of inflammation, this event may cause damage to neurons and to EGCs themselves 
due to a deregulated response of these cells to the virulence factors of pathogenic 
bacteria or pro-inflammatory mediators released by immune cells, neurons, or 
EGCs. This dual effects may have an important effect in the instability of the release 
of protective and dangerous factors, such as GDNF, an anti-apoptotic factor, and 
S100B, a pro-inflammatory cytokine, by EGCs [34, 35].
6.1.1 Ulcerative colitis and Crohn’s disease
A strong upregulation in levels of GDNF was reported in the intestinal crypts 
and in the myenteric and submucosal plexuses in patients with CD. In UC, GDNF 
immunoreactivity was reported to be less pronounced than CD. However, no altera-
tion in GFR-1 was evidenced in patients with CD and UC. GFR-1 is a receptor for 
GDNF binding that is predominantly found at the basolateral parts of the human 
colonic epithelium [37].
The EGCs regulate the epithelial barrier function and inflammation through the 
release of S-nitrosoglutathione (GSNO), a potent nitric oxide donor. Interestingly, 
EGCs are the main source of GSNO within the intestine. It has been shown that the 
levels of GSNO are reduced in CD and UC [35]. GSNO regulates the intestinal perme-
ability by stimulating in enterocytes the upregulation of proteins of tight junctions, 
such as occludins and ZO-1, and inhibiting the increase of phosphorylated myosin 
light chain (PMLC), as well as improving the location of these proteins [87].
EGCs from human colonic tissues with Crohn’s disease have reduced 
15-hydroxyeicosatetraenoic (15-HETE) synthesis. As GSNO, 15-HETE controls 
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the paracellular permeability of the IEB by inhibiting adenosine monophosphate-
activated protein kinase (AMPK) and regulating ZO-1 expression [88].
NO, such as tumor necrosis factor-α (TNF-α) and PGE2, plays an important 
role in the pathogenesis of ulcerative colitis and is secreted by EGCs. S100B can induce 
increased NO release, as well as TNF-α and PGE2, by murine and human EGCs via 
S100B/TLR4 [42, 82].
Losses in 61% of the enteric neurons and 38% of the EGCs have been reported during 
ulcerative colitis in human [77]. In fact, activation of EGCs during colitis induced 
by dinitrobenzene sulfonic acid (DNBS) in mice had been shown to be the central 
mechanism in the development of enteric neuropathy, since the gating of glial Cx43 
hemichannels by nitric oxide and subsequent ATP release are required for enteric 
neuron death [24].
6.1.2 Colitis by Clostridioides difficile
C. difficile is an obligate anaerobic, spore-forming Gram-positive bacillus that 
can colonize, germinate, and proliferate in the human gut after antibiotic use [89, 
90]. The incidence of C. difficile infection (CDI) across the world has increased 
with 107,760 admissions per year [91, 92]. The clinical disease ranges from mild 
diarrhea to toxic megacolon, colonic perforation, and death [93].
The major virulence factors of C. difficile are toxins A and B (TcdA and TcdB). 
TcdA and TcdB stimulate the release of a variety of mediators such as interleukin 
(IL)-1β, IL-17, IL-23, TNF-α, CXC motif chemokine ligand 4 (CXCL4), CXCL2, and 
inhibitory macrophage migration factor (MIF) in several cells, such as epithelial 
cells, immune cells, and enteric neurons [94–97]. In contrast to those cells, EGCs 
challenged with TcdA and TcdB do not release detectable levels of IL-1β, interferon-
gamma (INF-γ), and TNF-α [98].
The first studies on changes in the ENS evoked by C. difficile toxins showed 
that TcdA and TcdB excite enteric neurons stimulating the release of substance P 
and vasoactive intestinal peptide (VIP) via noradrenergic transmission inhibition 
and IL-1β pathway, respectively, resulting in neutrophil recruitment and secretory 
diarrhea [99–101].
A recent study demonstrated increased cell population expressing both HuC/D 
and SOX2 in inflamed colonic tissues in patients with CDI [65]. So, these EGCs are 
important for generating new neurons after intestinal injury.
A study of 447 and 444 patients with C. difficile-associated diarrhea acquired in 
the community and hospital, respectively, showed GI dysmotility in these patients 
after 1 year of the last diarrhea episode. Among the dysmotilities are IBD, gastro-
esophageal reflux disease, constipation, and dyspepsia [102]. These dysmotilities 
have been shown to be related to ENS changes. Deregulated activation of EGCs dur-
ing inflammation may alter their regulatory role in motility (discussed in topic 3), 
causing intestinal dysmotility.
It was demonstrated that TcdB stimulates morphological alteration and apoptosis in 
EGCs in vitro [98, 103]. TcdB-induced apoptosis of EGCs involves the NADPH oxidase/
ROS/JNK/caspase-3 signaling pathway independently of the mitochondrial pathway 
[103]. In addition, TcdB induces senescence in EGCs. Cell senescence is characterized 
by alterations in the cell cycle, changes in metabolism, morphology, and gene expres-
sion that together may contribute to persistent inflammation [104].
6.1.3 Inflammation by other causes
It has been demonstrated that EGCs are involved in decreased infection foci and 
IL-8 secretion and in the inhibition of alterations in IEB resistance in infection by 
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Shigella flexneri in rabbit ileal loop model. Similar findings were found in human 
colonic mucosa explants infected with S. flexneri. GSNO released by EGCs showed 
to be a mediator responsible for protecting epithelial cells from S. flexneri-induced 
effects [105].
Giardia duodenalis (also known as G. lamblia or G. intestinalis) is a protozoan 
parasite capable of causing sporadic or epidemic diarrheal illness. Giardia duodena-
lis-induced infection is one of the most common human parasitic diseases world-
wide [106]. Studies have shown a reduction in EGCs from the submucosal plexus of 
the mouse duodenum and jejunum during infection induced by assemblages A and 
B of G. duodenalis. However, only assemblages B of G. duodenalis were observed to 
induce a reduction in those cells from the duodenal myenteric plexus. Surprisingly, 
mice infected with G. duodenalis did not exhibit diarrhea and any alterations in GI 
transit time [107].
Antineoplastic drugs, such as 5-FU, irinotecan, and oxaliplatin, have been cur-
rently used to treat several types of cancer, including breast and colorectal cancer. 
Mucositis and diarrhea are common side effects of these antineoplastic drugs [108]. 
Many cells are stimulated to release inflammatory mediators during intestinal 
mucositis, and persistent GI over-contractility has also been demonstrated, even 
after inflammation has resolved, suggesting that chemotherapy might affect gut 
neuronal and EGC function [109].
During intestinal mucositis induced by oxaliplatin, reduced GFAP and increased 
S100B protein expression were evidenced, as well as reduced co-localization of 
GFAP and S100B in ileal myenteric plexus of mice [110].
In fact, increased S100B release by EGCs has been shown to be a mediator in 
charge of causing neuronal death, as well as reactive gliosis, epithelial damage, 
and inflammatory response (release of IL-6, TNFα, and NO) during 5-FU-induced 
intestinal mucositis via S100B/RAGE/NFκB [84].
As we will deepen later, EGCs can be stimulated by immune cells during intes-
tinal inflammation. A recent study showed that mediators released by mast cells 
cause reactive gliosis and neuronal death together with the intestinal mucositis 
induced by irinotecan [85].
Figure 2 shows a schematic highlighting how EGCs are affected by and partici-
pates on intestinal inflammation.
6.2 EGCs in neurodegenerative diseases
Due to its great interaction with neurons and modulation of neuronal responses, 
it is possible to imagine that EGCs play a central role in neurodegenerative diseases. 
Indeed, the role of EGCs seems to be compromised in many neurodegenerative 
diseases, and this is true for both CNS and ENS.
Enteric neurodegeneration is a common marker for a group of diseases classi-
cally known as enteric neuropathies. The changes found present as alterations in 
enteric smooth cells and/or compromised functioning of the ENS—often impact-
ing in GI motility [111]. The neuropathies chronic intestinal pseudo-obstruction 
(CIPO) and slow transit constipation (STC) are characterized by neurodegenera-
tion affecting the lower GI tract. Moreover, it has already been shown that enteric 
glia is implicated in Parkinson’s disease (PD), and participation in Alzheimer’s 
disease (AD) is speculated [111].
CIPO is a condition characterized by failure of GI motility without apparent 
mechanical lesion [112]. Histological patterns show different classes of the disease 
depending on the cell type involvement (enteric neurons, smooth muscle cells, and 
interstitial cells of Cajal). Enteric neuron degeneration promotes intestinal neuro-
muscular disorders [111, 113]. In chronic idiopathic intestinal pseudo-obstruction 
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the paracellular permeability of the IEB by inhibiting adenosine monophosphate-
activated protein kinase (AMPK) and regulating ZO-1 expression [88].
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hemichannels by nitric oxide and subsequent ATP release are required for enteric 
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6.1.2 Colitis by Clostridioides difficile
C. difficile is an obligate anaerobic, spore-forming Gram-positive bacillus that 
can colonize, germinate, and proliferate in the human gut after antibiotic use [89, 
90]. The incidence of C. difficile infection (CDI) across the world has increased 
with 107,760 admissions per year [91, 92]. The clinical disease ranges from mild 
diarrhea to toxic megacolon, colonic perforation, and death [93].
The major virulence factors of C. difficile are toxins A and B (TcdA and TcdB). 
TcdA and TcdB stimulate the release of a variety of mediators such as interleukin 
(IL)-1β, IL-17, IL-23, TNF-α, CXC motif chemokine ligand 4 (CXCL4), CXCL2, and 
inhibitory macrophage migration factor (MIF) in several cells, such as epithelial 
cells, immune cells, and enteric neurons [94–97]. In contrast to those cells, EGCs 
challenged with TcdA and TcdB do not release detectable levels of IL-1β, interferon-
gamma (INF-γ), and TNF-α [98].
The first studies on changes in the ENS evoked by C. difficile toxins showed 
that TcdA and TcdB excite enteric neurons stimulating the release of substance P 
and vasoactive intestinal peptide (VIP) via noradrenergic transmission inhibition 
and IL-1β pathway, respectively, resulting in neutrophil recruitment and secretory 
diarrhea [99–101].
A recent study demonstrated increased cell population expressing both HuC/D 
and SOX2 in inflamed colonic tissues in patients with CDI [65]. So, these EGCs are 
important for generating new neurons after intestinal injury.
A study of 447 and 444 patients with C. difficile-associated diarrhea acquired in 
the community and hospital, respectively, showed GI dysmotility in these patients 
after 1 year of the last diarrhea episode. Among the dysmotilities are IBD, gastro-
esophageal reflux disease, constipation, and dyspepsia [102]. These dysmotilities 
have been shown to be related to ENS changes. Deregulated activation of EGCs dur-
ing inflammation may alter their regulatory role in motility (discussed in topic 3), 
causing intestinal dysmotility.
It was demonstrated that TcdB stimulates morphological alteration and apoptosis in 
EGCs in vitro [98, 103]. TcdB-induced apoptosis of EGCs involves the NADPH oxidase/
ROS/JNK/caspase-3 signaling pathway independently of the mitochondrial pathway 
[103]. In addition, TcdB induces senescence in EGCs. Cell senescence is characterized 
by alterations in the cell cycle, changes in metabolism, morphology, and gene expres-
sion that together may contribute to persistent inflammation [104].
6.1.3 Inflammation by other causes
It has been demonstrated that EGCs are involved in decreased infection foci and 
IL-8 secretion and in the inhibition of alterations in IEB resistance in infection by 
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Shigella flexneri in rabbit ileal loop model. Similar findings were found in human 
colonic mucosa explants infected with S. flexneri. GSNO released by EGCs showed 
to be a mediator responsible for protecting epithelial cells from S. flexneri-induced 
effects [105].
Giardia duodenalis (also known as G. lamblia or G. intestinalis) is a protozoan 
parasite capable of causing sporadic or epidemic diarrheal illness. Giardia duodena-
lis-induced infection is one of the most common human parasitic diseases world-
wide [106]. Studies have shown a reduction in EGCs from the submucosal plexus of 
the mouse duodenum and jejunum during infection induced by assemblages A and 
B of G. duodenalis. However, only assemblages B of G. duodenalis were observed to 
induce a reduction in those cells from the duodenal myenteric plexus. Surprisingly, 
mice infected with G. duodenalis did not exhibit diarrhea and any alterations in GI 
transit time [107].
Antineoplastic drugs, such as 5-FU, irinotecan, and oxaliplatin, have been cur-
rently used to treat several types of cancer, including breast and colorectal cancer. 
Mucositis and diarrhea are common side effects of these antineoplastic drugs [108]. 
Many cells are stimulated to release inflammatory mediators during intestinal 
mucositis, and persistent GI over-contractility has also been demonstrated, even 
after inflammation has resolved, suggesting that chemotherapy might affect gut 
neuronal and EGC function [109].
During intestinal mucositis induced by oxaliplatin, reduced GFAP and increased 
S100B protein expression were evidenced, as well as reduced co-localization of 
GFAP and S100B in ileal myenteric plexus of mice [110].
In fact, increased S100B release by EGCs has been shown to be a mediator in 
charge of causing neuronal death, as well as reactive gliosis, epithelial damage, 
and inflammatory response (release of IL-6, TNFα, and NO) during 5-FU-induced 
intestinal mucositis via S100B/RAGE/NFκB [84].
As we will deepen later, EGCs can be stimulated by immune cells during intes-
tinal inflammation. A recent study showed that mediators released by mast cells 
cause reactive gliosis and neuronal death together with the intestinal mucositis 
induced by irinotecan [85].
Figure 2 shows a schematic highlighting how EGCs are affected by and partici-
pates on intestinal inflammation.
6.2 EGCs in neurodegenerative diseases
Due to its great interaction with neurons and modulation of neuronal responses, 
it is possible to imagine that EGCs play a central role in neurodegenerative diseases. 
Indeed, the role of EGCs seems to be compromised in many neurodegenerative 
diseases, and this is true for both CNS and ENS.
Enteric neurodegeneration is a common marker for a group of diseases classi-
cally known as enteric neuropathies. The changes found present as alterations in 
enteric smooth cells and/or compromised functioning of the ENS—often impact-
ing in GI motility [111]. The neuropathies chronic intestinal pseudo-obstruction 
(CIPO) and slow transit constipation (STC) are characterized by neurodegenera-
tion affecting the lower GI tract. Moreover, it has already been shown that enteric 
glia is implicated in Parkinson’s disease (PD), and participation in Alzheimer’s 
disease (AD) is speculated [111].
CIPO is a condition characterized by failure of GI motility without apparent 
mechanical lesion [112]. Histological patterns show different classes of the disease 
depending on the cell type involvement (enteric neurons, smooth muscle cells, and 
interstitial cells of Cajal). Enteric neuron degeneration promotes intestinal neuro-
muscular disorders [111, 113]. In chronic idiopathic intestinal pseudo-obstruction 
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(CIIP), EGC infection by JC virus (polyomavirus) has been described suggesting a 
role of enteric glia in this enteric neuropathy [114].
Constipation is a common functional GI disorder characterized by infre-
quent bowel motions and/or incomplete defecation [115]. Studies on the neu-
ronal subtypes involved in the STC pathogenesis are still very uncertain. It was 
pointed that excessive production of NO in the colonic myenteric plexus of STC 
patients would inhibit propulsive contraction. Results about other neurotrans-
mitters as VIP, substance P, and serotonin were contradictory [113]. Besides 
the decrease of enteric neurons and interstitial cells of Cajal, STC also presents 
a significant decrease of EGCs [116], and some discussion has emerged about 
constipation being a neuro-gliopathy [79]. Several reports showed that different 
conditions presenting constipation have a feature: loss of EGCs, and it points to 
a pathophysiological meaning since the EGC directly regulates enteric neurons 
and interstitial cells of Cajal through neurotrophic factors [116, 117] and ATP 
signaling [79, 118].
Figure 2. 
Mediator release by EGCs during intestinal inflammation and their role in the pathogenesis of intestinal 
inflammatory diseases. During intestinal inflammation promoted by ulcerative colitis, Crohn’s disease, colitis 
induced by C. difficile, irinotecan- and 5-FU-induced intestinal mucositis, and enteric glial factors (S100B, 
GDNF and GFAP) are upregulated. EGCs are stimulated to secrete S100B, GDNF, IL-6, ATP, TNF-α, PGE2, 
and NO. In addition, EGCs produce reduced levels of GSNO and 15-HETE during Crohn’s disease, resulting 
in increase of intestinal permeability by ZO-1 downregulation and PMLC upregulation. NO release by EGCs 
promotes Cx43 opening with consequent ATP release by EGCs, resulting in neuronal death in Crohn’s disease. 
In 5-FU-induced intestinal mucositis, S100B released by EGCs via RAGE receptor activation drives reactive 
gliosis, neuronal death, and immune cell activation, whereas mediators released by mast cells induce reactive 
gliosis and neuronal death during irinotecan-induced intestinal mucositis . In ulcerative colitis, S100B activates 
TLR4, resulting in TNFα, PGE2, and NO by EGCs. C. difficile Toxin B (TcdB) induces EGCs apoptosis and 
morphological changes.
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6.2.1 Parkinson’s disease
In the last years, the literature has shown that some pathological conditions, 
such as PD, classically described to compromise the CNS are now recognized as 
multicentric neurodegenerative processes since they affect different systems such as 
the ENS [119–122]. A number of non-motor symptoms in PD have been identified, 
and many of them manifest early, even before the clinical stage of the disease (char-
acterized by emergence of the classic motor features) when the diagnosis can be 
made [123]. They found lesions in autopsies of patients by identifying the presence 
of intraneuronal inclusions called Lewy bodies/neuritis, which are described as pro-
tein agglomerates where α-synuclein is the main constituent. The areas primarily 
affected were olfactory structures, the dorsal motor nucleus of the vagus nerve and 
the ENS [124, 125]. According to Braak’s hypothesis, there could occur a migration 
of the ENS lesion via the vagus nerve to the CNS [124]. Indeed, Lewy neurites are 
detectable in the presymptomatic stage of PD along the autonomic pathways and in 
the GI tract [126]. Besides, analysis of human colon biopsies obtained 2 to 5 years 
before PD onset showed the presence of pathologic α-synuclein in neurodegenera-
tion sites, suggesting that colonic α-synuclein staining can be considered a bio-
marker of premotor PD symptoms [127].
GI symptoms are the most debilitating PD non-motor features and are present 
in almost every patient at some stage of the disorder [124, 128, 129]. The symptoms 
commonly reported by patients are weight loss, dysphagia, decreased frequency of 
intestinal peristalsis, and difficulty in defecation [130]. Recent evidences indicate 
that PD pathological alterations in the gut involve EGCs and probably impairment 
of their critical role in GI physiology. In fact, colonic biopsies of PD patients showed 
an increased expression of GFAP both at the transcript and protein levels [131, 132] 
as well as a reduction in GFAP phosphorylation. These features strongly suggest that 
reactive gliosis may be associated with degenerative diseases [131].
In PD colon biopsies the upregulation of GFAP was accompanied by an increase 
in the expression of pro-inflammatory cytokines, mainly TNF-α, IFN-γ, IL-1β, and 
IL-6 [132]. These data suggest a link between glial dysfunction and enteric inflam-
mation in the colon of PD patients.
Alterations in IEB have been observed in patients and animal models of PD [133, 
134]. Modifications in protein levels and protein distribution that compose the 
barrier (e.g., occludin) were documented [128]. In agreement with this, PD patients 
show fecal biomarkers of inflammation as calprotectin and also increased intestinal 
permeability as alpha-1-antitrypsin [134]. It is known that the IEB is strongly regu-
lated by EGCs [37–39]. Since EGCs is sensitized in PD patients and modulates all 
these processes, it is speculated that IEB could be impaired by altered glial signaling 
which could contribute to the inflammatory process.
Intestinal dysmotility is the symptom that affects directly patient’s quality 
of life and is shared among PD patients. Constipation is the most common non-
motor symptom manifested in both prodromal and clinic phases of PD [135–137]. 
Recently, constipation was included as a criterion for prodromal PD diagnostic, and 
discussion about the validation of constipation as a risk factor for the development 
of PD has been recurrent [138]. As already discussed, impairments in EGCs activity 
produce constipation due to a loss in the neural control of gut motility [21].
However, despite the evidence, there is still no direct demonstration of how 
enteric glia is involved in PD, either in the cause of the disease or its consequences.
In this way, the suggestion that PD could onset in the gut emerges from the 
identification of activated EGCs, local inflammation, impaired IEB, aggregation 
of α-synuclein in neurons, and GI disorders in a window prior to the appearance 
of classic motor deficits. Recently, Seguella et al. suggest that EGCs could be the 
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(CIIP), EGC infection by JC virus (polyomavirus) has been described suggesting a 
role of enteric glia in this enteric neuropathy [114].
Constipation is a common functional GI disorder characterized by infre-
quent bowel motions and/or incomplete defecation [115]. Studies on the neu-
ronal subtypes involved in the STC pathogenesis are still very uncertain. It was 
pointed that excessive production of NO in the colonic myenteric plexus of STC 
patients would inhibit propulsive contraction. Results about other neurotrans-
mitters as VIP, substance P, and serotonin were contradictory [113]. Besides 
the decrease of enteric neurons and interstitial cells of Cajal, STC also presents 
a significant decrease of EGCs [116], and some discussion has emerged about 
constipation being a neuro-gliopathy [79]. Several reports showed that different 
conditions presenting constipation have a feature: loss of EGCs, and it points to 
a pathophysiological meaning since the EGC directly regulates enteric neurons 
and interstitial cells of Cajal through neurotrophic factors [116, 117] and ATP 
signaling [79, 118].
Figure 2. 
Mediator release by EGCs during intestinal inflammation and their role in the pathogenesis of intestinal 
inflammatory diseases. During intestinal inflammation promoted by ulcerative colitis, Crohn’s disease, colitis 
induced by C. difficile, irinotecan- and 5-FU-induced intestinal mucositis, and enteric glial factors (S100B, 
GDNF and GFAP) are upregulated. EGCs are stimulated to secrete S100B, GDNF, IL-6, ATP, TNF-α, PGE2, 
and NO. In addition, EGCs produce reduced levels of GSNO and 15-HETE during Crohn’s disease, resulting 
in increase of intestinal permeability by ZO-1 downregulation and PMLC upregulation. NO release by EGCs 
promotes Cx43 opening with consequent ATP release by EGCs, resulting in neuronal death in Crohn’s disease. 
In 5-FU-induced intestinal mucositis, S100B released by EGCs via RAGE receptor activation drives reactive 
gliosis, neuronal death, and immune cell activation, whereas mediators released by mast cells induce reactive 
gliosis and neuronal death during irinotecan-induced intestinal mucositis . In ulcerative colitis, S100B activates 
TLR4, resulting in TNFα, PGE2, and NO by EGCs. C. difficile Toxin B (TcdB) induces EGCs apoptosis and 
morphological changes.
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6.2.1 Parkinson’s disease
In the last years, the literature has shown that some pathological conditions, 
such as PD, classically described to compromise the CNS are now recognized as 
multicentric neurodegenerative processes since they affect different systems such as 
the ENS [119–122]. A number of non-motor symptoms in PD have been identified, 
and many of them manifest early, even before the clinical stage of the disease (char-
acterized by emergence of the classic motor features) when the diagnosis can be 
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lated by EGCs [37–39]. Since EGCs is sensitized in PD patients and modulates all 
these processes, it is speculated that IEB could be impaired by altered glial signaling 
which could contribute to the inflammatory process.
Intestinal dysmotility is the symptom that affects directly patient’s quality 
of life and is shared among PD patients. Constipation is the most common non-
motor symptom manifested in both prodromal and clinic phases of PD [135–137]. 
Recently, constipation was included as a criterion for prodromal PD diagnostic, and 
discussion about the validation of constipation as a risk factor for the development 
of PD has been recurrent [138]. As already discussed, impairments in EGCs activity 
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However, despite the evidence, there is still no direct demonstration of how 
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In this way, the suggestion that PD could onset in the gut emerges from the 
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“missing link” that connects the ENS to the CNS [139]. The authors called attention 
to enteric glial cell-mediated inflammatory response, which could reach the CNS 
by the gut-brain axis and lead to neuronal cell death and disruption of synaptic 
interactions [139, 140]. Thus, EGCs would function as an “entrance door” to 
noxious stimuli from the intestinal lumen that could damage the CNS. However, 
the mechanisms by which the pro-inflammatory glial mediators rise to the CNS still 
remains to be clarified [139].
6.2.2 Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder 
affecting people in the world. The neurodegeneration causes a progressive cognitive 
decline and loss of working memory [141]. Among the non-cognitive symptoms 
of AD are the GI symptoms which point to a role of ENS in AD [142]. In fact, the 
brain biomarker of AD, the extracellular plaques containing β-amyloid, has already 
been described in the intestinal submucosa of patients [143] which is in agreement 
with the expression of amyloid precursor protein in enteric neurons and also EGCs 
[144]. The discussion of the peripheral immune response has been widely debated 
as the pathogenic pattern of AD that contributes to central neurodegeneration 
[145, 146]. In this context, some discussion has been raised about EGC possibly 
acting as a peripheric coordinator of immune differentiation of T cells [139] since 
EGCs express the major histocompatibility complex II and T-cell costimulatory 
molecules [147–149]. As mentioned above, EGCs are able to respond to an inflam-
matory environment contributing to the process, activate enteric neurodegenerative 
mechanisms, and immunomodulate the IEB. All these features could contribute to 
an inflammatory peripheral state and sensibilization of CNS through the blood–
brain barrier [139]. It is still speculative to relate these glial interactions to AD, but 
there are indications of an immunomodulatory relevance of this cell in the GIT, as 
will be discussed again below.
6.3 Interactions between EGCs and the immune system
Recently, insightful and essential findings have shed light in the field of neu-
roimmunology, especially with the development of high solution technological 
approaches to underlie neuroimmune communications. It has been proposed 
that the immune and the nervous systems interact in health and disease and are 
expected to function alongside to promote tissue homeostasis [150]. More specifi-
cally, neuroimmune interactions have been suggested by understanding the relative 
anatomical positioning of cell types and their dynamics within the tissue in homeo-
stasis and response to insults. Moreover, the expression of corresponding ligands 
and receptors by immune and nervous cells, for instance, may determine physiolog-
ical interactions between the two systems. However, efforts to identify mechanisms 
to decipher how immune and neural cells interact in a steady-state environment and 
respond to genetic and epigenetic cues are still a challenge to be addressed.
Because the GI tract is the connection between the external with the internal envi-
ronments of the body, the ENS is continuously exposed and expected to interact with 
the extrinsic (dietary and microbiota-derived metabolites) and intrinsic (immune sys-
tem and stromal cells) environments of the gut. The strategical anatomical positioning 
of ENS and immune cells throughout the GI wall and their physiological features are 
crucial to defeat pathogens and maintain the intestinal homeostasis. Emerging studies 
have identified two distinct types of tissue-resident macrophages within the intestinal 
wall that are closely associated with ENS cells [150]. Lamina propria macrophages 
(LpMs) preferentially display pro-inflammatory phenotype and are the most abundant 
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cell group located just beneath the intestinal epithelium. These cells, together with 
neuronal processes and mucosal EGCs, form tight physical and functional barriers that 
protect the intestines against pathogens, although the mechanisms that underlie those 
interactions are still to be further explored [150].
At the level of the myenteric plexus, muscularis macrophages (MMs) are closely 
associated with neuron cell bodies and fibers and EGCs and present a tissue-pro-
tective phenotype. Similar to microglia in the CNS, MMs can phagocyte neuronal 
debris during homeostasis [70]. Another population of gut self-maintaining mac-
rophages (gMacs) was described to be fundamental for ENS homeostasis since the 
genetic depletion of those macrophages led to a loss of enteric neurons resulting in 
reduced intestinal function [151]. Moreover, enteric neurons and innate lymphoid 
cells type 2 (ILC2) functionally integrate to initiate type 2 immune responses. The 
integration between neuron-ILC2 units is necessary for cytokine production and 
inflammation repair upon worm infection [152, 153].
EGCs also appear to participate in immune responses, but so far, its impact on 
immune cells is still relatively unexplored under homeostasis. However, an excit-
ing study has recently discussed that GDNF secreted by EGCs activates IL-22-
producing ILC3 via Ret signaling [154]. Interestingly, Ret signaling regulates Peyer’s 
patches organogenesis, underlining the prospective role of EGCs in orchestrating 
innate immune functions in the gut [155]. Furthermore, experiments performed 
in the submucosal plexus (SMP) from patients with functional dyspepsia (FD) 
showed that morphological alterations both in EGCs and neurons are due to 
increased numbers of eosinophil and mast cell within ganglionic structures [156]. 
This also suggests that EGCs and the immune system work together to maintain the 
intestinal homeostasis.
It is known that EGCs protect T lymphocytes from cell death by upregulating the 
expression of IL-7 after exposure to pro-inflammatory cytokines such as IL-1β and 
TNFα [157]. Moreover, EGCs were suggested to have immunosuppressive charac-
teristics in CD by inhibiting T-cell proliferation [158]). Nonetheless, the cellular and 
molecular mechanisms that govern the role of EGCs in intestinal pathologies remain 
unclear. EGCs express MHCII [148] that is upregulated under inflammatory condi-
tions [149, 159], conferring an immunological feature to these cells in a pathological 
environment. Moreover, EGCs can secrete and respond to IL-1β, IL-6, and IL-10 
and nitric oxide in vitro, as already mentioned, suggesting another property of 
these cells in the mediation of inflammatory responses [24, 160, 161]. Although, 
it is plausible that EGCs have an important function in modulating neuroimmune 
interactions, understanding their specific contributions to the maintenance of the 
gut homeostasis would be useful to decipher their roles in inflammatory disorders.
This would possibly suggest an immune protective role of EGCs to maintain the 
mucosal barrier. However, those studies failed in showing direct evidence that EGCs 
are necessary for intestinal barrier function. On the other hand, studies in which 
EGCs were disrupted but not entirely ablated did not show any noticeable signs of 
inflammation. In contrast, disruption in EGC homeostasis culminated in changes 
in mucosal function as well as in neurochemical coding, leading to alterations in 
enteric neurons and consequently in motor activity [162–164]. Thus, taken together, 
the immunological roles of EGCs protecting the intestinal environment from dam-
age remain contentious by using genetic tools to ablate/disturb these cells.
7. Conclusion
As we could notice in this chapter, there are still many unexplained aspects of the 
EGCs physiology. Although we have already found interesting studies that show their 
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relation with neurons or alterations in cases of inflammation, the exact mechanisms by 
which EGCs activates neurons to control GI motility are still unknown. Little is known 
about their interaction with the immune system, for example, or their participation 
in neurodegenerative diseases that affect both ENS and CNS. Recently, Seguella et al. 
suggest that EGCs could be the “missing link” that connects the ENS to the CNS [139]. 
EGCs in the context of disease could be an important target for diagnosis and therapy 
of many intestinal and neurological disorders.
Taken together, these evidence show the importance of EGCs for the mainte-
nance of intestinal homeostasis and that disturbance of glial functions could alter 
GI physiology through the modulation of neurotransmission and of the responses 
of the different cellular types or even activation of cellular signals to enter the 
neuronal differentiation processes in specific situations.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Involvement of Astrocytes in the 
Process of Metabolic Syndrome
Ana Karolina Santana Nunes, Haniel Soares Fernandes 
and Sura Wanessa Santos Rocha
Abstract
Astrocytes constitute a very heterogeneous population of cells, which regulate pH, 
extracellular levels of ions and neurotransmitters, and energy metabolism in addition 
to actively participating in neurotransmission. In situations of damage to the CNS, 
the typical response is the degree of reactive gliosis, which can form glial scars. On 
the other hand, chronic diseases such as obesity, type 2 diabetes, hypertension, and 
atherosclerosis have been causally related to low-grade chronic inflammation in vari-
ous metabolic tissues. It has been pointed out that the identification of hypothalamic 
inflammatory alterations are triggered by overnutrition, orchestrated by the hypo-
thalamic immune system, and sustained by the pathophysiology associated with the 
metabolic syndrome. We discuss here the effects of astrocytes and the main astrocyte 
mechanisms involved in the metabolic syndrome and its comorbidities.
Keywords: astrocytes, neuroinflammation, metabolic syndrome, metabolism
1. Introduction
The cases of metabolic syndrome (MetS) in adults are increasing, due to several 
factors such as aging population, physical inactivity, obesity and chronic overnutri-
tion [1]. Metabolic abnormalities are involved in the metabolic syndrome, such 
as diabetes mellitus, hypercholesterolemia and dyslipidemia, hypertension, and 
central obesity [2]. Several studies in neuroscience and immunology are linked to 
overnutrition to neuroinflammation, particularly in the hypothalamus and in the 
hippocampus, due to interaction between accelerated adiposity, hyperglycemia, and 
cognitive decline [3–5].
The primary risk of cognitive decline in both obese and hyperglycemic indi-
viduals is the systemic and chronic inflammatory component of MetS, due to 
preparation of the resident population of glial cells to establish a form of low-grade 
neuroinflammation [6].
Astrocytes are active agents of the dynamic central nervous system (CNS) 
signaling. The astrocytes participate in a variety of essential physiological processes 
in the healthy brain, such as providing structural support to neurons, participating 
in the formation and maturation of synapses, control of homeostasis of ions and 
metabolites, receptor trafficking, neurotransmitter clearance, and modulating the 
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Abstract
Astrocytes constitute a very heterogeneous population of cells, which regulate pH, 
extracellular levels of ions and neurotransmitters, and energy metabolism in addition 
to actively participating in neurotransmission. In situations of damage to the CNS, 
the typical response is the degree of reactive gliosis, which can form glial scars. On 
the other hand, chronic diseases such as obesity, type 2 diabetes, hypertension, and 
atherosclerosis have been causally related to low-grade chronic inflammation in vari-
ous metabolic tissues. It has been pointed out that the identification of hypothalamic 
inflammatory alterations are triggered by overnutrition, orchestrated by the hypo-
thalamic immune system, and sustained by the pathophysiology associated with the 
metabolic syndrome. We discuss here the effects of astrocytes and the main astrocyte 
mechanisms involved in the metabolic syndrome and its comorbidities.
Keywords: astrocytes, neuroinflammation, metabolic syndrome, metabolism
1. Introduction
The cases of metabolic syndrome (MetS) in adults are increasing, due to several 
factors such as aging population, physical inactivity, obesity and chronic overnutri-
tion [1]. Metabolic abnormalities are involved in the metabolic syndrome, such 
as diabetes mellitus, hypercholesterolemia and dyslipidemia, hypertension, and 
central obesity [2]. Several studies in neuroscience and immunology are linked to 
overnutrition to neuroinflammation, particularly in the hypothalamus and in the 
hippocampus, due to interaction between accelerated adiposity, hyperglycemia, and 
cognitive decline [3–5].
The primary risk of cognitive decline in both obese and hyperglycemic indi-
viduals is the systemic and chronic inflammatory component of MetS, due to 
preparation of the resident population of glial cells to establish a form of low-grade 
neuroinflammation [6].
Astrocytes are active agents of the dynamic central nervous system (CNS) 
signaling. The astrocytes participate in a variety of essential physiological processes 
in the healthy brain, such as providing structural support to neurons, participating 
in the formation and maturation of synapses, control of homeostasis of ions and 
metabolites, receptor trafficking, neurotransmitter clearance, and modulating the 
synaptic plasticity moment by moment [7]. Many studies have shown their contri-
bution to information processing and memory formation in the brain, thus pointing 
to a role for astrocytes in higher integrated brain functions [8, 9].
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A vast arsenal at the disposal of astrocytes is being defined, as in the determina-
tion of functions and mechanisms of reactive astrogliosis, cellular hypertrophy, and 
glial scar formation with preservation of the cellular domains and rearrangement of 
the tissue structure as well as contributing to specific CNS disorders and lesions [9]. 
Neuroinflammation in the enteric system occurs due to the activation of enteric glial 
cells (EGCs) which are the most abundant cells within the enteric nervous system 
(ENS). EGCs are located adjacent to the neurons within the enteric ganglia and 
along the interganglionic connections of the myenteric and submucosal plexus but 
also protrude into the extraganglionic mucosal layer [10–13]. Their morphology and 
the expression of markers such as calcium-binding protein S100 and glial fibrillary 
acidic protein (GFAP) [14] resemble central nervous system astrocytes.
The EGCs can exert immunomodulatory functions; they can secrete inflamma-
tory signaling molecules such as interleukins IL-1β and IL-6 [10, 15] as well as other 
mediators, including nerve growth factor (NGF), S-nitrosoglutathione (GSNO), 
nitric oxide (NO), and S100B [16], and express class II major histocompatibility 
(MHC) complex molecules [16, 17]. CNS astrocytes activated by inflammation are 
characterized by hypertrophy and proliferation, coupled with a positive regulation 
of the GFAP’s cytoskeleton [18], due metabolic syndrome and inflammatory condi-
tions of the intestinal disease (IBD) [19].
Many studies have shown that multiple connections between peripheral and 
cerebral changes involving inflammatory, metabolic, and neural components have 
been identified under conditions associated with obesity [20–22]. Therefore, iden-
tifying and treating these conditions is of primary importance to people worldwide. 
Obesity-related chronic inflammation provides an important link to metabolic 
derangements including insulin resistance, cognitive impairment affecting the 
hypothalamus, and other brain regions [20].
The present study was designed to discuss the effects of astrocytes and the main 
astrocyte and neuroinflammatory mechanisms involved in the metabolic syndrome 
and their comorbidities, which gave rise to the field of immunometabolism.
2. Neuroimmunologic mechanisms and role of glial cells
Until recently the CNS was considered to be immunologically privileged, since 
many antibodies and peripheral immune system cells are usually blocked through 
the blood-brain barrier (BBB), a specialized structure composed of endothelial cells 
(ECs), pericytes, astrocytes, and microglia [23]. The BBB maintains the chemical 
composition of the neuronal microenvironment, which is necessary for the proper 
functioning of neuronal circuits, synaptic transmission, synaptic remodeling, 
angiogenesis, and neurogenesis [24].
The immune system influences the functioning of BBB, which in turn affects 
the functioning of the CNS in both physiological and pathological conditions. In 
some cases, the BBB separates the CNS from the immune system; in others it acts 
as a mediator of neuroimmune interactions, and in others it may act as a target for 
immune system attacks [25]. In physiological conditions, immune cells cross the 
BBB at a very low rate, through specific interactions, promoting the endothelial 
junctions that control the flow of cells through them [26–28]. On the other hand, 
neuropathological diseases, such as Alzheimer’s disease (AD), Parkinson’s disease 
(PD), lateral amyotrophic sclerosis (LAS), multiple sclerosis (MS), and BBB 
destruction or damage, can be induced or mediated by LPS (lipopolysaccharide), 
cytokines, prostaglandins, and nitric oxide. The BBB is capable of responding to 
LPS due to the presence of Toll-like receptor 4 (TLR4) and other Toll-like receptors 
on the membranes of the BBB cells [29]. Similarly, these cells have receptors for 
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cytokines, chemokines, and other immunological molecules [30, 31]. As a result, 
the immune system is able to affect the functions of the BBB beyond those of 
disruption.
Perivascular cells (astrocytes and microglia) in addition to endothelial cells 
produce several inflammatory factors, such as the release of cytokines and chemo-
kines that affect the BBB permeability and the expression of adhesion molecules. 
Cytokines (TNF-α, IL1-β, IFN-γ) can stimulate the expression of adhesion mol-
ecules (vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion mol-
ecule 1(ICAM-1)) in endothelial cells allowing the passage of activated leukocytes 
into the CNS [32]. Immune cell (macrophages, lymphocytes) traffic through the 
BBB should initiate or contribute to a vicious cycle resulting in progressive synaptic 
dysfunction and neuronal loss in neurodegenerative disorders [20, 24].
On the other hand, a specific subset of T cells is essential to suppress autoim-
munity and maintain immune homeostasis. T regulatory cells (Treg) have been 
characterized with important functions. Emerging evidence shows that Treg cells 
are not only important for maintaining immune balance at the periphery but also 
contribute to the self-tolerance and immune privilege in CNS [33]. Leukocyte 
extravasation requires interactions between adhesion molecules in endothelial cells 
and leukocytes. Leukocyte adhesion molecules (LAMs) expressed by ECs include 
P-selectin, E-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular cell 
adhesion molecule 1 (VCAM-1) [34]. Selectin binds to P-selectin-binding glyco-
protein (PSGL-1), while ICAM-1 and VCAM-1 bind to α4-integrins in leukocytes. 
After the initial binding event, immune cells roll along the vessel wall releasing 
chemokines that strengthen their binding interactions, promoting the state of 
neuroinflammation [35].
Neuroinflammation is recognized as a prominent feature of various patho-
logical conditions [36]. Thus, several lines of evidence strongly suggest that 
neuroinflammation is a crucial process involved in the progression of neuronal 
degeneration, a common feature observed in several neurodegenerative disorders 
such as degenerative neuropathologies [36]. In the inflammatory process, the 
main cellular events are observed, such as increased blood flow and vascular 
permeability with consequent venular dilation and recruitment of cells to the 
inflamed site. A significant role played by reactive oxygen species has been 
observed to develop inflammation, causing endothelial cell damage and increased 
microvascular permeability, chemotactic factor production, neutrophil recruit-
ment, oxidation, and lipid peroxidation [37]. Such inflammatory mediators play 
a regulatory role in the growth, differentiation, and activation of immune cells 
[38]. Glial cells (microglia, astrocytes, and oligodendrocytes) define cerebral 
homeostasis and are responsible for defense and preservation against neural tissue 
injury [14].
3. The role of astrocytes in neuroinflammation
Astrocytes are an important group of heterogeneous cells and play key roles in 
the physiology of the nervous system, including regulation of pH, extracellular lev-
els of ions and neurotransmitters, and energy metabolism. In addition, it plays an 
important role in the formation and functioning of the BBB [39] and also actively 
participates in neurotransmission [27]. In pathological situations in the CNS, the 
typical response of astrocytes is the state of reactive gliosis involving positive gene 
regulation of cytoskeletal proteins (e.g., glial fibrillary acidic protein (GFAP)) 
and corresponding to the change in morphology reaching a state of hypertrophy, 
hyperplasia, and glial scar formation [40–42].
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In addition, astrocytes play an important role in central immunity. The innate 
immune response is accurately adjusted by identifying the type of threat that is 
present. The molecular structures that are associated with threats are recognized 
by Pattern Recognition Receptors (PRRs). PRRs recognize molecular patterns 
associated with pathogens (PAMPs) are expressions such as microorganisms 
such as bacteria, viruses and viruses, and damage-associated diseases (DAMPs) 
that signal cellular damage and are therefore responsible for a state of stress or 
injury [14]. Among PRRs, one of the main classes is the family of transmembrane 
proteins of Toll-like receptors (TLRs). Generally pathogen response and tissue 
damage happen quickly, assuming some roles of the cells of the immune system, 
releasing cytokines (IL-1β, IL-6, TNF-α) and chemokines (MCP-1, CCR-2, 
COX-2), influencing other cells of the immune system (macrophages and lym-
phocytes), and modulating the BBB [14].
Among glial cells, astrocytes play a role in the release of Toll-like receptors [43]. 
Since the TLRs are expressed and detected by the binding of their binding genes, 
a signaling mediated by the myeloid differentiation gene 88 (Myd88) is initiated, 
having an activation of the nuclear transcription factor NFκB. In the activation 
of NFκB, the inflammatory process is released through the secretion of pro- 
inflammatory molecules (1β, IL-6, TNF-α, IL-12). In addition, there is no state of 
activation of astrocytes to recruit microorganisms, lymphocytes, and dendritic cells 
to the lesion site [44].
4.  Implications of metabolic syndrome in the central nervous system: 
the role of the bowel-brain axis
The increased obesity in the last 40 years is considered a consequence of the 
sedentary lifestyle and adherence to diets rich in saturated fat and refined carbohy-
drates that induce changes in the microbiota and underlying metabolic and psycho-
logical complications [45]. Bacteria, viruses, protozoa, archaea, and fungi represent 
the microorganisms that inhabit the intestinal tract of mammals, with bacteria 
composing the majority [46, 47] in concentrations between 101 to 103 cells per gram 
in the upper intestine and 1011 to 1012 cells per gram in the colon [48].
These microorganisms play a role in human physiology through various mecha-
nisms, such as the metabolism of nutrients and the regulation of immunological 
and neuroendocrine functions, as they bind to the CNS through the enteric nervous 
system (ENS) [49]. From the microbiota, the active metabolite LPS (lipopolysac-
charide), in addition to short-chain fatty acids (SCFA), from invasive and com-
mensal bacteria, respectively [50, 51], can be expressed in the intestinal lumen 
and influence the integrity of BBB [52], especially butyrate, in which it positively 
induces the expression of junction proteins, including claudin-2, occludin, cingulin, 
and occludens-1 and occludens-2 (ZO-1 and ZO-2), forming protein structures in 
the gut, like tight junction [53, 54]. These proteins form a mechanical link between 
epithelial cells and establish paracellular diffusion of fluids and solutes in the 
barrier [55]. Where high fiber and fruit meals were shown to reduce the increas-
esinduced by meals with high saturated fat and high carbohydrate content inlevels 
inflammatory response [56].
In mammals, colon epithelial cells, adipocytes, and peripheral blood mononuclear 
cells express a pair of G-protein-coupled receptors (GPR41 and GPR43) that are acti-
vated by SCFAs through the receptors on the T enteroendocrine cells [57]. They sense 
the amount of AGCC produced by bacteria in the colon and secrete the glucagon-like 
peptide 1 (GLP-1) and the tyrosine tyrosine peptide (PYY), allowing inhibition of 
intestinal motility and increased absorption of nutrients, respectively [58]. Thus, the 
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composition of the diet determines the type of nutrient that reaches the gastrointes-
tinal tract (GI) that can alter the composition of the intestinal microbiota and the 
production of metabolites to, consequently, influence intestinal permeability [59].
Bacterial products, such as LPS, can display a variety of PAMPs recognized 
by TLRs and nucleotide-binding oligomerization domain receptors (NOD) on 
macrophages and dendritic cells in the innate immune system, such as flagel-
lin, recognized by TLR5 to induce α-defensin secretion through Paneth cells, a 
NOD-dependent antimicrobial protein [60]. All TLRs recognize protein, lipid, 
or nucleotide PAMPs. TLR2, TLR4, and TLR6 recognize fungal PAMPs, while 
TLR9 and TLR11 recognize protozoan PAMPs [61]. Although TLRs can activate 
immune cell proliferation through an Akt-dependent pathway, they will all 
induce the expression and secretion of cytokines [61]. Although TLRs may 
activate immune cell proliferation via an Akt-dependent pathway, all but TLR3 
will induce the expression and secretion of tumor necrosis factor-α (TNF-α), 
interleukin 1β (IL-1β), and interferon-γ (IFN-γ), recruiting the primary myeloid 
differentiation response 88 (MYD88), which recruits the kinase family associ-
ated with the interleukin-1 receptor (IRAK), leading to phosphorylation of the 
inhibitory protein kappa B (I- kB) to induce translocation of nuclear factor kappa 
B (NF-kB) and influence the expression of inflammation [62, 63]. In addition, 
the activation of TLRs participates in the proliferation of epithelial cells and IgA 
secretion in the intestinal lumen, essential for intestinal barrier integrity and 
bacterial population balance, respectively [61]. Deregulation of these processes, 
or excessive activation of TLRs, can result in chronic inflammatory responses 
and exuberant repair [64].
In the epithelium, segmented bacterial filaments (SFB) and other commensal 
microbes activate dendritic cells (DCs) and macrophages in the lamina propria, 
inducing T helper 17 (TH17) cells through the production of interleukins IL-1β, 
IL-6, and IL-23 and helper T cells (TH1) by the possible production of interleu-
kin-12 (IL-12) [21]. TH17 cells regulate the gut microbiota community by secreting 
the IL-22-dependent antimicrobial lectin regenerating islet-derived 3 gamma 
(REGIIIγ). One of the microbial derivatives, polysaccharide A (PSA), stimulates 
intestinal epithelial cells to secrete growth factor and β transformation (TGFβ), 
inducing DCs and macrophages to secrete retinoic acid and interleukin 10 (IL-10) to 
promote activation of regulatory T cells and forkhead box P3 (FOXP3) and, subse-
quently, inactivation of TH17 and TH1 cells, in a type of negative feedback between 
the cells of defense in relation to the balance of the gut bacteria [65]. Activation 
of TLRs induces B cell-activating factor (BAFF) secretion, which differentiates B 
cells by increasing activation-induced cytidine deaminase (AID) expression and 
promotes differentiation of IgA-producing plasma cells, by maturing antibodies 
and casting in the intestinal lumen to alter the composition and function of the 
microbiota [65].
In obese individuals, due to imbalance of the microbiota (dysbiosis) and oxida-
tive stress, TLR4 is activated and recognizes the bacterial LPS and the flagellin of 
commensal bacteria, activating TLR5 for dendritic cell signaling and activation of 
innate lymphoid cells (ILCs), both processes to secrete REGIIIY [66]. ILCs commu-
nicate with the microbiota through cytokines, aryl hydrocarbon (AhR) receptors, 
and antimicrobial peptides and participate in the cross-talk of epithelial cells with 
the intestinal microbiota [67]. Divided into three groups, group ILCs (ILC1) are 
activated by interleukin-12 (IL-12) derived from myeloid cells, which in response 
secrete IFN-γ, whereas group ILCs (ILC2) interact with mast cells, eosinophils, 
basophils, and macrophages, and group 3 (ILC3) ILCs interact with cells of both 
innate and adaptive immune systems to secrete IL-22 and initiate an antimicrobial 
program along with restoration of the intestinal barrier [68].
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macrophages and dendritic cells in the innate immune system, such as flagel-
lin, recognized by TLR5 to induce α-defensin secretion through Paneth cells, a 
NOD-dependent antimicrobial protein [60]. All TLRs recognize protein, lipid, 
or nucleotide PAMPs. TLR2, TLR4, and TLR6 recognize fungal PAMPs, while 
TLR9 and TLR11 recognize protozoan PAMPs [61]. Although TLRs can activate 
immune cell proliferation through an Akt-dependent pathway, they will all 
induce the expression and secretion of cytokines [61]. Although TLRs may 
activate immune cell proliferation via an Akt-dependent pathway, all but TLR3 
will induce the expression and secretion of tumor necrosis factor-α (TNF-α), 
interleukin 1β (IL-1β), and interferon-γ (IFN-γ), recruiting the primary myeloid 
differentiation response 88 (MYD88), which recruits the kinase family associ-
ated with the interleukin-1 receptor (IRAK), leading to phosphorylation of the 
inhibitory protein kappa B (I- kB) to induce translocation of nuclear factor kappa 
B (NF-kB) and influence the expression of inflammation [62, 63]. In addition, 
the activation of TLRs participates in the proliferation of epithelial cells and IgA 
secretion in the intestinal lumen, essential for intestinal barrier integrity and 
bacterial population balance, respectively [61]. Deregulation of these processes, 
or excessive activation of TLRs, can result in chronic inflammatory responses 
and exuberant repair [64].
In the epithelium, segmented bacterial filaments (SFB) and other commensal 
microbes activate dendritic cells (DCs) and macrophages in the lamina propria, 
inducing T helper 17 (TH17) cells through the production of interleukins IL-1β, 
IL-6, and IL-23 and helper T cells (TH1) by the possible production of interleu-
kin-12 (IL-12) [21]. TH17 cells regulate the gut microbiota community by secreting 
the IL-22-dependent antimicrobial lectin regenerating islet-derived 3 gamma 
(REGIIIγ). One of the microbial derivatives, polysaccharide A (PSA), stimulates 
intestinal epithelial cells to secrete growth factor and β transformation (TGFβ), 
inducing DCs and macrophages to secrete retinoic acid and interleukin 10 (IL-10) to 
promote activation of regulatory T cells and forkhead box P3 (FOXP3) and, subse-
quently, inactivation of TH17 and TH1 cells, in a type of negative feedback between 
the cells of defense in relation to the balance of the gut bacteria [65]. Activation 
of TLRs induces B cell-activating factor (BAFF) secretion, which differentiates B 
cells by increasing activation-induced cytidine deaminase (AID) expression and 
promotes differentiation of IgA-producing plasma cells, by maturing antibodies 
and casting in the intestinal lumen to alter the composition and function of the 
microbiota [65].
In obese individuals, due to imbalance of the microbiota (dysbiosis) and oxida-
tive stress, TLR4 is activated and recognizes the bacterial LPS and the flagellin of 
commensal bacteria, activating TLR5 for dendritic cell signaling and activation of 
innate lymphoid cells (ILCs), both processes to secrete REGIIIY [66]. ILCs commu-
nicate with the microbiota through cytokines, aryl hydrocarbon (AhR) receptors, 
and antimicrobial peptides and participate in the cross-talk of epithelial cells with 
the intestinal microbiota [67]. Divided into three groups, group ILCs (ILC1) are 
activated by interleukin-12 (IL-12) derived from myeloid cells, which in response 
secrete IFN-γ, whereas group ILCs (ILC2) interact with mast cells, eosinophils, 
basophils, and macrophages, and group 3 (ILC3) ILCs interact with cells of both 
innate and adaptive immune systems to secrete IL-22 and initiate an antimicrobial 
program along with restoration of the intestinal barrier [68].
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5. Neuroinflammation from the intestine
The gut-brain axis is composed of the central nervous system, innervated by affer-
ents and efferents of the vagus nerve and extrinsic fibers of the autonomic nervous 
system (ANS) interconnecting it to the hypothalamic-pituitary-adrenal (HPA) axis, 
in addition to the intrinsic neurons of the enteric nervous system and the intestinal 
microbiota. Intrinsic intestinal innervations connect the intestine to the brain via 
vagal and spinal fibers, whereas the brain sends efferent sympathetic and parasympa-
thetic fibers to the intestine [69, 70]. The HPA axis is part of the limbic system and is 
the main regulator of stress response and intestinal function during digestion which, 
due to the corticotrophin releasing factor (CRF) secreted by the hypothalamus, can 
influence the motility, permeability, and level of intestinal inflammation [47, 71]. 
Therefore stress and emotions can influence the microbial composition of the intes-
tine by bacterial products that gain access through the bloodstream and the postrema 
area and due to the release of glucocorticoids and/or sympathetic neurotransmitters 
that influence the physiology of the intestine and alter the habitat of the microbiota, 
such as noradrenaline, which may even influence bacterial gene expression or signal-
ing among bacteria, altering the composition and activity of the microbiota [72].
After bacterial colonization, increased production of neurotransmitters, such as 
serotonin (5-HT) and γ-aminobutyric acid (GABA), and the expression of various 
cytokines are physiological implications essential for intestinal homeostasis and 
HPA axis programming, which plays an important role in stress responses [73]. The 
attention is focused on the stress due to serotonin, which is synthesized through 
tryptophan, in enterochromaffin cells (EC), about 90%, and in autonomic nerves, 
about 10%, i.e., at the level of the gastrointestinal tract [74].
Stress, corticosterone, and inflammation are the cornerstones of the catabolism 
of L-tryptophan (TRP) to kynurenine (KYN) and, subsequently, to quinolinic acid 
(QUIN) [75, 76]. TRP catalysis occurs through the enzymes indoleamine 2,3-dioxy-
genase (IDO), kynurenine monooxygenase (KMO), and tryptophan 2,3-dioxygen-
ase (TDO), where stress results in the production of corticotropin-release hormone 
(CRH) by the hypothalamus, which induces the synthesis of adrenocorticotropic 
hormone (ACTH) by corticotrope cells in the anterior pituitary to target by blood 
the adrenal cortex and synthesize glucocorticoids for induction of TDO and activa-
tion of intracellular glucocorticoid receptors (GR) and subsequent TRP catalysis 
in KYN and kynurenic acid (KYNA) by kynurenine aminotransferase (KAT) or in 
3-hydroxyquinurenine (3OH-KYN), both with neurotoxic potential of cataboliz-
ing 5-HT in 5-hydroxyindoleacetic acid (5-HIAA) by kynurenine monooxygenase 
[77]. On the other hand, stress induced by β-adrenergic receptors on the MSA axis 
(medullary sympathetic- adrenal) activates lymphoid cells and induces the release 
of proinflammatory cytokines IL-1β, IL-6 and IFN-γ and catecholamines [76].
These events induce the barrier permeability and increase of bacterial endotoxin 
through the gut, which stimulates immune cells in the lamina propria to secrete 
proinflammatory cytokines and prostaglandins (PGE2) to communicate the brain 
via afferent nerves, compromising the intestinal barrier and creating a cycle, where 
inflammatory cytokines will activate the SAM and HPA axes, resulting in barrier 
rupture, increased endotoxin translocation, and an inflammatory and stress state 
[78]. Where, one of the causes of this translocation, from the intestinal point of 
view, concerns LPS of invasive bacteria and their arrival in the intestinal lumen, in 
which it will induce a pro-inflammatory response in lymphoid and innate immune 
cells, and subsequent release of cytokines such such as IL-1β, IL-6 and TNF-α, in 
the bloodstream to the brain, from the axis of the gut-brain, affecting BBB integ-
rity, causing a pro-inflammatory stress cycle in CNS cells inducing neuroinflamma-
tion [79] Figure 1.
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6.  Mechanisms of neuroinflammation and the process of metabolic 
syndrome
The proinflammatory cytokines (IL-1β, IL-6 and IFN-γ) and catecholamines, 
are able to induce IDO within CNS, exactly within the astrocyte and microglia, so 
the uptake and metabolism of L-tryptophan into theses cells leads to the production 
of KYNA, was report have neuroprotective actions in the CNS, but the catabolism 
of L-tryptophan in the microglia gives rise to metabolites with reactive oxidative 
properties, such as 3OH-KYN, 3-HAA and QUIN, that can be transported through 
the BBB to serve as substrates and contribute to the kinurenine pathway in the CNS, 
where macrophages and microglia represent the main sources of QUIN, a agonist on 
N glutamate receptor subtype methyl-D-aspartate (NMDA) that acts as a being able 
contribute to excitotoxicity and neurotoxicity [80, 81].
The astrocytes do not appear to have KMO, which favors the formation of 
KYNA, which after being released in the presynaptic area preferentially inhibits the 
NMDARs and α7 nicotinic acetylcholine receptors (nAChRs) in the extra-synaptic 
[81] Figure 2.
This leads to more leukocyte inflammation and infiltration at the BBB, since tight 
junction proteins, including claudins, ZO-1, and occludins, are downregulated [82]. 
Figure 1. 
Mechanisms by which the intestine is able to influence actions in the central nervous system (Fernandes, HS 
and Nunes, AKS).
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In response to inflammation, leukocyte extravasation increases with positive regulation 
of VCAM-1 and ICAM-1 [39]. Once the functional capacity of astrocytes is compro-
mised, BBB is impaired, resulting in a significant increase in BBB permeability rate, a 
promotion of leukocytes in cerebrospinal fluid (CSF), and increased immune response, 
including pathogens and toxins in the CNS. This process favors the activation of astro-
cytes and microglia, which stimulates the continuous symptoms in the CNS, including 
the hypothalamus, with consequent response to the stress of insulin symptoms, as well 
as cognitive injury [83].
Within the metabolic syndrome, diabetes mellitus involves the CNS, and 
insulin signal transduction involves the activation of phosphatidyl-3 kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) pathways [84]. The insulin 
receptor (IR) has two subunits (α and β). The α-subunit is directed toward the 
extracellular medium. Insulin binding to the IR receptor promotes autophos-
phorylation of the receptor on β subunits, located within the plasma membrane. 
A phosphorylation cascade of the insulin receptor substrates (IRS) 1 to 4 is then 
followed, and PI3K is then recruited into the membrane and induces the insertion 
of the GLUT glucose transporter into the plasma membrane [85]. In addition, 
PI3K also phosphorylates AKT, which in turn phosphorylates the glycogen syn-
thase kinase 3 (GSK3) protein by inactivating it. This inactivation decreases the 
phosphorylation of Tau, which is present in neurons and has the function of stabi-
lizing the microtubules for the transport of synaptic vesicles and other cellular 
components [86]. Therefore, the neuroinflammatory process comprises several 
mechanisms through the activation of the glial cells that leads to neuronal damage 
and consequent damages to the CNS.
Figure 2. 
Mechanism of astrocytes and microglia during the metabolic syndrome. Increased BBB allows the invading cells 
of the peripheral immune system and promotes the activation of glial cells, with consequent release of cytokines. 
In parallax, description of the KYN mechanism (Fernandes, HS and Nunes, AKS).
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7. Conclusion
In metabolic syndrome and obesity-associated conditions, immune and meta-
bolic dysregulation results in chronic systemic inflammation, neuroinflammation, 
cognitive impairment, and other pathological manifestations. An understanding of 
this complex pathology requires providing new insight into the regulatory role of 
the astrocytes.
Although research to date in the fields of immunometabolism and neuroinflam-
mation has produced encouraging preliminary results, there remains a vast expanse 
of unexplored questions requiring the interdisciplinary knowledge of metabolism, 
neuroscience, and immunology.
In summary, the descriptions of this study indicate that astrocytes play an 
important role in immunity by triggering neuroinflammation mediated by meta-
bolic syndrome associated with obesity. Elucidating these mechanisms by binding 
the metabolism syndrome, inflammation, and CNS by astrocytes could generate 
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Abstract
A significant increase in inflammation has been shown to be a crucial fac-
tor in the progression of the Alzheimer’s disease (AD). Moreover, inflammatory 
signals are already present in mild cognitive impairment (MCI) patients before 
they develop AD. The amyloid hypothesis argues that in AD, there is an increase in 
oxidative stress caused by the accumulation of β-amyloid (Aβ) and that its elimina-
tion should be a priority. Also, hyperphosphorylation of the protein TAU occurs, 
which is characteristic of this disease. In AD oxidative stress processes occur and 
also inflammation. The basal chronic inflammation produces a cascade of cellular, 
such as astrocytes and microglial cells, and molecular processes in AD patients. We 
here have tried to explore the action of the inflammatory process and its implication 
in the neurodegenerative process of the AD. We can see that the role of Aβ is only 
one component that gives rise to inflammation, probably mediated by activation of 
microglia and astrocytes with the goal of getting rid of these brain waste products. 
In fact, it is related to a greater degree with the progression of the disease and 
worsening of the symptoms with the increase of phosphorylated TAU in different 
parts of the brain.
Keywords: astrocytes, microglia, neuroprotection, Alzheimer’s disease, 
inflammation, oxidative stress
1. Introduction
Inflammation is a physiological process in response to various factors such as 
infection, trauma, and a long list of diseases that can promote it [1]. It is not uncom-
mon to think that changes or failures that occur in their action mechanisms can lead 
to fatal consequences for humans. The inflammation originates because of a set of 
immune cells involved in the process that causes different changes in the inflamed 
area through signaling pathways composed of different groups of pro and anti-
inflammatory molecules [2]. The resolution of the inflammatory process happens 
after the neutralization of the trigger. The cells of the immune system generate 
an anti-inflammatory activity, including lipoxins (for example, LXA4, RvE1) and 
cytokines such as interleukin-10 and interleukin-37, transforming growth factor-
beta (IL-10, IL-37, TGF-β) [3]. Acute inflammatory processes will be resolved 
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1. Introduction
Inflammation is a physiological process in response to various factors such as 
infection, trauma, and a long list of diseases that can promote it [1]. It is not uncom-
mon to think that changes or failures that occur in their action mechanisms can lead 
to fatal consequences for humans. The inflammation originates because of a set of 
immune cells involved in the process that causes different changes in the inflamed 
area through signaling pathways composed of different groups of pro and anti-
inflammatory molecules [2]. The resolution of the inflammatory process happens 
after the neutralization of the trigger. The cells of the immune system generate 
an anti-inflammatory activity, including lipoxins (for example, LXA4, RvE1) and 
cytokines such as interleukin-10 and interleukin-37, transforming growth factor-
beta (IL-10, IL-37, TGF-β) [3]. Acute inflammatory processes will be resolved 
relatively quickly, while, however, resolution processes are not achieved in chronic 
inflammation [4].
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The differences between both types of inflammation, acute and chronic, reside 
at different levels. Regarding the cells involved in acute inflammation, neutrophils 
intervene in an infection context and eosinophils and mast cells in the case of aller-
gies [5]. The chemical mediators involved in acute inflammation would be the com-
plementary system, the kinins, the prostaglandins, the leukotrienes, the cytokines 
coming from several immune cells, and the gamma interferon of the T lymphocytes 
[6]. The lesions that are produced in this type of inflammation are itching, pus, 
and abscesses [7]. On the other hand, in chronic inflammation, we would have the 
participation of macrophages and lymphocytes mainly, which would produce cyto-
kines as the main chemical mediators of this type of inflammation. As alterations, 
we would also have a rash (in the context of a cutaneous disease), and unlike the 
findings we had in the acute, in chronic we can have fibrosis and granuloma. These 
last two injuries are ultimately responsible for the effects of deterioration at central 
nervous system (CNS) and peripheral (SNP) level [8]. The study of neurodegenera-
tive diseases excluded inflammation as an etiological agent of the disease. This was 
because there were no infiltrates of inflammatory cell similar to those that occur in 
infectious or autoimmune diseases [9]. Nowadays, there is an increasing amount 
of studies that position inflammation as being responsible for neurodegeneration 
through the participation of macrophages and the complementary system [10].
2. Specification of the process at the brain level
In the brain there is no reddening, local heat, or pain after acute inflammation. 
In the case of chronic inflammation in another organ, the participation of different 
immune cells takes place. But in the CNS, macrophages are essentially the represen-
tatives of the immune system [11].
In the CNS, the derivatives of tissue macrophages would be the microglia of 
the central nervous system. Microglia participate in numerous maintenance func-
tions such as synapse management, neurogenesis, regulation of certain cognitive 
processes, and immunological protection [12]. Thus, the main hypothesis on the 
pathogenesis of Alzheimer’s disease (AD) is that the plaques of β-amyloid (Aβ) and 
neurofibrillary tangles produce an acute inflammation in the brain, which activates 
these cells causing different inflammatory mediators, such as: proinflammatory 
cytokines, chemokines, macrophage inflammatory proteins, monocyte chemoat-
tractant proteins, prostaglandins, leukotrienes, thromboxanes, coagulation fac-
tors, reactive oxygen species (and other radicals), nitric oxide (NO), complement 
factors, proteases, protease inhibitors, pentraxins, and C-reactive protein [13]. Due 
to the chemical composition of the Aβ plaques and neurofibrillary tangles, they 
stimulate a chronic inflammatory reaction with the intention of eliminating these 
brain structures [13]. Finally, this inflammatory reaction will produce a neuronal 
dystrophy mediated by the inflammatory mediators that are secreted by the microg-
lial and astrocyte cells, as well as by the aggregates of amyloid fibrils [14].
3. Pathophysiology of Alzheimer’s disease
The pathophysiology of Alzheimer’s disease is very varied and there are different 
hypotheses on how it develops: the most accepted hypothesis in recent years was 
the amyloid hypothesis. The amyloid precursor protein (APP) will be able to be 
processed by either α-secretase, β-secretase, or γ-secretase. Depending on which 
enzyme does the app cut, we can have more or less neuroprotective profile; the 
α-secretase cleave produced a more neuroprotective one, while on the other hand, 
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if the β- and γ-secretase participate sequentially, we will obtain metabolites that are 
harmful to neurons, producing greater amount of Aβ [13].
3.1 Role of α-secretase
α-Secretases are a family of proteolytic enzymes that adhere to APP in their 
transmembrane region. The secretases adhere to the fragment that, however, is 
processed by β-secretases and γ-secretases and that increases the β amyloid peptide 
[15]. These enzymes are members of the ADAM (disintegrin and metalloprotease 
domain) family that are expressed on cell surfaces. Furthermore, a metabolite by 
the action of secretase is APPsα, which has a not only neuroprotective action, but 
also neurotrophic effects have been observed and, therefore, neuroplasticity can be 
favored [16].
3.2 Role of β- and γ-secretases
The amyloid plaques are composed of a fragment of the APP: the 4-kD 
amyloid-β protein. The enzymatic processing of APP, resulting in Aβ, requires two 
enzymes: the γ-secretase, which is dependent on presenilin, and β-secretase, which 
is an aspartyl protease β-site APP-cleaving enzyme (BACE) (also known as Asp2, 
memapsin 2) [17, 18]. The BACE1 will function to split the APP, giving as result the 
βCTF (beta C-terminal fragment), which will later be cleaved again by γ-secretase 
to give rise to Aβ. On the other hand, this second excision could be caused by a 
mechanism different from that carried out by γ-secretase, which would be depen-
dent on a 20S proteasome and whose malfunction would lead to an overproduction 
of Aβ in the same way [19].
3.3 The β-secretase: BACE
There are two BACEs, BACE1 and BACE2. BACE2 is a homolog discovered 
later than the enzyme BACE1 and shares 64% of similarity in its structure. By 
contrast, BACE2 is expressed at low levels in neurons and does not have the same 
activity against APP as BACE1 [20]. The BACE1 is doubly increased in the brains 
of patients with AD, compared to the brains of individuals without the disease. 
For this reason, it is considered that this enzyme is responsible for  
the initiation or acceleration of AD. Other studies show how BACE1 is also 
increased in response to stress: during oxidative stress, hypoxia ischemia, apop-
tosis, and brain trauma [18].
3.4 The γ-secretase
Research on the proteolytic processing of APP has provided information on 
the pathogenesis of Alzheimer’s disease and on an unusual form of regulation of 
proteolytic processing within the domains of some membrane proteins, includ-
ing APP, Notch, and ErbB4 [21]. Some of the enzymes responsible for α and β 
cleavage are already known. However, the molecular events that are involved in 
the cleavage produced by the γ-secretase, within the transmembrane domain of 
these proteins, are much more complex. Presenilins and nicastrin are necessary 
for this process. While the role of presenilins, in some cases, supports the idea 
that presenilins are found in the active site of the γ-secretase, other data indicate 
that they could have a more indirect function, as for example in the transport 
of substrates to the subcellular compartment for cleavage by the enzyme 
γ-secretase [22].
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3.5  Role of β-secretase: BACE1 and γ-secretase in voltage regulation by sodium 
channel
The sodium channels Na1s are responsible for regulating for regulating the 
passage of Na+ in the initial axonal fragments, Ranvier nodes, and neuromuscular 
junctions. These channels are formed by an α-subunit in the form of pore and 
two accessory β subunits which are transmembrane that modify the localization, 
surface cell expression, and inactivation of the alpha subunit by direct interac-
tion, specially β2 subunit of the Na-1 channel that plays an important role since 
it undergoes degradation by BACE1 and γ-secretase [23]. These enzymes cleave 
an intracellular fragment of the C-terminal fraction that results in a transcription 
factor for Na1.1 mRNA and other protein levels, so that Na 1.1 levels accumulate 
intracellularly [23]. This fact explains the decreased expression of sodium chan-
nels on the surface of the hippocampal neurons of patients with AD, as well as 
in neuroblastoma cells producing BACE1, resulting in a lower sodium current 
density [23].
3.6 Differences between Aβ40 and Aβ42
To better understand the fact why Aβ42 promotes, to a greater extent, inflam-
mation in AD than the Aβ40 peptide, it is necessary to emphasize its greater 
propensity to form amyloid plaques [24]. Studies performed by combining 
molecular dynamics and nuclear magnetic resonance (NMR) experiments with 
respect to the behavior of both peptides in water have shown that the Aβ42 
peptide forms tangles more prominently [24, 25]. The differences that exist at 
the level of the chemical formula between the two peptides are only two amino 
acid residues at the C-terminus. However, at the level of biochemical and con-
formational interactions, there are clear differences [25]. In addition, while the 
N-terminal half presents a much smaller spectrum of possible conformations in 
its secondary structure, the C-terminal half of the Aβ42 peptide allows a greater 
number of possible conformations. Despite this, these studies showed that Aβ42 
is more structured in water than Aβ40 [24]. Specifically, it is appreciated that 
the Aβ42 form has less flexibility than Aβ40 in its C-terminal half. This fact is 
produced by the formation of a beta hairpin in the sequence IIGLMVGGVVIA, 
involving short fragments of the structure between the residues of amino acids 
31–34 and 38–41, reducing the flexibility in the Aβ42 peptide. Specifically, this 
must be the cause of the greater capacity to form amyloid plaques. On the other 
hand, a β-turn type VIB, centered on residues 35 and 36, is important for the 
alignment of the threads involved. In addition, the existence of hydrogen bonds 
between the pairs A30-A42, I32-V40, and L34-G38 adds stability to the structure 
of the beta fork [24, 25].
4. Identification and definition of the problem-question
In epidemiological studies of Alzheimer’s disease, a significant increase in 
inflammation has been shown to be a crucial factor in the progression of the 
disease, as well as in the activation of microglia and in the increase of reactive astro-
cytes in these patients [26]. It should be noted that inflammatory signals are already 
present in mild cognitive impairment (MCI) patients before they develop AD [27]. 
In this study, we have tried to explore the action of the inflammatory process associ-
ated with Alzheimer’s disease and its implication in the neurodegenerative process 
of the disease.
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5. Interest of the review
Glial cells have a very important role in the protection of the central nervous 
system against damage and also in the repair of damaged nerve tissue [28]. Within 
the glia, astrocytes are the cell type prevalent in the brain [29]. Astrocytes increase 
neuronal viability and mitochondrial biogenesis, protecting neural cells from 
oxidative stress and inflammation induced by the toxic amyloid peptide [30–32]. 
Conversely, if chronic inflammation occurs, astrogliosis is triggered, produced by 
a reaction to inflammation and oxidative stress caused by toxic and inflammatory 
agents [33]. In Alzheimer’s disease, complex changes and specific conflicts occur 
in different brain regions. The number of reactive astrocytes increases, engulfing 
and reducing the amyloid plaques. In addition, astrocytes surround the amyloid 
plaques and secrete proinflammatory factors, such as tumor necrosis factor (TNF) 
or interleukin 1 (IL-1) [34]. Currently, no hypothesis about what causes Alzheimer’s 
disease has obtained favorable results. For years, it has been believed that the 
amyloid theory was the correct one and it was the most supported and financed by 
almost all the pharmaceutical companies around the world. The amyloid hypothesis 
argues that in AD, there is an increase in oxidative stress caused by the accumula-
tion of Aβ and that its elimination should be a priority. There is a lot of research 
showing that increased levels of ROS have been linked to Alzheimer’s disease [30, 
35] but the effects of antioxidants in clinical studies have been disappointing either 
because high concentrations of antioxidants are pro-oxidants, or because the oxida-
tive stress occurs relatively early in the course of the disease.
5.1 Mediators of the inflammatory process in AD
5.1.1 Cytokines
In AD, different cytokines have been detected, such as IL-1α, IL-1β, IL-6 and, 
similarly, higher amounts of the type B receptor IL-8 (IL-8RB) have also been found 
(in neurons in addition to the rest immune cells), unlike the type A receptor for 
IL-8RA that is only found in immune cells [36, 37]. It was already demonstrated that 
inflammatory signals are previously present in patients with mild cognitive impair-
ment or with MCI before they develop AD [27].
The cytokine IL-1β constitutes one of the first secreted cytokines in response to 
lesions, as it is an important mediator of proliferation, differentiation, and apopto-
sis [38, 39]. The concentration of the said cytokine has been increased near the sites 
where the amyloid plaques are located [40]. More recently, it was observed that old 
mice had an increased basal neuroinflammation and they express IL-1β and IL-10 in 
the hippocampus compared to adult mice [41].
A study conducted in autopsies of 10 patients clinically diagnosed with AD 
showed that they had amyloid plaques and immunoreactivity for the cytokine IL-6. 
On the other hand, the control patients did not have immunoreactivity for IL-6 
whether they presented plaques or not. From the plaques that were positive for the 
cytokine IL-6, it could be observed that they were most frequently found in dif-
fuse plaques, less frequently in primitive plaques, and rarely found in compact and 
classic plaques [42].
5.1.2 Role of lipopolysaccharide (LPS)
The role of lipopolysaccharides in Alzheimer’s disease has been studied by sev-
eral research groups and it has been observed that treatment with these LPS induces 
chronic neuroinflammation [43, 44] and can contribute to deficits in learning 
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3.5  Role of β-secretase: BACE1 and γ-secretase in voltage regulation by sodium 
channel
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it undergoes degradation by BACE1 and γ-secretase [23]. These enzymes cleave 
an intracellular fragment of the C-terminal fraction that results in a transcription 
factor for Na1.1 mRNA and other protein levels, so that Na 1.1 levels accumulate 
intracellularly [23]. This fact explains the decreased expression of sodium chan-
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in neuroblastoma cells producing BACE1, resulting in a lower sodium current 
density [23].
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respect to the behavior of both peptides in water have shown that the Aβ42 
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In this study, we have tried to explore the action of the inflammatory process associ-
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of the disease.
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5. Interest of the review
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mice had an increased basal neuroinflammation and they express IL-1β and IL-10 in 
the hippocampus compared to adult mice [41].
A study conducted in autopsies of 10 patients clinically diagnosed with AD 
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On the other hand, the control patients did not have immunoreactivity for IL-6 
whether they presented plaques or not. From the plaques that were positive for the 
cytokine IL-6, it could be observed that they were most frequently found in dif-
fuse plaques, less frequently in primitive plaques, and rarely found in compact and 
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eral research groups and it has been observed that treatment with these LPS induces 
chronic neuroinflammation [43, 44] and can contribute to deficits in learning 
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and memory [44–46]. As previously known, LPS is an activator of microglia in the 
central nervous system and can induce a 2-fold increase in the expression of APP in 
the brains of mice with the Swedish mutation for APP [47]. In addition, it also caused 
an 18-fold increase in βCTF, suggesting an increased activity in turn of BACE1 and in 
turn an increase by up to three times in the amount of Aβ40 and Aβ42 [47]. While the 
previous study observed an increase in the brain in a non-specific manner, another 
study specifically analyzed the increase in glial fibrillary acidic protein (GFAP)-
positive astrocytes in the cortex and hippocampus after treatment with LPS [48].
5.2 Alzheimer’s disease as taupathy
5.2.1 Structure of the TAU protein
In electrophoresis gels, the TAU protein has been found in different isoforms 
depending on how the RNA has been processed and different levels of phosphoryla-
tion. This RNA is located on chromosome 17, it has at least 16 exons [49]. Other 
proteins besides tubulin have been described that can bind to the TAU protein: 
spectrin protein phosphatase 1, protein phosphatase 2a, presenilin 1, α-synuclein. 
Recent studies that have used mass spectrophotometry techniques indicate that it is 
more appropriate to measure the bacterially expressed MT-binding region (MTBR) 
domain of TAU, instead of the total TAU protein, this technic is more accurate to 
calculate the amount of TAU neurofibrillary tangles [50].
5.2.2 AD as taupathy
The TAU protein is a member of the microtubule-associated proteins (MAPs). 
The microtubules in the cells have a multitude of functions, among which we can 
highlight at the level of the neurons the formation of dendrites, axons, and their 
specific contacts [51]. Therefore, the TAU protein is necessary for the functioning 
and development of the nervous system and the presence of modified forms of 
the TAU protein gives rise to important pathological effects in the neurons that 
leads to neurodegeneration. Specifically in AD, phosphorylation of TAU protein is 
produced by glycogen synthase 3ß (GSK3) [49]. This TAU protein is abnormally 
phosphorylated and will form the neurofibrillary tangles in the neuronal cyto-
plasm, constituting one of the most important histological features of Alzheimer’s 
disease. As previous works demonstrated, the number of these balls will be directly 
related to the severity of the symptoms of the disease [52]. The structure of these 
microtubules will be formed by double helix subunits that are intertwined with 
levorotatory filaments that are composed of the following proteins: intermediate 
filaments, neurofilaments of medium and high molecular weight; proteins associ-
ated with microtubules MAP2 and TAU; actin; and ubiquitins [53, 54], which show 
characteristics different from normal neurofilaments and normal microtubules.
In 1995, a study in autopsies done with eight patients with diagnostic criteria 
for Alzheimer’s disease and six control patients of similar ages indicated impor-
tant changes between TAU and inflammation. The brain of these 15 subjects was 
extracted without exceeding 15 h of postmortem and, later, samples were taken 
from the hippocampus; from the frontal, temporal, and occipital lobes; and 
from the cerebellum. AD patients presented a direct relationship between higher 
concentrations of the activated IL-α and higher load of neuritic plaque TAU2+ 
(TAU 2-immunoreactive). There is a strong association between the presence of 
IL-1α +, microglia, and TAU protein plates in patients with Alzheimer’s disease 
[55]. Recently, it was observed in a microglial culture model together with neu-
rons that the inflammatory response mediated by LPS-induced microglia leads to 
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hyperphosphorylation of TAU mediating the greater kinase of the TAU protein, 
GSK3β (kinase glycogen synthase kinase 3β) [56]. On the other hand, chronic 
inflammation causes phosphorylation of TAU and worsens pathology in neurons 
that express many inflammatory receptors and molecules, including, MHC-I, 
TNFR1, IL-1R, and TLR. As a result of this, it allows them to interact directly with 
microglia [57]. Inflammatory signals can consequently directly activate neuronal 
protein kinases and phosphatases, such as cyclin-dependent kinase 5 (CDK5), 
glycogen synthase kinase-3β (GSK3β), ERK, and protein-phosphatase 2A (PP2A), 
which regulates phosphorylation of TAU and the assembly of neuronal microtu-
bules [43, 44, 58, 59] (Figure 1).
TAU, and its function regarding neuronal and microglial interactions in brain 
immune chain reactions, as in AD and its progression, could be initiated, by age-
related chronic inflammation. There is an increase in scientific evidence suggesting 
the importance of the mechanism in the synaptic pruning regulation, neurogenesis, 
immunological chain reaction-mediated cognitive functions in brain cells, and LTP, 
even if its complete relevance is still to be confirmed [44].
The mechanisms of inflammation effects on TAU and its pathological influx 
remain constant even if broad investigations have been carried out on Aβ and 
inflammation pathway. Persistent microglial activity and inflammation are estab-
lished to be the causes of a broad release of TAU sub-species [44–47]. As for the 
mechanisms of TAU-induced inflammatory responses leading to pathology, several 
sources point to an acceleration of the onset of main protein kinases, which take 
care of the phosphorylation of the TAU protein. Microglia-perpetuated liberation of 
TNF-α has proven to provoke the accumulation and aggregation of TAU in in vitro 
neurons [48]. On the other hand, blocking microglia with minocycline reduces the 
inflammatory response and propagation of pathology related to TAU in experiments 
performed with hTau mouse models [60]. Moreover, the inhibition of inflamma-
tion by arginase-1 overexpression counteracts the activity of nitric oxide synthases, 
and facilitates autophagy and the decrease of TAU pathology in the TAU-transgenic 
mouse model rTg4510 [61]. A process that has been reported as important in stress-
induced mechanisms and which can be genetically suppressed by the corticotropin-
releasing factor receptor is the stimulation of toll-like receptor 4 (TLR4), which 
increases GSK-3β and CDK-5, which phosphorylate TAU [62].
To perform the “synaptic pruning” by the microglia, a cytosine secreted by 
the neural cells called fraktalkine (CX3CL1) that is excreted in large quantities in 
the brain compared to the rest of the organs of the body is needed [63]. Its recep-
tor CX3CR1 is expressed in large quantities by microglia [64]. Previously, it was 
demonstrated that neuroinflammation via the receptor deficiency for fractalkine 
(CX3CR1) promotes taupathy and neurodegeneration in mouse models in which 
systemic inflammation mediated by LPS had occurred. First, Mapt+/+ neurons 
Figure 1. 
TAU protein in health and Alzheimer’s disease.
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from the cerebellum. AD patients presented a direct relationship between higher 
concentrations of the activated IL-α and higher load of neuritic plaque TAU2+ 
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neurons [48]. On the other hand, blocking microglia with minocycline reduces the 
inflammatory response and propagation of pathology related to TAU in experiments 
performed with hTau mouse models [60]. Moreover, the inhibition of inflamma-
tion by arginase-1 overexpression counteracts the activity of nitric oxide synthases, 
and facilitates autophagy and the decrease of TAU pathology in the TAU-transgenic 
mouse model rTg4510 [61]. A process that has been reported as important in stress-
induced mechanisms and which can be genetically suppressed by the corticotropin-
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showed high levels of Annexin V (A5) and TUNEL (markers of neurodegeneration) 
when they were grown together with microglia Cx3cr1−/− treated with LPS. Second, 
a population of positive neurons for TAU protein phospho-S199 (AT8) in the 
dentate gyrus is also positive for (CC3) for mice treated with Cx3cr1−/−. Third, the 
genetic deficiency of TAU in Cx3cr1−/− mice resulted in reduced microglial activa-
tion, which altered the expression of inflammatory genes in those neurons positive 
for CC3 compared to Cx3cr1−/− mice [44]. These results suggest that pathological 
changes in TAU mediate the neurotoxicity induced by inflammation, while Mapt 
deficiency is neuroprotective. It was proposed that this earlier phenomenon was 
probably associated with the indirect reduction of microglial activity due to the 
decrease in the production of pathological species of TAU, observed in a transgenic 
mouse model rTg4510, which expresses the mutation in P310L (4R0N TauP301L) 
and initiates taupathy within 3–5 months. Brain stimulation of TLR4 by LPS in the 
aforementioned mouse model also produces activation of microglia and phosphory-
lation of TAU [65]. In another investigation using the 3xTg-AD transgenic mouse 
model, which develops both Aβ and taupathies, chronic treatment with LPS results 
in phosphorylation of CDK5-dependent TAU  without affecting Aβ levels in adult 
animals (~6 months old). TAU phosphorylation was observed by immunohisto-
chemistry techniques when treated with LPS and PBS samples of the aforemen-
tioned 3xTg-AD mice by two tests: in the first one in the Ser202/Thr205 residues 
that were recognized by AT8, they presented up to twice as much AT8 activity in 
the samples treated with LPS as those that were administered PBS; the second test 
detected that in the Thr231/Ser235 region, recognized by AT180, there was more 
activity this time of AT180 in the presence of LPS. However, the same did not 
happen in the Ser396/Ser404 region that was recognized by PHD finger protein 1 
(PHF-1), where the sample with LPS was not altered to a greater extent compared to 
that which was administered PBS [66]. TLR4’s activation has proven to initiate the 
TAU-mediated pathologies in a more powerful manner in aged 3xTg-AD mice (more 
than 12 months of age), which means that the influence of TAU over inflammatory 
mechanisms grows stronger with age. Older groups of 3xTg-AD, which received a 
chronic LPS treatment, showed TAU phosphorylation in AT8, AT180, and PHF-1 
epitopes, as well as TAU accumulation and aggregation as neurofibrillary tangles 
and cognitive deterioration, appearing, though, no changes in platelet saturation 
of Aβ. In this tested, aged animals, TAU pathology modulation induced by TLR4 
is principally dominated by GSK3β (glycogen synthase kinase-3ß), the latter data 
were verified through the inhibition with lithium of GSK3β, where a reduction was 
observed of the phosphorylation of TAU and the accumulation in its insoluble form 
together with the reversal of memory problems [67].
Another possible route deduced in a study done in the brains of patients with 
early onset of Alzheimer’s disease (FAD) with the Swedish mutation for APP, 
corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP) three 
well-known taupathies, which presented PS3 positive vesicles in the frontal cortex, 
which indicates that autophagic vesicles accumulated in the said location. In addi-
tion, LAMP1 (lysosomal-associated membrane protein 1) lysosomal markers were 
found in FAD and CBD, and cathepsin in the three mentioned diseases. Thus, this 
study presents a possible role of the autophagy-lysosome pathway that would con-
tribute to the development of primary taupathies as well as FAD [68]. The unbal-
anced increase in IL-1β expression in 3xTg-AD models generated inverse effects in 
amyloid-based pathologies and TAU accumulation, by increasing the addition of its 
pathological forms while decreasing the total quantities of Aβ plaques. The elimina-
tion of such plaques is powered up by the effects of IL-1β in an increase in Aβ plaque 
surrounding activated microglia. This process also augments the proinflammatory 
status, in a directly proportional intensity to age, by means of its elimination. In 
89
Astrocytes and Inflammatory Processes in Alzheimer’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.88701
turn, it was also found in this experiment that it generates the activation of GSK3β 
and p38-MAPK, which leads to a higher level of phosphorylation in TAU [69].
It has been demonstrated in an experiment carried out in 3xTg-AD transgenic 
mice that the inhibition of IL-1 signaling decreases the activation of the kinases 
CDK5/p25, GSK3β, and p38-MAPK, as well as reduces the phosphorylation levels 
of TAU [66]. On the other hand, the blockade of IL-1R showed that it altered the 
inflammatory responses of the brain (related to a lower activity of NF-κB), reduces 
cognitive deficits, and notably attenuates the pathology attributed to TAU, and 
decreases the oligomeric and fibrillary forms of Aβ. Similarly, it was found that 
there was a reduction of the cytokine derived from astrocytes, S100β, and in neu-
ronal signaling with Wnt/β-catenin in 3xTg-AD brains [66, 70]. In addition to the 
complex connection between inflammation and AD, it has been shown that oppo-
site effects can be seen in Aβ and TAU produced with inflammation. For example, it 
was shown that the main risk factor for Alzheimer’s disease, aging, seems to cause a 
decrease in the levels of sirtuin 1 (SIRT1), which is related to microglial aging. Thus, 
this deficiency in the microglial SIRT1 with age results in an excessive production of 
IL-1β, which in turn causes pathology through TAU in addition to cognitive deficits. 
The deficiency of microglial SIRT1 induces a hypomethylation of specific loci CpG 
in the promoter for IL-1β, with elevation of IL-1β transcription [71].
Parallel studies affirm what was previously stated. For example, CX3CR1 
deficiency in mouse models of amyloidosis mitigates the accumulation of Aβ by 
altering microglial activation and promoting microglial phagocytosis [65, 72]. On 
the other hand, blockade of CX3CR1 signaling increases IL-1β/p38-MAPK-mediated 
TAU phosphorylation in the hTau taupathy model [43]. The genetic suppression 
of CX3CL1 anchored to the membrane, ligand of CX3CR1, in models of amyloid 
pathology and taupathy in the APP/PS1 mouse models also reduces the deposition 
of Aβ through the increase of phagocytosis mediated by microglia and at the same 
time induces phosphorylation of neuronal TAU [73], thus having similar effects as 
in the deficiency of the microglial receptor CX3CR1, as shown above. In addition, 
it was already studied that a loss of function was mediated by mutations of pro-
granulin, which has been associated with frontotemporal dementia [74], and results 
in an increase in the activation signal of tyrosine kinase binding protein TYRO 
(TYROBP) and Aβ microglial phagocytosis in the APP/PS1 mouse model, while 
TAU pathology increases in mice expressing the human TA30 PIL mutation [75]. 
Obviously, these opposite effects induced by the immune signal in the accumulation 
of Aβ and TAU raise concerns as to the direction of the therapies relating to mitigate 
one or both of these effects by activating or inhibiting inflammation in the context 
of Alzheimer’s disease. As we have seen in previous experiments, it is already 
known clinically and is explicitly stated in a research that TAU levels correlate better 
with cognitive deficits observed during the disease process [76]. The development 
of strategies to modulate the immune system to act in the deposition of Aβ and TAU 
hyperphosphorylation will probably produce better clinical results.
5.2.3 Astrocytes and inflammation
Analogous to microglia, astrocytes play multiple roles in the organization and 
maintenance of brain structure and function. Multiple studies show that astrocytes 
dynamically modulate information processing, signal transmission, neural and 
synaptic plasticity. As well as, homeostasis of the blood-brain barrier, and its role 
in immune responses. The evidence shows us how during cerebral ischemia, it acts 
as a protector, whereas against inflammation mediated by the lipopolysaccharide 
of Escherichia coli, its intervention seems to be harmful [77]. In the cells of the 
retina, however, it has been proven that through the production of lipoxins, it has 
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turn, it was also found in this experiment that it generates the activation of GSK3β 
and p38-MAPK, which leads to a higher level of phosphorylation in TAU [69].
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mice that the inhibition of IL-1 signaling decreases the activation of the kinases 
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of TAU [66]. On the other hand, the blockade of IL-1R showed that it altered the 
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cognitive deficits, and notably attenuates the pathology attributed to TAU, and 
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there was a reduction of the cytokine derived from astrocytes, S100β, and in neu-
ronal signaling with Wnt/β-catenin in 3xTg-AD brains [66, 70]. In addition to the 
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site effects can be seen in Aβ and TAU produced with inflammation. For example, it 
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decrease in the levels of sirtuin 1 (SIRT1), which is related to microglial aging. Thus, 
this deficiency in the microglial SIRT1 with age results in an excessive production of 
IL-1β, which in turn causes pathology through TAU in addition to cognitive deficits. 
The deficiency of microglial SIRT1 induces a hypomethylation of specific loci CpG 
in the promoter for IL-1β, with elevation of IL-1β transcription [71].
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altering microglial activation and promoting microglial phagocytosis [65, 72]. On 
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it was already studied that a loss of function was mediated by mutations of pro-
granulin, which has been associated with frontotemporal dementia [74], and results 
in an increase in the activation signal of tyrosine kinase binding protein TYRO 
(TYROBP) and Aβ microglial phagocytosis in the APP/PS1 mouse model, while 
TAU pathology increases in mice expressing the human TA30 PIL mutation [75]. 
Obviously, these opposite effects induced by the immune signal in the accumulation 
of Aβ and TAU raise concerns as to the direction of the therapies relating to mitigate 
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known clinically and is explicitly stated in a research that TAU levels correlate better 
with cognitive deficits observed during the disease process [76]. The development 
of strategies to modulate the immune system to act in the deposition of Aβ and TAU 
hyperphosphorylation will probably produce better clinical results.
5.2.3 Astrocytes and inflammation
Analogous to microglia, astrocytes play multiple roles in the organization and 
maintenance of brain structure and function. Multiple studies show that astrocytes 
dynamically modulate information processing, signal transmission, neural and 
synaptic plasticity. As well as, homeostasis of the blood-brain barrier, and its role 
in immune responses. The evidence shows us how during cerebral ischemia, it acts 
as a protector, whereas against inflammation mediated by the lipopolysaccharide 
of Escherichia coli, its intervention seems to be harmful [77]. In the cells of the 
retina, however, it has been proven that through the production of lipoxins, it has 
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an anti-inflammatory and neuroprotective effect against acute and chronic lesions 
[78]. Similarly, the role of the cytokine IL-33 produced by astrocytes has recently 
been demonstrated for the microglial approach to the synaptic terminals, as well as 
the development of neural circuits [79]. In previously mentioned studies describing 
the action of IL-1α+, it is concluded that there is also a correlation between IL-1α 
and the greater number of GFAP+ astrocytes (GFAP-immunoreactive astrocytes) 
[80]. On the other hand, it has been demonstrated in an experiment carried out 
in mice with multiple sclerosis TNF-α alters synaptic transmission and produces 
interferences at the cognitive level [81]. Other studies have shown that the activa-
tion of certain transcription factors are also involved, developing protective effects 
(STAT3) [82] or injurious effects (NF-κB) [83] (Figure 2).
5.2.4 Role of astrocytes in amyloid production
The role of astrocytes in the amyloidogenic pathway is currently being widely 
studied. For a long time, it was thought that neurons were the only type of cell that 
expressed high levels of BACE1 and, therefore, that neuron was the only type of cell 
capable of producing Aβ [84]. However, studies have shown that astrocytes express 
BACE1 at sufficient levels to generate Aβ, and that expression can be increased by 
cell stress [85–89]. In addition, stressors can upregulate the expression of APP and, 
therefore, the secretion of Aβ. In contrast, the effect of cellular stress on the activity 
of γ-secretase in astrocytes has not yet been fully clarified.
The production of Aβ will lead to activation of the microglia and astrocytes in 
order to get rid of these brain waste products [90–92]. Similarly, genetic studies 
have identified polymorphisms of a single nucleotide in inflammatory genes that 
are associated with the risk of AD, highlighting the role of inflammation in AD [86, 
93–95]. In addition, it has been observed that patients with Alzheimer’s disease have 
more proinflammatory cytokines and activated inflammasomes [96]. As demon-
strated in studies that claim an increase in both glial fibrillary acid protein (GFAP) 
and S100β expression, they lead to greater astrogliosis in postmortem tissues of 
human patients and experimental models in mice. In the same way, a correlation has 
been found, in different studies, between the degree of astrogliosis and cognitive 
deterioration [32, 96, 97]. As astrocytes substantially exceed the number of neurons 
in the brain, the identification of cellular environment factors (such as inflamma-
tion), which promote the production of astrocytic Aβ, could redefine our therapeu-
tic targets when it comes to fighting Alzheimer’s disease.
Figure 2. 
Implication of astrocytes in inflammation.
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5.2.5 S100β and inflammation
The cytokine S100β is known to be an important neurotrophic agent during fetal 
development, both in neuroblasts and in the glia [98]. In addition to this known 
function, it is known that it directly contributes to the activation and subsequent 
gliosis, stimulating the proliferation of astrocytes and inducing morphological 
changes [70]. Furthermore, the IL-1 produced in the microglia, is the responsible 
for the overproduction of S100β.
The distribution of S100β contained in activated astrocytes by ELISA and 
immunohistochemistry was studied, as shown by many, few, or no neuritic plaques 
in the context of Alzheimer’s disease. Postmortem samples were obtained from both 
patients diagnosed with AD and control patients from the hippocampus, temporal 
lobes, frontal lobes, occipital lobes, brain stem, and cerebellum. The results indi-
cated that the density of cells that were S100β+, identified with activated astrocytes, 
was higher around the neuritic plaques in certain areas of the brain. By order, the 
concentration was found to be more remarkable in the hippocampus > temporal 
lobe > frontal lobe > occipital lobe > protuberance, and no neuritic plaques were 
found in the cerebellum. The importance of these results lies in the fact that the reg-
ulatory role of the cytokine S100β contributes to the development or maintenance 
of dystrophic neurites observed in neuritic plaques. Furthermore, overexpression 
of S100β shows that it has been related to a higher degree of dysfunction and neural 
loss in AD caused by an intracellular increase in calcium levels [70].
5.2.6 Astrogliosis
Astrogliosis occurs in the presence of a central nervous system lesion. 
Inflammatory mediators made by microglia, neurons, oligodendrocytes, endothelial 
cells, leukocytes, and other astrocytes initially cause astrocytes to become reactive 
[77]. To better understand the process of astrogliosis, we must bear in mind that a 
series of changes occur at the phenotype level of astrocytes, which induce a specific 
expression. This was demonstrated in an experiment using arrays (Affymetrix 
GeneChip arrays) to define the genetic expression of different populations of 
reactive astrocytes isolated at different time periods using two models of injury 
(neuroinflammation and ischemic stroke) in mice. It was observed that this reactive 
gliosis had a rapid, but rapidly diminished, pattern of induction of gene expression 
after damage, where Lcn2 and Sertapina3n were identified as the major markers 
of reactive astrocytes. It was also seen that the pattern of expression experienced 
during ischemic stroke had a protective profile, whereas in the population of mice 
in which neuroinflammation was induced by the use of LPS, it turned out to be, on 
the contrary, detrimental [77]. Moreover, using high-density microarray, reactive 
astrocytes also produced detrimental effects (in vitro models from multiple scle-
rosis, neoplasms and stroke), and was identified up to 44 different transcription 
patterns present in the different pathological models mentioned [99].
In astrocytes, the first morphological change is the process of hypertrophy that is 
intimately related to the greater expression of intermediate filaments, attributed to 
the action of GFAP [99]. Although the consequences of GFAP expression are not fully 
understood, it is known that they have a determining role in limiting the creation of 
Aβ plaques. The impact of this reactive astrogliosis is complex: reactive astrogliosis 
can be both harmful or beneficial at the time the cells are affected. Reagent astrocytes 
will surround the Aβ plaques and will express receptors such as receptor for advanced 
glycation end products (RAGE), receptor-like LDL protein (low-density lipopro-
tein), membrane-associated proteinglycans, as well as receptor-like scavenger recep-
tors to bind to Aβ [100]. Reactive astrocytes will be neurotoxic when they generate 
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reactive oxygen species or proinflammatory cytokines [101]. In order to understand 
the role of cerebral gliosis, the balance between the mechanisms that orient toward 
the neuroprotective or neurotoxic effect must be taken into account.
Patients with AD showed reactive astrocytes as shown by PET images [102, 103] 
and also, before the formation of plaques in transgenic APP mice [104]. Reactive 
astrocytes, depending on the level of gliotransmitters (including glutamate, ATP, 
serine-d and GABA) can produce inhibition of neuronal activity [105]. There is a 
consensus that the role of GABA is to protect neuronal cells in the brain [106]. In the 
amyloid plaques, an increase in the GABA protein has been detected in the reactive 
astrocytes that surround the plaques and that cause a greater release in the extracel-
lular space [105]. It has been studied that these investigations have their limitations, 
since normally studies are carried out in mouse models, while in the human species 
there are many more processes to take into account [107].
5.2.7 Astrocytes, chemokines, and cytokines
Astrocytes can sometimes release reactive oxygen species (ROS), chemokines, 
or cytokines (CCL3, CCL4, CCL1, IL-1, for example) [108, 109]. Normally, those 
responsible for expressing these substances are going to be the so-called reactive 
astrocytes that cause functional changes by the expression of genes and the for-
mation of glial scars that can be beneficial [81] or harmful to cells [82]. By using 
lipopolysaccharide (LPS) as an inducer, astrocytes increase the expression of many 
genes (C3a, C3b, C5, lectin) in the complement cascade that can be harmful [82]. 
On the other hand, it has been shown that positive regulation of trophic factors 
after ischemic damage is a protective mechanism [81]. Following the same line, 
inflammation is an essential factor in the progression of Alzheimer’s disease in 
humans, demonstrating that this inflammation promotes the activation of microg-
lia and an increase in reactive astrocytes that change their shape and increase the 
ramifications to go to the place of injury [110].
Relating astrogliosis to inflammation, both resting astrocytes and reactive 
astrocytes can secrete numerous cytokines capable of inducing inflammation, 
such as IFNγ, IL-1β, TNFα, IL-6, and TGFβ [37, 111–113]. IFNγ is a potent regula-
tory cytokine that activates microglia and promotes inflammation in the brain 
and is overproduced in the brains of patients with AD [114] both by microglia and 
astrocytes, despite which it is produced in the first instance by T cells [115, 116]. 
On the other hand, TNFα is a cytokine involved in the acute phase of inflamma-
tion and is also elevated in the serum, cerebral cortex, and cerebrospinal fluid 
of patients with AD [117]. In a study conducted by scientists at the Rostkamp 
Institute of the Department of Psychiatry at the University of South Florida, it 
was demonstrated in mice that those which were deficient in CD40, which is a 
gene that codes for the receptor TNF (Tumor Necrosis Factor), had a reduced 
activity of BACE, Aβ, and gliosis in comparison to the samples that presented 
normal quantities of CD40 [118]. IL-6 can have both proinflammatory and anti-
inflammatory effects and has also been found elevated in plasma, cerebrospinal 
fluid, and in the brains of Alzheimer’s patients [39, 119–122]. IL-1β constitutes one 
of the first cytokines secreted in response to lesions, as it is an important media-
tor of proliferation, differentiation, and apoptosis. The concentration of the said 
cytokine has been increased near the sites where the amyloid plaques are located 
[38–40].
A specific polymorphism in the transforming growth factor β1 (TGFβ1), 
an immunosuppressive cytokine, is also related to the risk of developing AD 
[123]. In addition, postmortem brains analyzed from Alzheimer’s patients 
contained higher levels of TGFβ, specifically in their plaques, suggesting their 
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involvement in the same disease [124, 125]. Other studies performed in older 
mice that overexpress TGFβ in astrocytes promoted the deposition of Aβ, and 
those astrocytes containing TGFβ1 were located in the vicinity of the Aβ depos-
its in those mice that overexpressed APP with Swedish mutation [126–129].
Finally, astrocytes release purines that can influence the development of AD 
and activate the production of inflammatory proteins, decreasing anti-inflam-
matory proteins [108].
5.2.8 Astrocytes and expression of APP
As it has been already mentioned before, APP is the substrate prior to Aβ after 
erroneous processing by the BACE1 and γ-secretase enzymes. The expression of 
APP by astrocytes has been demonstrated by the identification of APP695, APP751, 
and APP770 mRNAs found in non-neuronal cells [126] and in rat astrocytes [130]. 
In addition, it has been shown that multiple proinflammatory cytokines upregulate 
APP in both mouse and human brains (investigating neuroblastoma cells and 
other non-neuronal cells such as human astrocytes) [131]. These findings imply 
that neuroinflammation in reactive astrocytes expresses higher levels of APP than 
when mice are at rest and they, therefore, may end up producing more β amyloid. 
Similarly, in APP/PS1 mice, an increase in chemokines and their receptors, com-
pared to wild type mice, such as CCL3, CCL4, CCL1 and the receptors CCR5 and 
CCR8 was detected [108].
Several studies have shown that the transcription factor for APP (AP-1) is found 
in the promoter region of many of the acute phase proteins of inflammation that 
are induced by the cytokines IL-1β and IL-6, suggesting that the expression of 
APP is regulated in the same way by these specific cytokines [132, 133]. Moreover, 
astrocytes stimulated with different combinations of cytokines (LPS + IFNγ, 
TNFα + IFNγ, and TNFα + IL-1β + IFNγ) increased the expression of APP [89].
5.2.9 Astrocytes and cancer
The type of tumor and its location are determined by age; for example, infraten-
torial astrocytoma and midline tumors, such as medulloblastoma and pinealoma, 
anaplastic astrocytoma, and glioblastoma predominate in adulthood [134]. Although 
meningiomas are the most frequently detected in the series of autopsies, glioblas-
tomas are the most frequently detected in the brain. Some brain tumors such as 
schwannoma, sarcoma, glioma, and meningioma are detected after the patient has 
been exposed to cancer therapy with chemotherapy and/or radiotherapy. Until now 
it was thought that only glial cells and stem cells were responsible for the emergence 
of glioblastoma, but it is now known that mature neurons can also induce this type of 
cancer. This is due to the fact that these cells revert to an undifferentiated state that is 
directed to proliferate as an uncontrolled tumor [135].
Radial glia are stem cells that develop from a progenitor stem cell in the embryo 
and adult brain [136]. The neuroblastoma cells are radial glia or precursors of 
astrocytes that can develop before their differentiation into neurons. In the same 
way, glial cells can also develop different types of cells besides neurons such as oli-
godendroglia and astrocytes [137]. All these types of cells can turn into cancer and 
affect the normal function of the brain. Then, astrocytes and their progenitor cells 
can cause cancer and destroy many functions in the brain. It is interesting to note 
that in some astrocytomas, the patients increase their cognitive capacity, memory, 
and spatial vision, before the disease begins and also when the cancer is present 
[138], which makes us think and throws more evidence to the role of astrocytes in 
modulating cognitive brain functions or memory.
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modulating cognitive brain functions or memory.
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5.3 Protective role of astrocytes
5.3.1  Oxidative stress, AD, and the protective role of astrocytes against oxidative 
stress
Hydrogen peroxide (H2O2), superoxide (O2−) and hydroxyl radicals (OH−) are 
the aforementioned reactive oxygen species (ROS). Due to the rate of oxidative 
metabolism, the SNC is especially susceptible to the damage suffered by them 
[139]. Under stable physiological conditions, the homeostasis of ROS is under 
control and this is crucial for the proper organic functions. ROS stimulates the 
proliferation of brain cells, but at high concentrations, ROS has harmful effects 
on different cellular structures such as membranes, DNA, and enzymes, which 
can lead to cell death [140]. The reduction of molecular oxygen is not complete 
in the respiratory chain, producing ROS continuously and thus affecting differ-
ent cellular components such as proteins or lipids [141]. To return to the state of 
physiological equilibrium, the brain has several enzymes, such as peroxidase, 
superoxide dismutase (SOD), oxidase, and NADPH oxidase (NOX). Neurons 
have fewer defenses against ROS than astrocytes and cooperation between them is 
important for neuronal resistance against ROS [30, 142, 143]. Astrocytes contrib-
ute to the survival of neurons by detoxifying the ROS enzymes (GSH peroxidase 
and catalase), increasing antioxidant proteins (GSH or glutathione, vitamin E 
and ascorbate) and the biogenesis of mitochondria and reducing the activity of 
metals which can produce redox [31, 144–146]. The most powerful antioxidant 
protein in the brain is GSH produced by astrocytes and neurons, but neurons 
depend on astrocytes because they do not use extracellular cysteine  efficiently 
and, therefore, need astrocytes to supply it. In addition, with respect to ascorbic 
acid, another important antioxidant in the nervous system, we depend on diet to 
obtain it [147].
Ascorbic acid is released by the astrocytes in the extracellular space and is 
absorbed by the neurons, where thanks to ascorbate the formation of ROS dimin-
ishes and its oxidized form is converted to be recovered by the astrocytes and 
converted again to ascorbic acid [148]. In addition, the lactate shuttle between 
astrocytes and neurons is favored by ascorbic acid [149]. Changes in ascorbic acid 
homeostasis are actually involved in different neurodegenerative diseases and have 
been analyzed for the treatment of diseases, such as Parkinson’s and Huntington’s 
disease [148]. In addition, astrocyte prevention in redox production caused by 
active metals has been demonstrated as a result of the ability to sequester metals by 
this cellular type [144].
The increase in ROS levels is related to AD [35], but the effects of antioxidants 
in clinical studies have been disappointing because the high concentration of 
antioxidants acts, in many cases, as pro-oxidants. It may also be due to the fact that 
oxidative stress occurs relatively early in the course of AD and therefore, by its 
administration at later stages, no results are obtained, or else that the combination 
of antioxidants does not work in clinical situations in humans [150]. As already 
shown, astrocytes protect neurons from oxidative stress, producing antioxidant 
proteins. The toxic amyloid beta peptide causes the production of hydrogen perox-
ide by astrocytes [151], as shown previously [30], and they release ROS in response 
to beta amyloid through the pentose-phosphate pathway [151]. In addition, in 
patients with Alzheimer’s disease, there is a fall in the brain cleansing process 
produced by astrocytes during the sleep period. On the other hand, Haydon showed 
that the sleep/wake cycle is modulated by astrocytes and is also altered in AD 
[152]. This finding also demonstrates the close relationship between astrocytes and 
Alzheimer’s disease.
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After demonstrating the important role of astrocytes in protecting neurons 
from oxidative stress, we can deduce that all those conditions mentioned where the 
astrocyte undergoes changes in its function, beyond the strictly physiological, will 
result in poor protection of the said neurons and the rest of brain structures in front 
of different harmful agents and neuronal damage.
5.3.2 Prejudicial and protective role of astrocytes
As we have seen previously, the role of astrocytes is essentially protective. This 
was also demonstrated by another group finding a mechanism different from 
those previously studied by cytokines and other inflammatory agents, in which 
it was shown that the astrocytes surrounding the plates increase the release of 
ATP in transgenic APP/PS1 mice and this happens because the Ca2+ concentration 
increases within the cell [153]. This last fact gives us the idea that an increase in 
ATP in astrocytes and neurons could help to reduce the neuronal death that occurs 
in Alzheimer’s disease. The increase in the production of ATP by the mitochondria 
of astrocytes could help to recover and reduce the development of the disease 
[153]. The neurotransmitter glutamate is released by astrocytes in the presence of 
Aβ and can cause neuronal loss as well as synaptic damage by activation of NMDA 
receptors [154, 155]. In addition, astrocytes release purines that can influence 
the development of AD and activate the production of inflammatory proteins, 
decreasing anti-inflammatory proteins, such as PPAR-γ [108, 156]. This is prob-
ably due to the effect of reactive astrogliosis that may have beneficial effects [82] 
or detrimental effects [83] for neurons, and because these two different reactions 
depend on the type of triggering of the astrogliosis. Nevertheless, in our labora-
tory, we demonstrated that astrocytes play a significant role in neuron protection. 
Astrocytes promote neural viability and improve oxidative stress defense mecha-
nisms with anti-inflammatory effects against Aβ1–42 peptide toxicity. It is probable 
that the protective effects of astrocytes are related with the mitochondrial biogen-
esis (Figure 3). This could be a complex epigenetic process in Alzheimer’s disease 
pathogenesis [30].
In conclusion, we can see that the role of Aβ, which had been an essential pillar 
in the etiopathogenesis of Alzheimer’s disease for decades, is only one component 
that gives rise to inflammation, probably mediated by activation of microglia and 
astrocytes with the goal of getting rid of these brain waste products, although 
this effect has already been shown to be produced in the same way by different 
Figure 3. 
Protective effects of astrocytes.
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mediators. In fact, it is related to a greater degree with the progression of the disease 
and worsening of the symptoms with the increase of phosphorylated TAU in differ-
ent parts of the brain. In the last years, the therapies have been focused on elimina-
tion of the Aβ from the brain of the Alzheimer’s patient with poor results [157]. In 
addition, reactive astrocytes greatly increase NRF-2, which is an antioxidant protein 
and could produce beneficial effects in Alzheimer’s disease [157]. The regulation 
of oxidative stress or inflammation could help the conservation of neurons located 
near astrocytes and microglia. Future therapies should be aimed at the development 
of specific drugs that control the formation of reactive astrocytes and that favor the 
correct resolution of the inflammation produced by Alzheimer’s disease. The study 
of the genetic mechanisms that predispose to increase amounts of hyperphosphory-
lated TAU or those that decrease phosphorylation of TAU would be interesting in 
order to understand cellular mechanisms implicated in AD [157]. Furthermore, the 
study of the main trigger of this basal chronic inflammation that worsens the clini-
cal symptoms of AD patients, should be crucial to find new therapeutic strategies. 
Finally, regarding the relationship that exists between the astrocytes and the cells of 
the nervous system, there would be a greater study of the functions of these cells in 
the healthy individual. The control of the mechanisms and the understanding of the 
relationship between astrocytes with other neural cells could help, in the same way, 
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Abstract
We are in the midst of a glial renaissance; astrocytes, essential for brain 
homeostasis and neuroprotection, have experienced resurgence in focused 
analyses. New roles in synaptic plasticity, innate immunity and control of 
recruited immune cells have placed astrocytes at the center of central nervous 
system functions. Astrocytes have been shown to receive and convey information 
to all neural cell types in a coordinated effort to respond to injury and infection, 
initiating reparative mechanisms. Astrocytes detect injury and infection signals 
from neurons, microglia, oligodendrocytes and endothelial cells, responding 
by secreting cytokines, chemokines and growth factors, which may activate 
immune defenses. While regional heterogeneity in astrocyte form and function 
has been appreciated since the early 1990s, technologic advances have allowed 
scientists to show only that astrocytes may be as individualized as neurons. Adult 
astrocytes may undergo a morphological and functional transformation referred 
to as astrogliosis. Newly generated astrocytes exhibit heterogenous phenotypes; 
thus, some remove toxic molecules, restore blood-brain barrier function, and 
promote extracellular matrix components to support axonal growth and repair, 
while others inhibit neuronal repair and regeneration. This chapter will introduce 
some of the cellular and molecular components involved in astrocyte responses 
induced by inflammatory mediators or pathogens during neuroinflammation or 
neuroinfectious diseases.
Keywords: astrocyte, cytokines, chemokines, pathogens, viruses, bacteria, 
astrogliosis
1. Introduction
Astrocytes are a principle participant in central nervous system (CNS) responses 
to neurological disorders or diseases [1–3]. During development and homeostasis, 
astrocytes coordinate immune responses by regulating microglia activation and 
blood-brain barrier (BBB) formation [4, 5]. Through dedicated molecular cascades, 
astrocytes also provide growth factors to neurons, support synapse formation, 
and help regulate extracellular balance of ions and neurotransmitters, making 
these glial cells essential for brain homeostasis [6, 7]. In response to CNS injury 
and disease, astrocytes undergo a process termed astrogliosis, a multifactorial 
and complex remodeling of astrocytes [7–10]. Despite the use of a single term to 
describe astrocyte reaction to insult, astrogliosis results in a spectrum of heterog-
enous changes in a context specific manner that vary with etiology and severity of 
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1. Introduction
Astrocytes are a principle participant in central nervous system (CNS) responses 
to neurological disorders or diseases [1–3]. During development and homeostasis, 
astrocytes coordinate immune responses by regulating microglia activation and 
blood-brain barrier (BBB) formation [4, 5]. Through dedicated molecular cascades, 
astrocytes also provide growth factors to neurons, support synapse formation, 
and help regulate extracellular balance of ions and neurotransmitters, making 
these glial cells essential for brain homeostasis [6, 7]. In response to CNS injury 
and disease, astrocytes undergo a process termed astrogliosis, a multifactorial 
and complex remodeling of astrocytes [7–10]. Despite the use of a single term to 
describe astrocyte reaction to insult, astrogliosis results in a spectrum of heterog-
enous changes in a context specific manner that vary with etiology and severity of 
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CNS injury [9–13]. Classically, this process is characterized by upregulation of glial 
fibrillary acid protein (GFAP) and vimentin, key astrocyte intermediate filaments, 
and hypertrophy of astrocyte processes [14] (Figure 1). Changes in astrocyte 
biochemistry and physiology that may result in the secretion of anti-inflammatory 
and pro-inflammatory factors also contribute to this process [10, 15–17].
2. Astrogliosis
Functionally, astrogliosis results in the expression of molecules that provide 
neurotrophic support to injured neurons, isolate damaged area and CNS inflam-
mation from healthy CNS tissue, rebuild and maintain a compromised BBB, 
and contribute circuitry remodeling around the lesioned region [7, 9–12, 18]. 
Consistent with this, studies using animal models of traumatic brain injury, 
spinal cord injury, and autoimmunity, all reveal that the loss of reactive astro-
cytes during acute processes leads to the exacerbation of clinical symptoms, 
recruit of immune molecules, changes in BBB integrity, and neuronal death 
[7, 10, 19]. The overall goals of these functional reactions are therefore beneficial 
for the CNS. However, past research has also highlighted detrimental and inhibi-
tory effects of astrogliosis, including augmentation of inflammation, as well as 
inhibition of neuronal repair and axonal growth [20, 21]. The dual outcomes 
of astrogliosis highlight the time- and context-specific way this process may be 
regulated. Future studies of this process may ultimately determine mechanisms 
to manipulate astrogliosis as a therapeutic target to improve CNS injury outcomes 
[10, 22].
Astrogliosis is induced and regulated by a variety of extracellular molecules, 
such as neurotransmitters, steroid hormones, cytokines and neurodegeneration-
associated molecules (Table 1). Intracellular signaling pathways, such cyclic AMP 
(cAMP), signal transducer and activator of transcription 3 (STAT3), nuclear factor 
kappa B (NFκB), Rho-kinase, and calcium have all been observed to induce the 
expression of GFAP or vimentin [11, 45–47]. Extracellular signaling pathways, 
including responses to epidermal growth factor (EGF), fibroblast growth factor 
Figure 1. 
Astrogliosis is typically characterized by hypertrophy of astrocyte processes. Expression of GFAP+ astrocytes 
(green) and DAPI (blue) in a mock-infected mouse CA3 hippocampus (A) and in a West Nile virus-infected 
CA3 hippocampus 7 days post infection (B). Viral infection triggers reactive astrogliosis in the hippocampus, in 
which the processes of activated astrocytes show hypertrophy.
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(FGF), sonic hedgehog (SHH), and albumin, can also regulate astrocyte prolifera-
tion [9, 48–50]. Specific pro- and anti-inflammatory effects of reactive astrocytes 
may be regulated separately. Thus, the genetic ablation of STAT3 within astrocytes, 
or its associated membrane receptor gp130, leads to increased inflammation 
during autoimmune disease, traumatic injury and infection [24, 37–39, 51], while 
genetic deletion of NFκB or the suppressor of cytokine signaling 3 (Soc3) signal-
ing pathway in astrocytes decreases the recruitment of immune cells [31, 32, 37]. 
Furthermore, recruited immune cells release numerous cytokines that may further 
stimulate astrocyte activation (Table 1). In addition, recent studies indicate that 
microglia critically induce astrogliosis via expression of pro-inflammatory cyto-
kines, including interleukin (IL)-1β, tumor necrosis factor (TNF), and interferon 
(IFN)-γ [26, 52, 53].
In response to injury, reactive astrocytes were previously believed to migrate 
to the lesion site. Recent live imaging studies, however, indicate that astrocytes do 
not migrate towards the lesion site [54]. Instead, astrocytes remain in their tiled-
domains and become hypertrophic [54, 55]. Neither proliferation nor migration of 
astrocytes contribute to the total increase of GFAP positive cells observed at lesion 
sites. This has led to a new focus on identifying other sources for adult astrocytes. 
Currently, there is evidence that radial glia, neuronal progenitor cells (NPCs) 
within the subventricular (SVZ) and subgranular (SGZ) zones, locally proliferating 
glia, in addition to NG2+ cells may all contribute to newly generated pools of reac-
tive astrocytes after injury [56].
3. Astrocytes as the gatekeeper to the CNS
During homeostasis, astrocyte end-feet enwrap the brain microvascular endo-
thelial cells, helping maintain the integrity of the BBB. Their physical interaction 
with the BBB allows astrocytes to influence the entry of peripheral immune cells 
into the CNS during injury or disease as well as modulating their activity once 
entering the CNS parenchyma. In health, astrocytes, along with multiple other cell 
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A variety of intracellular signaling molecules have been shown to induce reactive astrogliosis or to modulate aspects 
of the reactive astrogliosis process. In response to a range of CNS injuries, all cell types within the CNS, such as 
neurons, microglia, other astrocytes, endothelium, and pericytes, can release signaling molecules that are able to 
trigger astrogliosis.
BBB = blood-brain barrier, CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, 
ER = estrogen receptor, Gp = glycoprotein, IL = interleukin, IFN = interferon, NFκB = nuclear factor kappa 
B, EAE = experimental autoimmune encephalomyelitis, ECM = extracellular matrix, SHH = sonic hedgehog, 
Soc3 = suppressor of cytokine signaling 3, STAT3 = signaling transducer and activator of transcription 3, 
TGF = transforming growth factor β, TNF = tumor necrosis factor.
Table 1. 
Triggers of reactive astrogliosis.
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access into the CNS parenchyma [17, 57–59]. However, CNS damage caused by 
stroke, traumatic injury, infection, autoimmune disease, and neurodegenerative 
disorders leads to the disruption of the BBB, which may increase the CNS entry of 
immune cells [24, 25, 38, 39, 60–66].
During injury or infection, astrocytes detect molecular changes in their 
extracellular environment and in neighboring cells. In stroke, astrocytes become 
reactive when oxygen and glucose deprivation occurs [67, 68]. In most neurologi-
cal disorders, the release of neurotransmitters and adenosine triphosphate (ATP) 
from damaged neurons is detected by astrocytes via P2X and P2Y purinergic 
receptors [69, 70]. During viral infections, toll-like receptors (TLRs), such as 
TLR3, 7, and 9, and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), 
are expressed on neurons, astrocytes, and microglia. These receptors are examples 
of pattern recognition receptors (PPRs) that are differentially activated by patho-
gen-associated molecular patterns (PAMPs) derived from invading bacteria, fungi, 
or viruses [71]. Activation of TLRs and RLRs by PAMPs or damage-associated 
molecular patterns (DAMPs) have been shown to contribute to neuronal damage, 
induce microglia and astrocyte activation and production of cytokines, including 
type I IFNs [72–74]. Type I IFNs, along with numerous other innate cytokines, 
such as IL-6, IL-1β, IFN-γ, and TNF, have been shown to regulate BBB integrity 
through a variety of different mechanisms that include the regulation of Rho 
GTPases, activation of matrix metallopeptidase 9 (MMP9), and suppression of 
other pro-inflammatory cytokines, including IL-1β, IL-6, and TNF [75, 76]. In 
support of this, the genetic astrocyte-specific deletion of the type I IFN receptor, 
IFNαβR (IFNAR), results in enhanced BBB permeability in a murine viral infec-
tion model [77].
The entry of leukocytes into the CNS parenchyma involves their passage across 
the BBB, whose permeability is regulated by astrocytes and pericytes, as well as 
multiple other cell types [57–59]. Once leukocytes traverse the BBB, they local-
ize within perivascular spaces and where they interact with numerous cell types, 
including astrocytes [78]. Astrocytes, thus, take part in both the recruitment and 
restriction of leukocytes in the CNS [58, 59, 151]. Their functions, however, occur 
in a context-specific manner via specific signaling events. It is remarkable how 
astrocytes are able to respond to a diverse number of signaling mechanisms in the 
orchestration BBB disruption, the recruitment of leukocytes, and the amplifica-
tion of their pro-inflammatory effects [17, 57, 79, 80], while also being capable of 
contributing to BBB repair, restricting leukocyte trafficking, and exerting anti-
inflammatory effects that promote the resolution of inflammation [6, 9–11].
4. Reactive astrocytes as a physical barrier
At the site of injury, newly proliferated astrocytes form scars, in which 
bundles of reactive astrocytes polarize with extracellular matrix (ECM) compo-
nents and physically surround the lesioned site [38]. The earliest studies focused 
on the formation of the astrocyte scar and its importance in repairing the BBB 
after traumatic brain injury [61, 62]. Astrocyte scars form a physical, functional 
barrier that restricts the entry of leukocytes after traumatic brain injuries, 
ischemia, neurodegeneration and autoimmune inflammation [37, 38]. This is 
achieved through the upregulation of ECM proteins, such as fibronectin and 
laminin, as well as chondroitin sulfate proteoglycans (CSPGs) [41, 42, 81–84]. 
Structural proteins, such as GFAP and vimentin, have also been shown to be 
important for the formation of the astrocyte scar [14]. Mice with global genetic 
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(FGF), sonic hedgehog (SHH), and albumin, can also regulate astrocyte prolifera-
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A variety of intracellular signaling molecules have been shown to induce reactive astrogliosis or to modulate aspects 
of the reactive astrogliosis process. In response to a range of CNS injuries, all cell types within the CNS, such as 
neurons, microglia, other astrocytes, endothelium, and pericytes, can release signaling molecules that are able to 
trigger astrogliosis.
BBB = blood-brain barrier, CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, 
ER = estrogen receptor, Gp = glycoprotein, IL = interleukin, IFN = interferon, NFκB = nuclear factor kappa 
B, EAE = experimental autoimmune encephalomyelitis, ECM = extracellular matrix, SHH = sonic hedgehog, 
Soc3 = suppressor of cytokine signaling 3, STAT3 = signaling transducer and activator of transcription 3, 
TGF = transforming growth factor β, TNF = tumor necrosis factor.
Table 1. 
Triggers of reactive astrogliosis.
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access into the CNS parenchyma [17, 57–59]. However, CNS damage caused by 
stroke, traumatic injury, infection, autoimmune disease, and neurodegenerative 
disorders leads to the disruption of the BBB, which may increase the CNS entry of 
immune cells [24, 25, 38, 39, 60–66].
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TLR3, 7, and 9, and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), 
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of pattern recognition receptors (PPRs) that are differentially activated by patho-
gen-associated molecular patterns (PAMPs) derived from invading bacteria, fungi, 
or viruses [71]. Activation of TLRs and RLRs by PAMPs or damage-associated 
molecular patterns (DAMPs) have been shown to contribute to neuronal damage, 
induce microglia and astrocyte activation and production of cytokines, including 
type I IFNs [72–74]. Type I IFNs, along with numerous other innate cytokines, 
such as IL-6, IL-1β, IFN-γ, and TNF, have been shown to regulate BBB integrity 
through a variety of different mechanisms that include the regulation of Rho 
GTPases, activation of matrix metallopeptidase 9 (MMP9), and suppression of 
other pro-inflammatory cytokines, including IL-1β, IL-6, and TNF [75, 76]. In 
support of this, the genetic astrocyte-specific deletion of the type I IFN receptor, 
IFNαβR (IFNAR), results in enhanced BBB permeability in a murine viral infec-
tion model [77].
The entry of leukocytes into the CNS parenchyma involves their passage across 
the BBB, whose permeability is regulated by astrocytes and pericytes, as well as 
multiple other cell types [57–59]. Once leukocytes traverse the BBB, they local-
ize within perivascular spaces and where they interact with numerous cell types, 
including astrocytes [78]. Astrocytes, thus, take part in both the recruitment and 
restriction of leukocytes in the CNS [58, 59, 151]. Their functions, however, occur 
in a context-specific manner via specific signaling events. It is remarkable how 
astrocytes are able to respond to a diverse number of signaling mechanisms in the 
orchestration BBB disruption, the recruitment of leukocytes, and the amplifica-
tion of their pro-inflammatory effects [17, 57, 79, 80], while also being capable of 
contributing to BBB repair, restricting leukocyte trafficking, and exerting anti-
inflammatory effects that promote the resolution of inflammation [6, 9–11].
4. Reactive astrocytes as a physical barrier
At the site of injury, newly proliferated astrocytes form scars, in which 
bundles of reactive astrocytes polarize with extracellular matrix (ECM) compo-
nents and physically surround the lesioned site [38]. The earliest studies focused 
on the formation of the astrocyte scar and its importance in repairing the BBB 
after traumatic brain injury [61, 62]. Astrocyte scars form a physical, functional 
barrier that restricts the entry of leukocytes after traumatic brain injuries, 
ischemia, neurodegeneration and autoimmune inflammation [37, 38]. This is 
achieved through the upregulation of ECM proteins, such as fibronectin and 
laminin, as well as chondroitin sulfate proteoglycans (CSPGs) [41, 42, 81–84]. 
Structural proteins, such as GFAP and vimentin, have also been shown to be 
important for the formation of the astrocyte scar [14]. Mice with global genetic 
Glia in Health and Disease
114
deletion of these molecules display increased inflammation and pathology as 
well as worsened functional outcomes in various CNS injury models, such as 
ischemia, traumatic injury, autoimmune inflammation, infection, and neurode-
generation [11, 63, 64, 85–88].
The astrocyte scar is also important for localizing immune cells and limiting the 
invasion of infectious pathogens, to the lesion site. For example, the genetic dele-
tion of GFAP+ cells leads to increases in immune cell infiltrations in murine models 
of traumatic injury and autoimmunity [60, 61]. Genetic loss of GFAP expression 
also increases pathogen burden in various infections, including Staphylococcus 
aureus and Toxoplasma gondii [89]. Multiple studies have shown that the restriction 
of leukocyte entry and migration after infection, autoimmune inflammation, and 
traumatic brain injury is mediated by astrocyte anti-inflammatory functions via 
the JAK2-STAT3 signaling pathway in GFAP+ cells [25, 38, 39]. The genetic deletion 
of astrocyte derived STAT3 signaling prevents scar formation and limits immune 
cell infiltration in a spinal cord injury model [39]. These observations suggest that 
the astrocyte scar serves as a functional barrier to restrict cytotoxic inflammatory 
molecules and cells.
Studies genetically deleting essential components of the ECM, such as MMP9, or 
inhibiting signaling pathways, including Rho/ROCK, to block CSPG activity have 
shown astrogliosis to exacerbate inflammation after traumatic injury or autoim-
mune inflammation as well as preventing axonal growth and behavioral recovery 
[81, 90–92]. The astrocyte scar has also been shown to exhibit a diverse array of 
molecules known to prevent axonal growth, such as CSPGs, semaphoring 3A, 
keratan sulfate proteoglycans (KSPGs) and ephrins/Eph receptors [19, 93, 94]. The 
complexity of astrocytes in producing, recruiting and restricting inflammatory cells 
and other molecules have made these cells a difficult target for potential therapeutic 
manipulation.
5. Astrocytes as a regulator of the innate immune response
After CNS injury or infection, reactive astrocytes release molecules that attract, 
recruit and facilitate the migration of immune cells to the lesion site (Figure 2). 
Astrocytes express leukocyte adhesion molecules, including vascular cell adhesion 
and intercellular adhesion molecules, in models of ischemia, autoimmunity, and 
infection [30, 33, 95]. Specifically, in an ischemia model, astrocytes release NF-κB, 
which increases both vascular cell adhesion and intercellular adhesion molecules 
[33, 96]. These adhesion molecules promote intercellular interactions that contrib-
ute to the trafficking of immune cells to the lesion site.
Like microglia, the resident macrophages of the CNS, astrocytes play a role in 
innate immune responses by producing cytokines and chemokines, such as type 
I and II IFNs and TNF, that promote the expression of hundreds of interferon-
stimulated genes (ISGs), such as those that participate in inflammatory cell infil-
tration [97, 98]. Microglia also upregulate the expression of numerous receptors 
and produce various chemokines after CNS injury, such as chemokine (C-X3-C 
motif) receptor 1 (CX3CR1) and chemokine (C-C motif) receptor 2 (CCR2) [99]. 
Similarly, reactive astrocytes also express many of these receptors and chemokines, 
suggesting that astrocytes and microglia communicate via chemokines. In fact, 
astrocyte release of chemokines has been shown to be important for attracting 
peripheral and CNS myeloid cells to the lesion site. In models of traumatic injury 
and parasitic infection, astrocytes are a source of chemokine (C-C motif) ligand 
2 (CCL2) [100, 101]. Astrocytes have also been shown to produce chemokine 
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(C-X3-C motif) ligand 1 (CXC3L1) and CXCL1, detected by monocytes and 
microglia, in response to viral infection and spinal cord injury, respectively 
[102–104].
After entry into the brain, or activation within the brain, innate immune cells 
demonstrate a spectrum of phenotypes, ranging from pro- and anti-inflammatory 
states, and can express a variety of cytokines and chemokines, including IL-1β, 
IFN-γ, and TNF, that contribute to neuroinflammation [105]. Reactive astrocytes 
have a demonstrated role in modulating immune responses by releasing cytokines 
that stimulate microglia and macrophages to adopt either pro- or anti-inflammatory 
responses. For example, after injury or infection, astrocytes have been shown to 
release cytokines, such as IFN-γ, TNF, and IL-12, that shift microglia and macro-
phages to a more pro-inflammatory phenotype [106, 107]. Under similar conditions, 
however, astrocytes have also been observed to produced cytokines, including IL-10 
and transforming growth factor beta (TGF-β), which can shift monocytes towards a 
less inflammatory states [108–110]. These findings support the notion that astrocyte 
responses may be context dependent.
6. Astrocytes as a regulator of the adaptive immune response
During the adaptive immune response, astrocytes are a major source of T and 
B cells chemoattractants. Reactive astrocytes express CCL5 as well as CXCL10 in 
infection models, both chemoattractants of T cells [111–113]. In viral infection 
models, CXCL10 has been shown to be an important ligand for CXCR3 on CD8+ T 
cells [114]. The recruitment of such CXCR3+ T cells results in improved viral con-
trol and survival after infection [115]. In brain samples from patients with multiple 
Figure 2. 
Reactive astrocytes regulate immune responses. Activation of astrocytes, either directly by purinergic 
receptors or PRRs or indirectly, promote expression of inflammatory cytokines and chemokines as well 
as growth factors. The astrocyte response to molecular changes in their microenvironment shapes the 
recruitment and activation of peripheral immune cells, modulation of the BBB, and cell-cell interaction 
(not shown). ATP = adenosine triphosphate, BAFF = B-cell activating factor, BBB = blood-brain barrier, 
CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, DAMPs = damage-associated 
molecular pattern, IL = interleukin, IFN = interferon, PAMP = pathogen-associated molecular pattern, 
PRR = pattern recognition receptor, TNF = tumor necrosis factor.
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deletion of these molecules display increased inflammation and pathology as 
well as worsened functional outcomes in various CNS injury models, such as 
ischemia, traumatic injury, autoimmune inflammation, infection, and neurode-
generation [11, 63, 64, 85–88].
The astrocyte scar is also important for localizing immune cells and limiting the 
invasion of infectious pathogens, to the lesion site. For example, the genetic dele-
tion of GFAP+ cells leads to increases in immune cell infiltrations in murine models 
of traumatic injury and autoimmunity [60, 61]. Genetic loss of GFAP expression 
also increases pathogen burden in various infections, including Staphylococcus 
aureus and Toxoplasma gondii [89]. Multiple studies have shown that the restriction 
of leukocyte entry and migration after infection, autoimmune inflammation, and 
traumatic brain injury is mediated by astrocyte anti-inflammatory functions via 
the JAK2-STAT3 signaling pathway in GFAP+ cells [25, 38, 39]. The genetic deletion 
of astrocyte derived STAT3 signaling prevents scar formation and limits immune 
cell infiltration in a spinal cord injury model [39]. These observations suggest that 
the astrocyte scar serves as a functional barrier to restrict cytotoxic inflammatory 
molecules and cells.
Studies genetically deleting essential components of the ECM, such as MMP9, or 
inhibiting signaling pathways, including Rho/ROCK, to block CSPG activity have 
shown astrogliosis to exacerbate inflammation after traumatic injury or autoim-
mune inflammation as well as preventing axonal growth and behavioral recovery 
[81, 90–92]. The astrocyte scar has also been shown to exhibit a diverse array of 
molecules known to prevent axonal growth, such as CSPGs, semaphoring 3A, 
keratan sulfate proteoglycans (KSPGs) and ephrins/Eph receptors [19, 93, 94]. The 
complexity of astrocytes in producing, recruiting and restricting inflammatory cells 
and other molecules have made these cells a difficult target for potential therapeutic 
manipulation.
5. Astrocytes as a regulator of the innate immune response
After CNS injury or infection, reactive astrocytes release molecules that attract, 
recruit and facilitate the migration of immune cells to the lesion site (Figure 2). 
Astrocytes express leukocyte adhesion molecules, including vascular cell adhesion 
and intercellular adhesion molecules, in models of ischemia, autoimmunity, and 
infection [30, 33, 95]. Specifically, in an ischemia model, astrocytes release NF-κB, 
which increases both vascular cell adhesion and intercellular adhesion molecules 
[33, 96]. These adhesion molecules promote intercellular interactions that contrib-
ute to the trafficking of immune cells to the lesion site.
Like microglia, the resident macrophages of the CNS, astrocytes play a role in 
innate immune responses by producing cytokines and chemokines, such as type 
I and II IFNs and TNF, that promote the expression of hundreds of interferon-
stimulated genes (ISGs), such as those that participate in inflammatory cell infil-
tration [97, 98]. Microglia also upregulate the expression of numerous receptors 
and produce various chemokines after CNS injury, such as chemokine (C-X3-C 
motif) receptor 1 (CX3CR1) and chemokine (C-C motif) receptor 2 (CCR2) [99]. 
Similarly, reactive astrocytes also express many of these receptors and chemokines, 
suggesting that astrocytes and microglia communicate via chemokines. In fact, 
astrocyte release of chemokines has been shown to be important for attracting 
peripheral and CNS myeloid cells to the lesion site. In models of traumatic injury 
and parasitic infection, astrocytes are a source of chemokine (C-C motif) ligand 
2 (CCL2) [100, 101]. Astrocytes have also been shown to produce chemokine 
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(C-X3-C motif) ligand 1 (CXC3L1) and CXCL1, detected by monocytes and 
microglia, in response to viral infection and spinal cord injury, respectively 
[102–104].
After entry into the brain, or activation within the brain, innate immune cells 
demonstrate a spectrum of phenotypes, ranging from pro- and anti-inflammatory 
states, and can express a variety of cytokines and chemokines, including IL-1β, 
IFN-γ, and TNF, that contribute to neuroinflammation [105]. Reactive astrocytes 
have a demonstrated role in modulating immune responses by releasing cytokines 
that stimulate microglia and macrophages to adopt either pro- or anti-inflammatory 
responses. For example, after injury or infection, astrocytes have been shown to 
release cytokines, such as IFN-γ, TNF, and IL-12, that shift microglia and macro-
phages to a more pro-inflammatory phenotype [106, 107]. Under similar conditions, 
however, astrocytes have also been observed to produced cytokines, including IL-10 
and transforming growth factor beta (TGF-β), which can shift monocytes towards a 
less inflammatory states [108–110]. These findings support the notion that astrocyte 
responses may be context dependent.
6. Astrocytes as a regulator of the adaptive immune response
During the adaptive immune response, astrocytes are a major source of T and 
B cells chemoattractants. Reactive astrocytes express CCL5 as well as CXCL10 in 
infection models, both chemoattractants of T cells [111–113]. In viral infection 
models, CXCL10 has been shown to be an important ligand for CXCR3 on CD8+ T 
cells [114]. The recruitment of such CXCR3+ T cells results in improved viral con-
trol and survival after infection [115]. In brain samples from patients with multiple 
Figure 2. 
Reactive astrocytes regulate immune responses. Activation of astrocytes, either directly by purinergic 
receptors or PRRs or indirectly, promote expression of inflammatory cytokines and chemokines as well 
as growth factors. The astrocyte response to molecular changes in their microenvironment shapes the 
recruitment and activation of peripheral immune cells, modulation of the BBB, and cell-cell interaction 
(not shown). ATP = adenosine triphosphate, BAFF = B-cell activating factor, BBB = blood-brain barrier, 
CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, DAMPs = damage-associated 
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sclerosis, astrocytes have been shown to express CXCL12, a T cell chemoattractant, 
and B-cell activating factor (BAFF), a B cell chemoattractant [116, 117]. Like their 
influence on microglia and macrophages, cytokines released by reactive astrocytes 
can shift T cells to adopt either a more beneficial or detrimental phenotype. For 
example, reactive astrocytes during autoimmunity release pro-inflammatory 
cytokines, including TNF, IFN-γ, and IL-17, which may induce T cells to adopt a 
more pro-inflammatory state. However, astrocytes have also been shown to release 
IL-10 that shifts T cells towards the anti-inflammatory spectrum [23, 24, 32, 118, 
119]. Similarly, in a murine spinal cord injury model reactive astrocytes have been 
shown to release anti-inflammatory TGF-β [31]. Further studies examining the 
influences of reactive astrocytes on T cells are needed to better understand the 
long-term effects of astrogliosis on adaptive immune cells during CNS recovery 
after injury.
7. Reactive astrocytes as a pro-inflammatory regulator
Reactive astrocytes can release a variety of molecular signals that contribute 
to the inflammatory state of the CNS after injury or disease by directly activating 
immune defenses with the release of cytokines, chemokines, and other growth 
factors (Table 2). Recent advancements in astrocyte transcriptome analysis have 
begun to reveal the context specific production of pro-inflammatory molecules 
by astrocytes as well as molecular triggers that induce their production. Analysis 
of the astrocyte transcriptome after in vivo exposure to lipopolysaccharide (LPS) 
or infection significantly promoted the production of a pro-inflammatory, 
neurotoxic molecular profile [26, 52]. However, the astrocyte transcriptome 
shifts towards an anti-inflammatory, neuroprotective profile in an in vivo isch-
emia model [52]. Future studies should utilize single-cell sequencing techniques 
to transcriptionally define individual astrocyte responses during health and 
disease.
Despite the number of astrocyte transcriptome data available, few studies have 
attempted to elucidate mechanisms and signaling cascades that mediate astrocyte 
pro-inflammatory production. Recent studies have indicated NFκB and SOC3 as 
transcriptional regulators of pro-inflammatory astrocytes after a traumatic brain 
injury and during autoimmune inflammation [31, 32, 37]. In a model of autoim-
munity, genetic deletion of astrocyte derived NFκB results in increased expression 
of ECM components and pro-inflammatory cytokines [129]. Astrocytes have also 
been shown to release CCL2 and CXCL10 to recruit perivascular leukocytes dur-
ing autoimmune inflammation [124–126]. While the role of CCL2 and CXCL10 is 
diverse, evidence suggests that these molecules produced by astrocytes promote 
leukocyte migration in the CNS parenchyma [124]. In an autoimmune inflammation 
model, IL-17 inflammatory induction has been shown to be mediated by astrocyte 
Act1 signaling. Genetically deleting Act1/IL-17 signaling from astrocytes in an 
EAE model prevents the induction of pro-inflammatory cytokines [28]. Reactive 
astrocytes can also shift towards a more pro-inflammatory state by overexpressing 
pro-inflammatory cytokines. In spinal cord injury and autoimmune models, the 
overexpression of IL-6 in astrocytes leads to increased immune cell infiltration. 
The proinflammatory cytokine, IL-1β, produced by astrocytes, has also been shown 
to initiate a signaling cascade that releases vasoactive endothelial growth factor 
(VEGF), leading to increased BBB permeability and leukocyte leakage [127, 128]. In 
general, there is also evidence that astrocytes contribute to triggering inflammatory 
responses due to increases in neuronal activity in epilepsy, neuropathic pain, and 
stress [130].
117
Astrocytes: Initiators of and Responders to Inflammation
DOI: http://dx.doi.org/10.5772/intechopen.89760
8. Reactive astrocytes as an anti-inflammatory regulator
Despite the growing body of work that suggests pro-inflammatory roles for 
astrocytes, there is an equal amount of evidence suggesting these cells limit 
inflammation. Recent loss-of-function experiments have also revealed essential 
anti-inflammatory roles of astrocytes after a variety of CNS injury and disease 
states (Table 2). These studies have also revealed specific molecular mechanisms 
that mediate these anti-inflammatory roles. The astrocyte TGF-β response seems 
to selectively affect astrocyte cytokine and chemokine production after ischemia 
in murine models. The genetic deletion of TGF-β signaling in astrocytes leads 
to diffused inflammation and enhances myeloid cell activation [43, 44]. After 
toxoplasmic encephalitis, the genetic loss of astrocyte TGF-β signaling can 
lead to the increase of infiltrating T cells. Notably, in both examples, astrocyte 





Cytokines IL-6 and IL-10 Activation of numerous anti-
inflammatory signaling pathways
[95, 120]
Growth factors TGF-β Activation of numerous anti-
inflammatory signaling pathways
[121, 122]





STAT3 Suppression of multiple pro-
inflammatory signaling pathways
[37–39]








Increase recruitment of leukocytes [95, 120, 122, 
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Cytokines IL-6, IL-17, IL-1β, 
and TNF
Activation of numerous pro-
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Growth factors VEGF Increase of BBB permeability, 




NFκB and Soc3 Activation of numerous pro-
inflammatory signaling pathways
[31, 32, 37]
Act1 Activation of IL-17-mediated pro-
inflammatory signaling pathways
[28]
As immune-competent cells, astrocytes can detect injury signals and respond with the release of cytokine, chemokines, 
and growth factors as well initiating intracellular signaling pathways. Data suggests that the downstream effects of 
astrocyte activation is context- and time-dependent, and that both factors as well as other microenvironment stimuli 
can shift reactive astrocytes to either a more beneficial or detrimental phenotype.
Act = actin, CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, Gp = glycoprotein, 
IL = interleukin, IFN = interferon, NFκB = nuclear factor kappa B, EAE = experimental autoimmune 
encephalomyelitis, SHH = sonic hedgehog, Soc3 = suppressor of cytokine signaling 3, STAT3 = signaling 
transducer and activator of transcription 3, TGF = transforming growth factor β, TNF = tumor necrosis factor, 
VEGF = vascular endothelial growth factor.
Table 2. 
Pro- and anti-immune responses of astrocyte molecules.
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sclerosis, astrocytes have been shown to express CXCL12, a T cell chemoattractant, 
and B-cell activating factor (BAFF), a B cell chemoattractant [116, 117]. Like their 
influence on microglia and macrophages, cytokines released by reactive astrocytes 
can shift T cells to adopt either a more beneficial or detrimental phenotype. For 
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119]. Similarly, in a murine spinal cord injury model reactive astrocytes have been 
shown to release anti-inflammatory TGF-β [31]. Further studies examining the 
influences of reactive astrocytes on T cells are needed to better understand the 
long-term effects of astrogliosis on adaptive immune cells during CNS recovery 
after injury.
7. Reactive astrocytes as a pro-inflammatory regulator
Reactive astrocytes can release a variety of molecular signals that contribute 
to the inflammatory state of the CNS after injury or disease by directly activating 
immune defenses with the release of cytokines, chemokines, and other growth 
factors (Table 2). Recent advancements in astrocyte transcriptome analysis have 
begun to reveal the context specific production of pro-inflammatory molecules 
by astrocytes as well as molecular triggers that induce their production. Analysis 
of the astrocyte transcriptome after in vivo exposure to lipopolysaccharide (LPS) 
or infection significantly promoted the production of a pro-inflammatory, 
neurotoxic molecular profile [26, 52]. However, the astrocyte transcriptome 
shifts towards an anti-inflammatory, neuroprotective profile in an in vivo isch-
emia model [52]. Future studies should utilize single-cell sequencing techniques 
to transcriptionally define individual astrocyte responses during health and 
disease.
Despite the number of astrocyte transcriptome data available, few studies have 
attempted to elucidate mechanisms and signaling cascades that mediate astrocyte 
pro-inflammatory production. Recent studies have indicated NFκB and SOC3 as 
transcriptional regulators of pro-inflammatory astrocytes after a traumatic brain 
injury and during autoimmune inflammation [31, 32, 37]. In a model of autoim-
munity, genetic deletion of astrocyte derived NFκB results in increased expression 
of ECM components and pro-inflammatory cytokines [129]. Astrocytes have also 
been shown to release CCL2 and CXCL10 to recruit perivascular leukocytes dur-
ing autoimmune inflammation [124–126]. While the role of CCL2 and CXCL10 is 
diverse, evidence suggests that these molecules produced by astrocytes promote 
leukocyte migration in the CNS parenchyma [124]. In an autoimmune inflammation 
model, IL-17 inflammatory induction has been shown to be mediated by astrocyte 
Act1 signaling. Genetically deleting Act1/IL-17 signaling from astrocytes in an 
EAE model prevents the induction of pro-inflammatory cytokines [28]. Reactive 
astrocytes can also shift towards a more pro-inflammatory state by overexpressing 
pro-inflammatory cytokines. In spinal cord injury and autoimmune models, the 
overexpression of IL-6 in astrocytes leads to increased immune cell infiltration. 
The proinflammatory cytokine, IL-1β, produced by astrocytes, has also been shown 
to initiate a signaling cascade that releases vasoactive endothelial growth factor 
(VEGF), leading to increased BBB permeability and leukocyte leakage [127, 128]. In 
general, there is also evidence that astrocytes contribute to triggering inflammatory 
responses due to increases in neuronal activity in epilepsy, neuropathic pain, and 
stress [130].
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Despite the growing body of work that suggests pro-inflammatory roles for 
astrocytes, there is an equal amount of evidence suggesting these cells limit 
inflammation. Recent loss-of-function experiments have also revealed essential 
anti-inflammatory roles of astrocytes after a variety of CNS injury and disease 
states (Table 2). These studies have also revealed specific molecular mechanisms 
that mediate these anti-inflammatory roles. The astrocyte TGF-β response seems 
to selectively affect astrocyte cytokine and chemokine production after ischemia 
in murine models. The genetic deletion of TGF-β signaling in astrocytes leads 
to diffused inflammation and enhances myeloid cell activation [43, 44]. After 
toxoplasmic encephalitis, the genetic loss of astrocyte TGF-β signaling can 
lead to the increase of infiltrating T cells. Notably, in both examples, astrocyte 
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[28]
As immune-competent cells, astrocytes can detect injury signals and respond with the release of cytokine, chemokines, 
and growth factors as well initiating intracellular signaling pathways. Data suggests that the downstream effects of 
astrocyte activation is context- and time-dependent, and that both factors as well as other microenvironment stimuli 
can shift reactive astrocytes to either a more beneficial or detrimental phenotype.
Act = actin, CCL = chemokine (C-C motif), CXCL = chemokine (C-X-C motif) ligand, Gp = glycoprotein, 
IL = interleukin, IFN = interferon, NFκB = nuclear factor kappa B, EAE = experimental autoimmune 
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transducer and activator of transcription 3, TGF = transforming growth factor β, TNF = tumor necrosis factor, 
VEGF = vascular endothelial growth factor.
Table 2. 
Pro- and anti-immune responses of astrocyte molecules.
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the immune response profile. Astrocyte signaling involving gp130, a receptor 
for IL-6, or estrogen receptor 1α has also been shown to be anti-inflammatory. In 
autoimmune and infection models, the genetic deletion of gp130 from astrocytes 
results in increased inflammatory cytokine production [24, 25]. Similar outcomes, 
such as increased myeloid infiltration and mortality, are observed in autoimmune 
models when estrogen receptor 1α is conditional deleted from astrocytes [23]. 
During autoimmunity, mice deficient in functional IFNγ signaling in astrocytes 
result in exacerbated disease and mortality due to enhanced leukocyte infiltration 
and an upregulation of inflammatory gene expression, including CCL1, CCL5, 
CXC10, and TNF [119]. These mice also had a reduction in anti-inflammatory 
cytokines, such as IL-10 and IL-27, when compared to mice with functional IFNγ 
in astrocytes [119].
9. Reactive astrocytes as a neuroprotector of the CNS
In addition to astrocyte regulation of the immune response, these glial cells can 
respond to CNS injury by altering neuronal function or survival. Neuronal insults 
result in the release of numerous signals, including increased glutamate production, 
ATP release and vascular damage. During numerous CNS disease states, including 
stroke, traumatic injury, epilepsy, neurodegeneration, and viral infection, injured 
and dying neurons release glutamate, which is harmful to neurons [131–134]. 
Astrocytes have been shown to take up excessive extracellular glutamate and 
dampen the neurotransmitter’s excitotoxicity on neurons, resulting in decreased 
neuronal death [135]. In vitro studies have also shown that glutamate signaling in 
astrocytes decrease their production of CCL5, a T cell chemoattractant, reducing 
overall neuroinflammation [136].
10. Reactive astrocytes as a neurotoxin of the CNS
Inflammation itself can unfortunately impair astrocyte uptake of glutamate, 
which leads to increased neuronal toxicity and a positive feedback of neuroin-
flammation [137]; for example, in an in vitro study TNF, released by microglia, 
signals to astrocyte to release glutamate, increasing excitotoxicity [138]. Neuronal 
injury and death also lead to the release of potassium and ATP. Both potassium 
and ATP can activate the inflammasome complex, which is an innate immune 
mechanism that when activated, resulting in the production of proinflammatory 
cytokines and increased inflammatory responses. The activation of the inflamma-
some complex, in this case, is through pannexin 1 channels, expressed by astro-
cytes [139, 140]. Pannexin 1 channels are opened by potassium and ATP, and once 
opened, activate the inflammasome complex, leading to the increased production 
of pro-inflammatory mediators, such as IL-1β, reactive oxygen and nitrogen 
species, and CCL2, a myeloid cell chemoattractant [139, 141–143]. ATP also can 
induce the release of glutamate from astrocytes, which can contribute to overall 
excitotoxicity [144]. During health, astrocytes release stored glycogen which 
is converted to lactate and transported to metabolically support neurons [145]. 
Neurons can resist excitotoxicity when astrocytes increase their glycogen uptake 
and lactate delivery [146]. Pro-inflammatory cytokines, including IL-1β as well 
as IFN-γ, TNF, and IL-6, negatively impacts this process by reducing glycogen 
storage and lactate transport in astrocytes that is necessary as an energy source of 
neurons [147, 148].
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11. Conclusions
Despite the recent advances in defining the role of astrocytes in regulating 
neuroinflammation, our understanding of these complex glial cells is only begin-
ning. A few studies have demonstrated astrocyte polarization after various CNS 
injuries [26, 52, 95]. In this model, “A1” reactive astrocytes are pro-inflammatory, 
neurotoxic while “A2” reactive astrocytes are anti-inflammatory, neuroprotective. 
Future research, however, is needed to determine whether, like the inflammatory 
microglia and macrophages, reactive astrocytes shift phenotypes along a spectrum 
of responses. The amount of new technology available to researchers will also make 
it possible to further dissect the complexity of astrocytes. Single-cell transcriptional 
profiling techniques, specifically, can be used as a tool to identify astrocyte subtypes 
as well as intracellular signaling networks. This method has already been utilized to 
reveal distinct astrocyte types with regionally restricted distribution in the healthy 
mouse brain [149]. A key goal, however, for researchers in the future will be to 
elucidate signaling networks that are relevant to CNS injury and disease and how 
immune pathways influence astrocyte reactivity.
While current research focuses primarily on astrocyte interactions with other 
CNS cell types, such as neurons, microglia, pathogens and infiltrating immune 
cells, future studies will need to examine how other biologic variables, including 
age and sex, influence astrocyte effects within the central and peripheral immune 
systems. Additionally, there is already some evidence that astrocyte immune regula-
tion is influenced by the gut microbiome [150], but the implications and effects of 
this process on health and disease are unknown.
In summary, astrocytes exhibit diverse and sometimes conflicting roles in the 
setting of neuroinflammatory diseases. These multipurpose glia cells not only sense 
and influence damaged neurons but appear to summate multiple signals to develop 
specific responses that modulate neuroinflammation. It is our hope that under-
standing how astrocytes receive and response to information as they perform these 




BAFF B-cell activating factor
BBB blood-brain barrier
cAMP cyclic AMP
CCL chemokine (C-C motif) ligand
CCR chemokine (C-C motif) receptor
CNS central nervous system
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Chapter 7
Astrocytes in Pathogenesis of 
Multiple Sclerosis and Potential 
Translation into Clinic
Izrael Michal, Slutsky Shalom Guy and Revel Michel
Abstract
Astrocytes are the most abundant glial cells in the central nervous system (CNS) 
and play a pivotal role in CNS homeostasis and functionality. Malfunction of astro-
cytes was implicated in multiple neurodegenerative diseases, including amyotrophic 
lateral sclerosis (ALS), Parkinson’s disease (PD), Alzheimer’s disease (AD), and 
multiple sclerosis (MS). The involvement of astrocytes in the pathology of neuro-
degenerative disorders supports the rationale of transplantation of healthy human 
astrocytes that can potentially compensate for diseased endogenous astrocytes. In 
this review, we will focus on the roles of astrocytes in the healthy CNS and under 
MS conditions. We will describe the cell sources and current cell-based therapies for 
MS with a focus on the potential of astrocyte transplantation. In addition, we will 
cover immerging early-stage clinical trials in MS that are currently being conducted 
using cell-based therapies.
Keywords: astrocytes, multiple sclerosis, neurodegenerative diseases, autologous 
hematopoietic stem cells (AHSC), mesenchymal stem cells (MSC)
1. Multiple sclerosis
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating, and 
degenerative disease of the CNS. The disease leads to permanent neurological 
disability, including limb weakness, sensory loss, vision disturbances, pain, and 
muscle spasms [1]. MS is affecting more than 2 million people worldwide, most of 
them are females between the age of 20 and 40 years. The most prevalent clinical 
course of the disease (approximately 80% of the cases) is relapsing-remitting MS 
(RRMS), characterized by a period of functional disability (relapses) and fol-
lowed by spontaneous improvements (remissions) [1]. With the progression of 
the disease, most of the patients will develop a course of secondary progressive MS 
(SPMS), characterized by a steady decline in neurological function, with no phases 
of remissions [2]. A less common form of MS is primary progressive MS (PPMS), 
representing approximately 10% of MS cases. PPMS is characterized by a develop-
ment of gradual progressive disease with no remission phases [2, 3]. Currently, 15 
disease-modifying treatments (DMTs) are approved by the FDA for the treatment 
of MS [4]. The mechanisms of action of these DMTs are diverse; however, they all 
aim to modulate or suppress the immune system. The current DMTs have benefit in 
reducing frequency and severeness of relapses and buildup of disability in RRMS; 
nevertheless, they have only limited impact on the progressive forms of MS [2, 5, 6].
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and play a pivotal role in CNS homeostasis and functionality. Malfunction of astro-
cytes was implicated in multiple neurodegenerative diseases, including amyotrophic 
lateral sclerosis (ALS), Parkinson’s disease (PD), Alzheimer’s disease (AD), and 
multiple sclerosis (MS). The involvement of astrocytes in the pathology of neuro-
degenerative disorders supports the rationale of transplantation of healthy human 
astrocytes that can potentially compensate for diseased endogenous astrocytes. In 
this review, we will focus on the roles of astrocytes in the healthy CNS and under 
MS conditions. We will describe the cell sources and current cell-based therapies for 
MS with a focus on the potential of astrocyte transplantation. In addition, we will 
cover immerging early-stage clinical trials in MS that are currently being conducted 
using cell-based therapies.
Keywords: astrocytes, multiple sclerosis, neurodegenerative diseases, autologous 
hematopoietic stem cells (AHSC), mesenchymal stem cells (MSC)
1. Multiple sclerosis
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating, and 
degenerative disease of the CNS. The disease leads to permanent neurological 
disability, including limb weakness, sensory loss, vision disturbances, pain, and 
muscle spasms [1]. MS is affecting more than 2 million people worldwide, most of 
them are females between the age of 20 and 40 years. The most prevalent clinical 
course of the disease (approximately 80% of the cases) is relapsing-remitting MS 
(RRMS), characterized by a period of functional disability (relapses) and fol-
lowed by spontaneous improvements (remissions) [1]. With the progression of 
the disease, most of the patients will develop a course of secondary progressive MS 
(SPMS), characterized by a steady decline in neurological function, with no phases 
of remissions [2]. A less common form of MS is primary progressive MS (PPMS), 
representing approximately 10% of MS cases. PPMS is characterized by a develop-
ment of gradual progressive disease with no remission phases [2, 3]. Currently, 15 
disease-modifying treatments (DMTs) are approved by the FDA for the treatment 
of MS [4]. The mechanisms of action of these DMTs are diverse; however, they all 
aim to modulate or suppress the immune system. The current DMTs have benefit in 
reducing frequency and severeness of relapses and buildup of disability in RRMS; 
nevertheless, they have only limited impact on the progressive forms of MS [2, 5, 6].
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2. Astrocytes in the naive CNS
Although the major players in the onset and development of MS are immune 
cells, oligodendrocytes, and neurons, astrocytes also play a crucial role in all stages 
of the pathogenesis of the disease [7]. Astrocytes are the most abundant glial cells 
in the CNS, making at least 30% of its cell mass in mammalians, having a pivotal 
role in maintaining the physiologic functions in the CNS [8–10]. Astrocytes can 
be classified based on their morphological and structural characteristics into two 
subtypes, namely, protoplasmic and fibrous. Protoplasmic astrocytes are widely 
distributed in the gray matter, extending processes from their soma to neurons and 
blood vessels [11]. Their extended end feet are associated with blood vessels to form 
the glial limiting membrane of the blood-brain barrier (BBB). They also interact 
with synapses and play an important role in modulation of synaptic functions 
and uptake of glutamate [12–14]. Conversely, fibrous astrocytes have a starlike 
appearance, and they are found mainly in the white matter, sending long and thin 
processes through axonal bundle [15]. Fibrous astrocytes express higher levels of 
the intermediate filament glial fibrillary acidic protein (GFAP) as compared to 
protoplasmic astrocyte. Despite the differences in morphology and distribution, 
both subtypes of astrocytes share many similar functions [16–18].
Astrocytes provide functional support to neurons by maintaining levels of 
glutamate, extracellular ions, energetic metabolism, pH, and water homeostasis 
[10, 19]. Astrocytes are also involved in the creation, elimination, and modulation 
of synapses [20–22]. They modulate the synaptic transmission of neurons by the 
formation of tripartite synapses that regulate the release of neurotransmitters such 
as glutamate, d-serine, and gamma-aminobutyric acid (GABA) and by buffering 
extracellular potassium ions [23–26]. They can also regulate synaptic activity by 
uptake of neurotransmitters from the synaptic cleft [27, 28]. Astrocytes are impor-
tant in maintaining the survival of neurons in the CNS, as they secrete neurotrophic 
and neuroprotective factors such as glial cell line-derived neurotrophic factor 
(GDNF) and brain-derived neurotrophic factor (BDNF) that directly support neu-
ronal survival [29, 30]. Astrocytes play a pivotal role in formation and maintenance 
of the blood-brain barrier (BBB), a highly selective physical border that separates 
the CNS parenchyma from blood circulation through extension of processes of an 
end-foot membrane that surrounds CNS capillaries [31]. The end-foot membrane 
contains the channel protein aquaporin-4 (AQP4) and the gap junction protein 
connexin 43 (Cx43) that allow astrocytes to tightly regulate the selective exchange 
of water-soluble molecules and ions with blood vessels [32]. In a healthy state, 
astrocytes constitutively secrete low basal levels of the anti-inflammatory cytokines 
including transforming growth factor-β (TGF-β) [33] and interleukin-10 (IL-10) 
[34] to maintain a stable noninflammatory environment. In an inflammatory state, 
astrocytes change the permeability of the BBB by releasing cytokines such as IL-6, 
IL-1β, and tumor necrosis factor-α (TNF-α), specifically acting on the endothelial 
tight junctions of the BBB [35–37]. The close vicinity to blood vessels also allows 
astrocytes to transfer glucose from the blood to neurons as a source of energy [38]. 
Astrocytes can also protect neurons from oxidative stress by secretion of antioxi-
dants, such as glutathione and thioredoxin to their coupled neurons [39, 40].
3. Reactive astrocytes
Activation of astrocytes, known also as astrogliosis, is a process that is charac-
terized by proliferation of astrocytes, accompanied by profound morphological 
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and functional changes [41]. Astrocytes become active in response to changes 
in the CNS homeostasis or under pathological conditions. Cues that lead to 
astrogliosis include (i) CNS injury that causes the release of damage-associated 
molecular patterns (DAMPs), (ii) pro-inflammatory cytokines in response to 
damaged CNS tissue, (iii) pathogen-associated molecular patterns (PAMPs) 
produced by microbial infection, and (iv) oxidative or chemical stress [42–44]. 
Although all reactive astrocytes share similar attributes, they can still be distin-
guished by two different phenotypes, A1 and A2, resembling the M1/M2 states 
of macrophages [45]. The A1 astrocytes are neurotoxic and induced in response 
to inflammatory microglia, e.g., those found in neurodegenerative disease such 
as Huntington’s disease (HD) and Parkinson’s disease (PD) but also in MS [45, 
46]. The A2 reactive astrocytes are formed in response to ischemic damage and, 
in contrast to the A1-type astrocytes, exhibit anti-inflammatory properties and 
secrete neurotrophic factors such as BDNF and nerve growth factor (NGF) [93, 
45]. Yet, the definition of these two types of reactive astrocytes may be quite elu-
sive, as intermediate phenotypes with mixed characteristics of A1/A2 states were 
also observed [41]. A1 and A2 astrocytes can appear during different phases of a 
pathological process and sometimes may even coexist. Their distinct functions 
allow to attract microglia and T cells by A1 astrocytes at the first stages of the 
pathology and to support tissue repair by inhibiting inflammation and secreting 
neurotrophic factors at a later recovery stage [41].
Depending on the severity of the injury, astrogliosis can lead to the formation 
of a glial scar. The glial scar isolates the inflamed area, restricts the damage to the 
lesion, and provides structural support to the CNS parenchyma [16]. Based on 
their environmental cues, reactive astrocytes produce pro- and anti-inflammatory 
cytokines including IL-1, IL-6, TNF-α, IL-10, and TGF-β [47]. They can also attract 
circulating leukocytes by secreting chemokines such as CXCL8, CXCL10, CCL2, 
CCL5, and CCL20 from their end feet at the surface membrane of blood vessels of 
the BBB [47–49]. Reactive astrocytes also present cell adhesion molecules such as 
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion protein 1 
(VCAM-1), which are important for migration of T cells [50]. Reactive astrocytes 
can also protect neurons by secretion of neurotrophic factors such as NGF, BDNF, 
GDNF, and VEGF [51–53]. Although the morphology and activities of reactive 
astrocytes are well defined, there is no exclusive marker that clearly distinguishes 
between reactive and nonreactive astrocytes. The major marker of astrogliosis is 
the intermediate filament GFAP, which is abundant in all astrocyte populations but 
upregulated upon activation. However, the functional contribution of GFAP in the 
activation process is still not clear yet [54]. In addition to GFAP, expression of other 
astrocytic markers is also upregulated in reactive astrocytes, including glutamine 
synthetase 1, aldehyde dehydrogenase 1 (ALDH1), and S100β [55, 56].
4. Reactive astrocytes in MS
Astrocytes are involved in all stages of the formation and development of the 
plaques in MS. Their contribution starts already at a very early stage of the lesion, 
before demyelination is actually seen [57].
Lesions in MS can be classified in four categories.
i. Early pre-active lesions do no not show demyelination damage yet. However, 
the presence of reactive astrocytes and microglia is the indication for a 
development of pathological process in the area [58]. Studies in experimental 
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autoimmune encephalomyelitis (EAE) mice suggest that activation of 
astrocytes can actually occur even before the immune cells cross the BBB into 
the CNS parenchyma [59].
ii. Active-acute lesions contain hypertrophic astrocytes with enlarged soma 
and processes comprising high levels of GFAP filaments. In the active-acute 
plaque, the astrocytes are in close proximity to oligodendrocytes, probably 
interacting with them. Although the nature of this oligodendrocyte-astro-
cyte interaction is not completely understood [60–62], it is suggested that 
astrocytes clear debris of myelin by phagocytosis [63]. Reactive astrocytes 
in MS may also lose their surface contact with blood vessels of the BBB, 
enhancing the infiltration of leukocytes to the CNS [57]. The hypertrophic 
astrocytes also recruit T cells, macrophages, and microglia to the lesion by 
expressing a set of cell adhesion molecules and chemokines such as ICAM-1 
and CCL2 [64–67].
iii. Active-chronic lesions contain a plaque core with a profound active demy-
elination, which is accompanied by remyelination activity and infiltration 
of immune cells, especially at the periphery of the lesion. Astrocytes in this 
type of lesions can be of either A1 or A2 types, and it is suggested that they 
contribute to the clearance of tissue debris from damaged areas and protect 
remaining intact regions [45].
In the lesion, reactive astrocytes produce matrix metalloproteinases (MMP), 
extracellular matrix-remodeling proteins, that changes BBB permeability, allow-
ing immune cell infiltration to the CNS parenchyma and thus inhibiting repair 
processes [68]. On the other hand, reactive astrocytes also secrete tissue inhibitors 
of metalloproteinases (TIMPs) in the lesioned area that inhibit the activity of 
MMPs, help to stabilize BBB permeability, and eventually to promote remyelination 
[69–71]. Thus, the balance between TIMP and MMP expression can influence the 
ratio between demyelination and remyelination.
Reactive astrocytes in MS also express a variety of trophic factors that mediate 
protective and repairing processes in the lesion. Examples of neurotrophic factors 
which are secreted by astrocytes include neuroprotective factors such as vascular 
endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT3), and insulin-like growth factor-1 (IGF-1) [72, 73]. Reactive 
astrocytes secrete the cytokine IL-6 that, in addition to its pro-inflammatory activ-
ity, also promotes remyelination and neuroprotection [74, 75].
iv. Inactive lesions contain astrocytes with a small cytoplasm and elongated thin 
processes. The astrocytes in the inactive lesion are rich in GFAP and form a 
glial scar around the core of the plaque, while occasionally they can be found 
also within the core [76].
With the progression of MS pathogenesis, reactive hypertrophic astrocytes 
form a glial scar, which is the most severe grade of astrogliosis, around the core 
of the demyelinated plaque [10]. The astrocytes in the glial scar form a compact 
structure that is held by tight junctions on their filament-rich processes [77, 78]. 
The scar primarily serves as a physical barrier surrounding the demyelinated 
area, and this prevents widespread of the damage to the surrounding paren-
chyma [79, 80]. The glial scar also maintains the structure of the BBB, provides 
structural support, and prevents immune cell infiltration [10, 57]. The glial 
scar is generally considered as a non-supporting environment for remyelination 
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since it prevents oligodendrocyte progenitor cells (OPCs) from approaching the 
demyelinated axons surrounded by the glial scar [81, 82].
5. Cell-based therapy
Currently, the available DMTs for MS focus on targeting inflammation pro-
cesses. These therapies can be divided into two main groups: drugs for the treatment 
of acute relapses (corticosteroids) [83] and drugs which affect the course of the 
disease [84]. The second group can be further subdivided into immunosuppressive 
drugs (e.g., methotrexate and mitoxantrone) and drugs with immunomodulatory 
activity (e.g., interferon-β [84] and antibodies) [85]. Although these treatments 
are effective in treating relapsing-remitting MS (RRMS), they show no significant 
therapeutic benefits in the progressive forms of the disease. A new therapeutic 
approach with a dual mode of action that is based on tissue repair in addition to 
immunomodulation has an enormous potential to further attenuate the progression 
of the disease and to prevent the transition to the progressive course. Cell-based 
therapies might serve as promising candidates for such a therapy.
The mechanisms of action (MOA) by which therapeutic cells can exert their 
activities in the CNS include (i) secretion of neurotrophic factors that promote 
neuronal survival and outgrowth, (ii) reduction of oxidative stress in lesioned 
areas, (iii) clearance of toxic factors from the CNS environment, (iv) promotion 
of remyelination, and (v) immunomodulation. In this context, astrocytes hold a 
promising therapeutic potential, as they share these mechanisms of action [86].
During the last two decades, cell-based therapies from different cell sources 
were tested in EAE models, and some of them have been further evaluated in clini-
cal trials.
6. Sources of cells for treatment of MS
6.1 Autologous hematopoietic stem cell (AHSC)
Increasing scientific evidence demonstrate that antigen-specific immune 
response mediates the inflammation process in MS. The immune milieus that depict 
MS inflammation include (i) immunoglobulins (oligoclonal Igs) that are found 
in the CSF of the majority of MS patients, but not in their serum [87]; (ii) com-
mon clonal T-cell populations in the peripheral blood, cerebrospinal fluid (CSF), 
and CNS parenchyma [88]; (iii) MHC class II HLA-DRB1 that plays a role in the 
development of MS [89, 90]; and (iv) specific T-cell receptor (TCR) repertoire in 
distinct lesions as found in postmortem brains of MS patients [91]. Silent nucleotide 
exchanges within the V-CDR3-J region of TCR suggest that the corresponding T-cell 
clones were recruited and stimulated by particular antigens. It was demonstrated 
that some of the pervasive T-cell clones belonged to the CD8+ compartment, sup-
porting the pathogenic relevance of this T-cell subset [88, 91, 92]. Studies in EAE 
models and the presence of Th1 and Th17 cells contributed to the notion that self-
reactive lymphocytes induce inflammation in response to myelin epitopes [93–95].
One of the approaches to reset the immune system in MS is to use a myeloabla-
tive protocol and transplant autologous hematopoietic stem cells (AHSC) similarly 
to those used in hematologic malignancies [96, 97]. However, immunoablation 
and reconstitution of the immune system that reset the autoreactive immuno-
inflammatory process and restore self-tolerance are still considered as an intensive 
approach as compared to the current DMTs in MS [97, 98].
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6.1.1 Clinical data
One explanation for the therapeutic effect by autologous hematopoietic stem cell 
transplantation (AHSCT) is reset of the immune system by immune reconstitution 
following their transplantation. This effect is obtained through deletion of patho-
genic clones by a combination of direct ablation and induction of a lymphopenic 
state. Another explanation might be that the immunosuppression regimen depletes 
T-cell populations for a long period. AHSCT therapy after immunoablation has been 
studied for the last 20 years [98]. The results of thousands of patients who have 
received AHSCT for different types of MS were collected by international trans-
plant registries and showed benefits in a subset of patients with highly active relaps-
ing forms of MS. For instance, recently, a study that was performed in 110 RRMS 
patients who received AHSCT along with cyclophosphamide (immunosuppressant) 
and anti-thymocyte globulin, or disease-modifying treatments, was found to 
prolong the time to disease progression. In the first year, mean of expanded disabil-
ity status scale (EDSS) scores decreased (improved) from 3.38 to 2.36 in the AHSCT 
group and increased (worsened) from 3.31 to 3.98 in the DMT group [99]. Other 
recent trials in MS, mainly in RRMS [99–102], demonstrated a degree of disease sta-
bilization after AHSCT. In addition, recent publications showed a sustained disease 
attention following AHSCT in a subset of patients with highly active inflammatory 
disease [103].
The process of immunoablation and reconstitution of the immune system is 
complicated and includes multiple steps: mobilization of hematopoietic stem cells 
(HSC), collection and preservation of CD34+ HSCs, immunoablative conditioning, 
infusion of HSCs, and posttransplant care [104]. It is important to note that immu-
noablation strategies are also associated with infertility and short-term higher rate 
of cerebral atrophy that might lead to neurological disability, and hence optimizing 
treatment regimen is required in order to minimize mortality and morbidity. In 
addition, this treatment was not found effective for the treatment of primary or 
secondary progressive MS [105].
6.2 Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent, non-hematopoietic, 
stromal cells that can differentiate into mesodermal lineage including osteo-
blasts, chondrocytes, and adipocytes as well as into ectodermal cells (neurons 
and glia) and endodermal cells (hepatocytes) [106, 107]. Typically, the bone 
marrow is used as the source of MSCs. These bone marrow stem cells do not 
contribute to the formation of blood cells and do not express the hematopoietic 
stem cell marker CD34 [108]. Alternative tissues that can be used as a source 
for MSCs include umbilical cord cells that consist of young and most primitive 
MSCs, adipose tissue, developing tooth bud (molar cells), and the amniotic fluid 
[109–111]. MSCs present immunomodulatory properties such as activation of 
regulatory T cells, maturation of dendritic cells, suppression of B- and T-cell 
proliferation, and inhibition of natural killer functionality. The hypothesis is 
that the immunomodulatory effect is mediated by paracrine signals and homing 
of MSCs to the damaged area [112]. Injection of MSCs to EAE animal models 
demonstrated a slowdown in disease progression, lesser immune cell infiltra-
tion, and a decline in demyelination and axonal damage [113, 114]. MSCs were 
found to possess immunomodulatory effect when administered intraventricular 
(IVT), intravenously (IV), intrathecally (IT), and intraperitoneally (IP)  
[113, 115, 116].
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6.2.1 Clinical data
In 2007, Mohyeddin et al. were the first to publish their clinical results using 
MSCs for treatment of MS [117]. The aim of the study was to evaluate the safety 
and therapeutic potential of autologous MSCs to ameliorate clinical manifestations 
in MS patients. In this study, 10 MS patients were injected intrathecally with MSCs. 
The results of the study showed that the use of MSCs is safe, but no significant 
clinical benefits were observed. In order to provide MSCs with neuromodulatory 
properties, in addition to their immunomodulatory properties, a few groups differ-
entiated the MSCs into neural-like cells or glial-like cells that secrete neurotrophic 
factors. IT transplantation of these autologous cells to MS patients demonstrated 
their safety profile and tolerability [118–120]. Recently, Harris et al. [121] also 
reported that IT injection of neural-like cells derived from MSCs was safe and well 
tolerated. The 20 subjects in the clinical trial completed all 60 planned treatments 
without having serious adverse events. The minor adverse events included transient 
fever and mild headaches. Posttreatment disability score analysis demonstrated 
improvement in median EDSS. The beneficial affect was greater in a subset of 
SPMS patients and in ambulatory subjects (EDSS ≤ 6.5). In addition, 70 and 50% 
of the subjects demonstrated improved muscle strength and bladder function, 
respectively [121].
6.3 Neural stem cells and oligodendrocyte precursor cells
In the recent years, clinical trials using cell therapies in MS patients were mainly 
based on autologous transplantation of MSCs and AHSCs [122]. While showing 
promising clinical effects, the transplantation of autologous cells is limited to the 
donor. It would therefore be advantageous to develop allogeneic cell treatments as 
shelf-products that could be used for large populations of patients. In addition, the 
potential therapeutic effect of AHSCs and MSCs on MS is mostly mediated through 
immunomodulatory cues. Finding a cell source that triggers remyelination and 
tissue, in addition to immunosuppression properties, has a great DMT potential. 
Neural stem cells (NSCs) can migrate to demyelinated areas and differentiate into 
neurons and glial-restricted cells (i.e., oligodendrocytes and astrocytes) [7]. NSCs 
can differentiate to oligodendrocytes that can potentially remyelinate demyelinated 
axons in MS [123]. The benefits of NSCs might arise not only from their potential to 
differentiate into oligodendrocytes but also from their capacity to differentiate into 
astrocytes and neurons, the former having neurotrophic and immunomodulatory 
properties [86, 123]. Endogenous NSCs are found in germinal niches, such as the 
subgranular zone (SGZ) of the dentate gyrus and subventricular zone (SVZ) of the 
lateral ventricles [124, 125]. These NSCs play a pivotal role in early stages of MS, 
but fail to do so in later stages of the disease. Thus, replenishing endogenous NSCs 
with allogenic NSCs has a great therapeutic potential. Transplantation of NSCs in 
EAE animal models demonstrated that the cells can migrate into inflamed white 
matter plaques and differentiate into oligodendrocytes [126, 127]. Another study 
showed that transplantation of NSCs derived from induced-pluripotent stem cells 
(iPSCs) reduced T-cell infiltration as well as white matter damage [128]. To date, 
no clinical trial in MS evaluated NSCs in MS. A few groups used pluripotent stem 
cells (human embryonic stem cells or induced-pluripotent stem cells) as a source 
for neural lineage following an in vitro differentiating protocol [129]. Transplanted 
hESC-derived NSCs in EAE MS animal models demonstrated neuroprotective and 
immunosuppressive effect; however, remyelination was not observed  
[127, 130]. Another study showed that transplantation of iPSC-derived NSCs to 
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6.1.1 Clinical data
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EAE model significantly reduced infiltration of T cells to the lesion and reduced 
demyelination areas. Consistent with this histopathological improvement, the 
clinical score of the disease was also rescued in the iPSC-NSC-treated group of 
mice [128]. Transplantation of hESC-derived OPCs (A2B5+) demonstrated that 
these cells remyelinate brains of shiverer mice and partially rescue their clinical 
deficiencies [131–133]. The platelet-derived growth factor α receptor (PDGFAR)-
positive OPCs presented even a greater myelinogenic potential [134, 135]. Similarly, 
intracortical implantation of iPSC-derived OPCs to a nonhuman primate model of 
progressive multiple sclerosis (MS) showed that the cells can migrate to the lesions 
and remyelinate denuded axons [136].
6.4 Astrocyte progenitor cells
As discussed above, astrocytes have multiple roles in maintaining the homeosta-
sis of the CNS. Some of the mechanisms of action, which are crucial for the main-
tenance of the CNS, are postulated to contribute also to the treatment in MS. The 
diverse modes of action of astrocytes may be more effective in treating MS compared 
to a single pathway-based drug. Transplantation of healthy astrocytes was proven 
effective in other neurodegenerative diseases such as ALS [137, 138]. In ALS animal 
model, it was shown that intrathecal injections of human astrocytes significantly 
delayed disease onset and improved motor performance compared to sham-injected 
animals. In this study, the astrocytes were found to secrete various neurotrophic fac-
tors and decrease glutamate neurotoxicity [138]. In spinal cord injury (SCI) model, 
it was demonstrated that transplantation of human astrocytes promotes functional 
recovery [139–141]. In addition, transplantation of subtype of astroglia was found to 
possess protective effects against ischemic brain injury [142, 143].
There are several cell sources for human astrocytes. Glial-restricted progenitors 
(GRPs) represent early cell population of the CNS that can self-renew and give rise 
to astrocytes and oligodendrocytes. GRPs can be isolated from human fetal tissues 
[144]. In vivo transplantation of human GRPs into the spinal cord-injured animals 
showed that the cells can survive and differentiate into astrocytes [139, 140]. 
However, human astrocytes from primary brain tissue, obtained from cadaveric 
donors, are challenging due to limited availability and robustness.
Other sources for derivation of astrocytes include pluripotent stem cells (PSC) 
such as embryonic stem cells and induced-pluripotent stem cells (iPSCs) [145]. 
These sources potentially provide unlimited supply of cells for clinical use. Methods 
for producing neural precursor cells from PSCs and their further differentiation 
into glial lineage were demonstrated in pioneering studies in animal models of 
neurodevelopment. In these studies, the key steps for neural commitment in vivo 
were identified and recapitulated in a stepwise process in culture. Specific commit-
ment of pluripotent stem cells toward astrocytes can be achieved using factors such 
as sonic hedgehog (SHH), Wnt proteins, fibroblast growth factors (FGFs), epider-
mal growth factors (EGFs), retinoic acid (RA), and bone morphogenetic protein 
(BMP) [146–150]. Most recently, direct-reprogramming approaches of somatic cells 
into neural cells and astrocytes, including transduction of specified transcription 
factors or by using a combination of defined chemical, have been reported [151]. 
Caiazzo et al. [152] described a conversion of mouse fibroblast into astrocytes 
(iAstrocytes), which are comparable to endogenous astrocytes. This was carried out 
by transducing the transcription factors nuclear factors IA and IB (NFIA, NFIB) and 
SOX9. Another approach for direct conversion or reprogramming of mammalian 
fibroblasts into astrocytes is by culturing the cells in the presence of a cocktail of 
small molecules that includes histone deacetylase inhibitor VPA, TGFβ, and GSK3β 
inhibitor CHIR99021, among other factors [153].
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7. Conclusions
MS is a multifactorial disease involving dysregulation of molecular pathways 
and immunomodulatory processes. Transplantation of healthy functional cells 
that can affect the CNS via diverse mechanisms of action that work in parallel such 
as anti-inflammatory, immunomodulatory, clearance of the toxic environment, 
secretion of neurotrophic factors, and triggering remyelination has great therapeu-
tic potential in treating multiple sclerosis. Yet, bringing new cell-based therapies to 
the clinic faces a few challenges, e.g., what is the optimal injection site in the CNS, 
and what cell dose will be effective? In MS the demyelinated lesions are spread 
throughout the CNS, and it still not clear whether the transplanted cells have long-
distance migratory capacity to reach these plaques from their injection site. Once 
the cells reach to lesion, it is still questionable whether they can remyelinate axons 
under a hostile inflammatory environment. Finally, the safety profile of trans-
planted cells and their long-term tumorigenic potential should be further tested.
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